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Resumo 
A Organização Mundial de Saúde considera a doença da Hepatite B como a oitava causa de 
mortalidade a nível mundial e estima que aproximadamente 400 milhões de pessoas estarão infetadas 
nos dias de hoje. O vírus da hepatite B é caracterizado por ter um tamanho reduzido, possuir uma 
conformação genómica baseada em 4 “open reading frames” (ORFs), ser transmitido de forma 
singular e com um modo ação muito efetivo. Pacientes infetados com o vírus da hepatite B, 
dependendo da idade em que foram infetados, podem ser diferenciados em pacientes agudos ou 
devido ao historial de progressão da doença ser considerados pacientes crónicas, tendo um risco 
elevado de virem a contrair uma de duas patologias no futuro – cirrose hepática e cancro do fígado. 
Actualmente existem dois regimes terapêuticos utilizados contra a hepatite B crónica, sendo estes 
“Nucleos(t)ide analogues” (NUCs) e tratamentos a base de interferões. Contudo, apesar de 
promoverem uma cura funcional, estes tratamentos são considerados ineficazes a longo prazo contra a 
infeção, uma vez que não conseguem erradicar o ADN viral (cccADN) dos hepatócitos infetados e o 
seu consumo é imprescindível a partir do momento do seu diagnóstico.  
À semelhança de outras doenças virais crónicas, como HIV e Hepatite C também pacientes 
infectados com o virus da Hepatite B devido á exposição do mesmo por tempo indeterminado até ao 
final da vida, ficam sujeitos a uma continua disfunção a nivel celular. As células T, membros activos 
do nosso sistema imunitário, após combate contínuo perante a infeção, acabam por perder 
gradualmente a sua função contra o virus e acabam por entrar num estado de exaustão. Este processo 
está documentado em vários estudos científicos e sugere que não é necessariamente o grau e 
intensidade da infeção viral que aumenta, mas sim o  próprio sistema imunitário que, por estar em 
constante esforço, acaba por ser ineficaz em erradicar o virus do corpo humano. No entanto, a 
comunidade científica está a direcionar esforços para a criação de novas medidas terapêuticas, que 
passam por fazer um targeting viral e utilizar mecanismos de imunoterapia que promovam a 
erradicação do vírus via a eliminação do ADN viral das células infetadas.  
Como exemplo, as células “mucosal-associated invariant T” (MAIT) são vistas como uma 
possível nova abordagem imunoterapêutica contra o vírus da hepatite B. As células MAIT constituem 
um subsistema das células T, sendo caracterizadas por serem inatas, não convencionais e 
reconhecerem metabolitos de riboflavina microbiana (Vitamina B2). Este reconhecimento acontece no 
seguimento da secreção de riboflavina microbiana por parte de diversas espécies bacterianas e fungos 
e são apresentadas as células MAIT por intermédio da molécula não-polimórfica do complexo de 
histocompatibilidade principal (“major histocompatibility complex”, MHC) classe I (MR1). Estas 
células estão ainda evolutivamente conservadas entre várias espécies e podem ser encontradas em 
larga escala nos tecidos da mucosa humana, sangue periférico e fígado, existindo uma correlação 
direta com a acumulação por parte destas células em locais de infeção e fornecimento de proteção 
contra infeções. Tendo por base a sua localização celular e a sua frequência no fígado, é sugerido que 
em ambientes de exaustão imunitária como é o caso da hepatite B, as células MAIT podem subsistir e 
estar funcionalmente ativas, imitando o papel imunitário das células T contra a infeção.  
Adicionalmente, as células MAIT dispõem de diversas funções effectoras quando estimuladas 
e, consequentemente, activas. A produção de citoquinas pro-inflamatórias, tais como IFN-ү e TNF-α, 
assim como degranulação, citotoxicidade, proliferação celular (marcador Ki-67) e respostas 
dependentes/independentes da presença do MR1, previamente referido, são algumas das funções 
effectoras relevantes levadas a cabo por estas células e que influenciam o seu desempenho junto do 
corpo humano. É importante mencionar que as células MAIT só recentemente comecaram a ser 
estudadas de uma forma mais abrangente estando associadas a diferentes patologias, como é o caso 
deste projecto, no qual nos focamos no papel destas células no contexto do virus da hepatite B. 
Contudo, na sua grande maioria, os marcos existentes referentes á função celular destas células 
iv 
remetem para infeções bacterianas, uma vez que estas células activamente reconhecem metabolitos 
produzidos por espécies bacterianas, nomeadamente no caso da Eschericia coli. 
O foco do nosso projecto passou pela caracterização de células MAIT, previamente isoladas 
de amostras de PBMCs de dadores saudáveis e doentes crónicos infetados com hepatite B, com o 
intuito de comparar o seu fenótipo, assim como a sua resposta funcional aquando estimulação com 
citoquinas recombinantes, neste caso as interleucinas IL-12 e IL-18. Além disso, estas células foram 
ainda avaliadas quanto à expressão de três painéis de anticorpos diferentes: 1) “Checkpoint 
Inhibitors” (PD-1, TIM3 e LG3), 2) “Activation Markers” (CD25, CD38, CD69 e HLA-DR) e 3) 
“Pro-Inflammatory Cytokines” (IFN-ү, TNF-α e IL-2), e analisadas através de citometria de fluxo. Ao 
mesmo tempo, o perfil expressivo de citoquinas e quimiocinas das células MAIT foi examinado na 
presença de uma linhagem celular humana (B lymphoblast - C1R) e aquando estimulação com um 
composto agonista do MR1 (Diclofenac). As células MAIT de 3 pacientes saudáveis e 3 pacientes 
crónicos infectados com o virus da hepatite B foram testadas. É sabido que os marcadores avaliados 
são expressos pelas células MAIT em pacientes saudáveis. Contudo, o intuito de avaliarmos os 
mesmos em pacientes infectados passou por perceber se, na presença de uma infeção crónica, estas 
células conseguiriam permanecer funcionais. Ainda assim, foi necessário perceber se o virus ou o 
tempo de infeção, que pode variar de paciente para paciente, promove uma alteração na frequência 
das células MAIT e na produção dos diversos marcadores testados.    
Embora os nossos dados preliminares sejam indicativos de que as células MAIT são 
ativamente funcionais em pacientes crónicos com hepatite B, comparativamente com os pacientes 
saudáveis testados, no futuro é necessária a recriação destas experiências num maior número amostral, 
uma vez que o nosso valor de N neste projeto é limitado. Não obstante, foi possível concluir com este 
projeto que células MAIT de pacientes infectado com HBV conseguem ser estimuladas e activadas 
pelas duas citoquinas recombinantes anteriormente referidas, IL-12 e IL-18, produzindo diversas 
citoquinas necessárias para que a sua actividade citotóxica seja equiparável as células MAIT de 
pacientes saudáveis. No entanto, foi verificado que a frequência dos marcadores de exaustão testados 
aparenta ser superior em pacientes crónicos. Contudo, seria importante testar células MAIT 
provenientes de amostras hepáticas de pacientes crónicos, com o objetivo de comparar com os 
resultados obtidos neste projecto, uma vez que o fígado é um órgão de alto risco em caso de infeção 
por hepatite B. Não descurando, os dados obtidos neste projeto mostram que as células MAIT poderão 
ter um papel imunoterapêutico promissor contra o vírus da hepatite B em combinação com terapias já 
existentes.  
O estudo cientifico realizado no âmbito de tese de mestrado demonstrou que as células MAIT 
não seguem o caminho clássico de exaustão celular e conseguem reter parcialmente a sua 
funcionalidade em ambientes desfavoráveis, como é o caso do fígado e sangue de pacientes crónicos 
com hepatite B. Por conseguinte, isto é indicativo de que as células MAIT são um alvo promissor 
quanto ao seu uso no âmbito da imunoterapia em infeções virais crónicas e no tratamento tumoral 
onde o local activo da infeção seja um ambiente resiliente. Para concluir, torna-se imeprativo 
mencionar que existem diversas questões para as quais não existem ainda respostas evidentes 
relativamente ao papel activo das células MAIT. Contudo, sabemos que estas células representam um 
facção substancial de células T especifícas circulatórias e teciduais no corpo humano. Deste modo, 
um maior número de estudos ciêntificos são fundamentais para compreender a contribuição das 
células MAIT para uma resposta imunitária contra o virus do HBV e outras infeções virais. 
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Abstract 
Hepatitis B is considered by the World Health Organization (WHO) as the eight most frequent cause 
of mortality worldwide, with approximately 400 million infected people and without a definitive cure 
available. The main hallmarks of HBV are its small size, genomic conformation, transmission 
mechanism and mode of action. Chronic HBV patients present higher risk of disease progression to 
state of liver cirrhosis and hepatocellular carcinoma (HCC).  
Currently, there are two treatment regimens for chronic HBV infection – Nucleos(t)ide analogues 
(NUCs) and IFN-based therapies – that when used can stop viral replication and induce the innate 
immune system to fight and control the infection, even though with less than 10% cure rate. However, 
these treatments are still ineffective in eradicating HBV infected hepatocytes, since its cccDNA 
genome formation is considered ultra-stable.  Nonetheless, viral targeting and immunotherapeutic 
approaches are emerging, since a therapy that involves adaptive immunity (T cells) is required that 
can control the infection and promotes viral clearance from infected cells. Unfortunately, in 
chronically infected patients, HBV specific T cells are non-functional (exhausted), hence we looked 
into mucosal-associated invariant T (MAIT) cells because these cells are capable to sustain effector 
function despite having upregulated PD-1 exhaustion marker and are present in high frequency within 
the liver. With these qualities, MAIT cells are viewed as a possible new cell-based 
immunotherapeutic approach against HBV infection.  
MAIT cells are unconventional innate-like T cells subset characterized for recognizing microbial 
riboflavin metabolites (Vitamin B2) secreted by numerous bacteria and fungi species presented via the 
non-polymorphic major-histocompatibility complex (MHC) class-I related molecule (MR1). Besides 
being evolutionary conserved among species, MAIT cells also play a protective role that can be 
directly related to a highly abundant frequency in human mucosal tissues, peripheral blood and liver, 
as well as an increased tendency to accumulate at the infection sites. Based on these cells’ localization 
and high frequency within the liver, it is suggested that in an HBV infected liver environment, MAIT 
cells can still be actively functional and can be developed into a therapeutic cure for chronic HBV 
infection. 
In this project, we characterized the phenotypic signature of MAIT cells isolated from healthy and 
chronically infected HBV patients’ PBMCs as well as their functional response upon stimulation with 
IL-12 and IL-18 recombinant cytokines. MAIT cells were evaluated regarding the expression of three 
different antibody panels – 1) checkpoint inhibitors, 2) activation markers and 3) pro-inflammatory 
cytokines – and analyzed using a FACS flow cytometer. Furthermore, MAIT cell cytokine and 
chemokine expression profile were assessed, when in contact with human B lymphoblast antigen 
presenting cell line and while stimulation with a MR1 agonistic compound (diclofenac).   
Although our preliminary data shows that MAIT cells from chronic HBV patients are functional in  ex 
vivo stimulation, it will be of interest to further test the developed assays with additional human 
PBMC samples, since our sample size in this project is limited. Also, it would be of high relevance to 
test MAIT cells retrieved from chronic HBV patients’ liver samples and compare the data with our 
results. Nonetheless, the data obtained in this project shows that MAIT cells are functional, even 
though these cells do not possess a TCR, which leads to the unrecognition of recognize infected 
hepatocytes. Nonetheless, MAIT cells are considered as a promising cell-based therapeutic approach 
that could be used against HBV in combination with the already existent therapies.  
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1.1 Molecular Virology of Hepatitis B Virus  
Besides being one of the smallest virus present in nature, hepatitis B virus (HBV),  is also 
known to have a highly compact genetic organization within its genome, where 4 open reading frames 
(ORFs) overlap with each other1–3. The human HBV belongs to the Hepadnaviridae viral family of 
enveloped and primarily hepatotropic DNA viruses4. In the presence of a suitable host this virus is 
capable of replication and assembly exclusively in hepatocytes where virions are discharged non-
cytopathically over the cellular secretory system, as well as sub-viral particles (SVPs). Hepatitis B 
viral genome has a partially double stranded relaxed-circular (rc) DNA features 4 ORFs: PreS/S, 
preCore/Core, Pol/RT and X (Figure 1.1)1,2,5,6.  
 
 
These ORFs encode for 7-8 known proteins, that are displayed during the viral life cycle of 
HBV7. The preS/S open reading frame encodes for three fundamental but related envelope 
glycoproteins. These proteins have overlapping ORFs, and synthesis of each one individually is 
initiated by start codons that are specific for each viral antigen present. They are termed small (S), 
middle (M) and large (L) proteins. There is another characterization possible, Pre-S, Pre-S2 and Pre-
S1 respectively, supported by the fact that surface envelope proteins such as these may be known as 
Hepatitis B surface antigens (HBsAg, Figure 1.2)2,4,8. The polymerase/reverse transcriptase (Pol/RT) 
ORF is considered very complex due to many functions it needs to attend, meaning that this ORF 
encodes for the viral polymerase, which basically is a multifunctional protein with reverse 
transcriptase functionalities, as well as DNA-dependent DNA polymerase and RNase H activity1,2,5. 
Additionally, the Pol/RT ORF is also described as functioning as a terminal protein used in priming. 
The preCore/Core domain encodes for a structural protein of the viral nucleocapsid, the core antigen 
Figure 1.1. HBV genome structure, genes and mRNAs. The 3.2-kb partially double-stranded relaxed circular DNA 
genome of HBV is displayed in the center. The colored arrows surrounding the HBV rcDNA are representative of the 
locations of the four overlapping open-reading frames (ORFs) within HBV genome – HBcAg Core (Pre-Core/Core); HBsAg 
Surface (Pre-S1/L, Pre-S2/M and S); HBV DNA Polymerase and HBx. All open reading frames have a clockwise direction. 
The outer layer arrows indicate the major HBV mRNAs, all of which end at a common polyadenylation signal located in the 
core open reading frame. DR1 and DR2 represent 11 base direct repeats that have an important role in viral DNA synthesis. 
AAA: Polyadenilated Tail; PC: preCore; DR1: Direct repeat 1; DR2: Direct repeat 2. Adapted from Seeger et al, 2016. 
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(HBcAg)7 and a non-structural secreted HBV protein, the hepatitis B e antigen (HBeAg)2,4. Lastly, the 
X region encodes a small but regulatory protein (HBx)9. This protein is of vital importance for 
hepatitis B viral replication and regulation of transcription upon infection modulating in concordance 
host and viral gene expression10. 
 
 
The life cycle of HBV initiates with the virus attachment to its receptor on the hepatocyte 
surface (Figure 1.3). Interestingly, the rationale behind this receptor function for HBV remained 
uncharacterized for years. However, more recently it has been noticed that sodium taurocholate co-
transporting polypeptide (NCPT) performs as one possible receptor for the HBV life cycle8,11. In vitro 
studies confirmed that the expression of the human NCPT receptor, when placed on HBV non-
permissive mouse cell lines, weakened those cells’ ability to become permissive. This fact may 
suggest the requirement of other receptors granting HBV entry into hepatocytes. Another possibility is 
indeed the lack of host factors that influence viral replication in these animals. Simultaneously, upon 
hepatocytes viral uptake, the translocation of the HBV nucleocapsid from the cytoplasm to the 
nucleus occurs. After viral uptake, relaxed circular DNA (rcDNA) is released to the nucleus through 
nuclear pores and converted into the covalently closed circular DNA (cccDNA). This phenomenon 
takes place within the nucleoplasm via DNA repair mechanisms of the host himself 1,3,4. The newly 
synthesized DNA sequence is then wrapped around histones, so that it may form an episomal 
chromatinized architecture as mini-chromosomes and responsible for the establishment of chronic 
HBV6. It is essential to point out that cccDNA displays a major function as a stable template for viral 
replications, as well as a key element for viral persistence. Although this entire pathway is of extreme 
importance for viral replication, it is used as a transcription template for the 4 poly-A-tailed viral 
mRNA transcripts and gives insight on some of the features behind Hepatitis B viral infection1,2,7,8 
When transported to the cytoplasm, these mRNAs are translated and give origin to all the different 
proteins described above, within their ORFs and their place of action4,12. Also, is important to mention 
that this cascade of events might not take place if the nucleocapsid dimerization and self-assembly of 
the pre-genomic viral RNA (pgRNA), is not reversibly transcribed into rcDNA within the viral 
capsid. Nevertheless, DNA nucleocapsids within the cytoplasm happen to undergo one of two 
Figure 1.2. HBV virion schematic representation. Structurally, the HBV virion consists of an envelope containing three 
HBV secreted surface proteins (S-, M-, and L-proteins) and lipids. Also, HBV virion contains an icosahedral nucleocapsid, 
which is constituted by the core protein (HBcAg) enclosing the viral DNA genome in a covalent linked manner to the 
terminal protein of the HBV DNA polymerase. Adapted from Pollicino et al, 2014 
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resolutions: is recycled into the nucleus to preserve the cccDNA supply levels or it is wrapped and 
secreted via the endoplasmic reticulum due to their excess amount of proteins produced exceeding the 
level needed for virion assembly2. This excessive number of proteins, mainly envelope proteins, are 
subjected to dimerization/multimerization processes, which result is a mature growth in the 
endoplasmic reticulum (ER) and/or Golgi compartments as non-infectious spherical and filamentous 
SVPs or as virions (Figure 1.3). In a typical manner, these SVPs outnumber the virions values by 
1000 to 10000-fold13–16. This characteristic may explain why SVPs are constantly found within the 
circulating immune complexes as well as immune tolerance induction by the mechanism of “viral 
apoptotic-like mimicry”13,17. Like other viruses that affect hepatocytes and the liver, HBV genome 
integration in the host genome may occur in a randomly manner. Despite not being mandatory for 
viral replication, viral genome integration is still involved in hepatocyte transformation, as well as a 
source for new infections13.  
 
 
1.1.1 Genetic Variability of HBV  
Due to the lack of reverse transcriptase proofreading activity, there is a movement towards the 
emergence of new viral mutations affecting HBV genome configuration. As a result, these frequent 
mutations can induce the appearance of genetically unique viral species, also notated as quasispecies, 
which will mature due to tension from the different hosts1. The relationship between the different 
characters of an HBV infection, the host, the virus, hepatocytes, immune responses and even antiviral 
treatments are believed to push towards the emergence of hepatitis B virus mutants. On their 
Figure 1.3. HBV life cycle. HBV enters hepatocytes through  the NTCP channel, followed by the uncoating and consequent 
nuclear transport of the rcDNA. The rcDNA is converted in cccDNA, which serves as the template for transcription of the 
preC RNA, pgRNA, preS/S mRNAs, as well as HBx mRNA. Shortly after these RNAs are transported to cytoplasm, where 
protein translation takes place. The pgRNA is selectively bundled inside core particles, and subjected to reverse 
transcription, where it is degradated and gives place to RC DNA. Such mature core particles can be enveloped for release as 
virions or transported to the nucleus to generate more cccDNA. Adapted from Balmasova et al, 2014. 
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counterpart, these HBV mutants have the competence to evade several immune stimuli or antiviral 
treatment responses1,5 These mutations that accumulate in the different viral genomes echo on the 
duration of active HBV infection and consequently the strength rate of the immune response towards 
the virus2. The relationship between virus/host is always present in the immunologic features of any 
infectious disease as a measurement for the virus itself survival or dissolution1,5,18. Presently, and 
throughout the analysis of genome-wide nucleotide diversity, 9 genotypes (A-I) and several sub-
genotypes were identified for HBV18. Also, the existence of a 10th HBV genotype (J) is considered, 
but its characterization is not fully understood. HBV genotypes differ in their genomic sequences, as 
well as their geographic distribution around the globe acting in a diverse manner. Nonetheless, all 
HBV genotypes induce and affect the transmission, progression and pathologies on HBV disease 
progression. Despite considering that there is not a more common HBV genotype than others, it is 
thought that HBV genotype C can be considered as critical, since it shows an increased viral mutation 
rate and high replication capacity, which is correlated to the emergence of cirrhosis and hepatocellular 
carcinoma (HCC) in chronic HBV patients. 
1.2 Immunopathogenesis of Chronic Hepatitis B  
Like other infectious diseases, Hepatitis B is known for having two initial stages, an acute and 
a chronic stage of infection. While these two stages share some similarities, they are still distinct. The 
main characteristic distinguishing these two stages, besides the timeline of infection, is whether the 
infection occurred perinatally/early infancy or already in adulthood. The other parameter that differs 
between the two stages is HBV immunopathogenic mechanisms, with several immune response 
pathways along the course of disease progression in infected patients. 
In acute resolving infections, HBV-infected adults normally acquire self-limited and short-
term hepatitis, and it is estimated that in 95% of the infections indeed end with viral clearance, as well 
as establishment of protective antibodies19,20. It is also theorized that innate and adaptive immune 
responses to HBV are decisive and well timed, when encountering a case of acute resolving infection 
improving the chance for viral clearance1. Thus, it is essential that a strong adaptive T cell reaction 
takes place early for control of infection, which leads to a cytolytic dependent/independent antiviral 
outcome via the expression of antiviral cytokines such as interferon γ (IFNγ) and tumor necrosis 
factor α (TNFα), as well as B-cells stimulation 21,22. Upon stimulation, B-cells start secreting 
neutralizing antibodies that alongside antiviral cytokines prevent additional hepatocyte infection and 
virus spreading21. Furthermore, since viral spread is inhibited and hepatocyte turnover mechanisms 
occur there is a decline in HBV cccDNA levels1. However, when the infection progresses to a chronic 
state HBV specific T-cell function becomes impaired. Therefore, there is a decrease in proliferation, 
cytotoxic activity and production of antiviral cytokines such as IFNγ and TNFα, leading to 
phenomenon called T cell exhaustion 23. During its chronical state, HBV infection spread exerts its 
effect through various disease stages, which are strongly thought to be associated with age1. 
Interestingly, it was recently observed that HBV infection acquired at younger age, for example 
perinatally, shows a tendency for evolving to a state of chronic HBV infection. In addition, it is 
thought to be directly related to their immune profile, since it is less compromised when compared to 
older infected patients and more susceptible to disease progression21,22,24. 
HBV is acknowledged for its capacity on engaging several immune elements during the 
natural course of infection, as it manages to adapt and progress through its pathogenesis25. 
Pathologically, HBV chronic patients display a greater risk to develop cirrhosis and HCC. 
Nonetheless, HBV is unable to have a direct cytopathic outcome on hepatocytes and currently it is 
well-established that hepatocytes death in chronic hepatitis B (CHB) patients results from their 
apoptotic state as consequence of immune responses, due to active viral replication and liver 
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injury19,26,27. HBV-specific cytotoxic lymphocytes (CTLs) are considered key players in hepatocytes 
killing, since they show strong reactivity responses to viral antigens in chronic HBV infection. Per 
contra, these lymphocytes are not strong enough to mediate the full eradication of HBV19,28,29. In 
concordance, CTLs try to mobilize HBV-nonspecific inflammatory cells such CD8+ T cells, natural 
killer (NK) cells and neutrophils19,30. All these immunological players consequently induce CHB 
immunopathological functions. Despite all the continuous immune responses against HBV infection, 
it is still not clear why viral clearance is so rare in HBV patients, since HBV-specific T cells are 
exhausted and incapable of killing infected hepatocytes, which means no liver injury and no control of 
infection19,25,31. During HBV chronic infection, there is a progressive synergistic relation between the 
viral replication and host immune responses to HBV1. However, not all patients exhibiting chronic 
HBV infection progress and develop CHB1. CHB has been divided in different stages according to its 
natural viral progression 25,32. Also, its nomenclature has changed over time, since new scientific 
breakthroughs about the disease were discovered, as well as parameters present in HBV regulation. 
Recently, chronic HBV infection is divided into 4/5 branches or states, depending on the report1. 
Chronic HBV nomenclature bears in mind distinct parameters such as the presence of HBeAg (HB e 
antigen), HBV DNA levels, alanine aminotransferase (ALT) values and the presence/absence of liver 
inflammation25,31 (Figure 1.4). Also, the new chronic states annotations are mainly based in two 
central attributes of chronicity: infection and hepatitis1. Nonetheless, it is wrong to establish an 
immediate viral infection stage classification, since a single measurement of HBV replication markers 
and disease activity mediators might not be enough to take solid conclusions. Thus, evaluation and 
monitoring of the different disease parameters is necessary to speculate about possible therapeutic 
approaches administered individually or in group against HBV. Curiously, despite the 4/5 existing 
phases for HBV chronic infection, it does not necessarily mean that all phases follow a sequential 
order. 
CHB infection initial stage is nominated HBeAg-positive or, as previously called, “immune 
tolerant phase”1,4 (Figure 1.4). Also, this stage is well-characterized by the presence of HBeAg in 
patient’s serum, high viral load (HBV DNA) and ALT values within the documented range of 
approximately 40 IU/L1,4,25,31,33,34. As for the liver inflammatory level within this infection stage, there 
is no apparent necroinflammation or fibrosis in liver tissues1,25,34,35. However, HBV DNA integration, 
as well as clonal hepatocyte spread, might still occur. Furthermore, this could be an indication of 
initial hepatocarcinogenesis manifestations1,4,36,37. The preservation of HBV specific T-cell 
functionalities is more frequent and prolonged in this stage, progressing until young adulthood if 
patients are infected perinatally4,36–38. Importantly, loss and seroconversion of HBeAg to anti-HBeAg 
is normally low in this phase, which decreases the chances of disease remission4,25,39,40.  
As HBV infection progresses, ALT values show a tendency to increase leading to the next 
chronic HBV stage - CHB HBeAg positive or “immune clearance stage”1,4 (Figure 1.4). Nonetheless, 
HBeAg frequency in patients’ serum and HBV DNA levels remain similar to the previous stage, 
whereas in the liver the signs of necroinflammation and fibrosis become moderate or even severe in 
singular cases1,4,38,41. This medical condition is frequently found among subjects infected during 
adulthood and it may arise after numerous years of the previous disease state1. CHB patients in this 
stage can have one of two outcomes – manage to seroconvert HBeAg and suppress HBV DNA levels 
or fail to control HBV infection – the latter allowing the entrance in the HBeAg negative CHB phase 
1,4,38,42. 
Following this, since HBeAg loss gives rise to the production of anti-HBeAg, CHB patients 
eventually reach the “inactive carrier stage” or currently noted as HBeAg negative CHB infection 
phase1,4,25,43 (Figure 1.4). At this stage, HBV patients are subjected to a change in the parameters 
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defining chronic HBV infection4. Patients’ serum shows traces of anti-HBeAg in constant rise, HBV 
DNA levels are considered minimal and ALT parameter is described as stable and in mild values. In 
addition, the risk for disease progression into a cirrhosis and HCC in this stage is considered low 
1,38,44. Although this CHB phase is considered stable, there are cases of patients suddenly progressing 
deeper into the infection, which could be related to the emergence in viral load with no apparent 
changes in liver ALT values, but residual signs of necroinflammation45. The HBeAg negative CHB 
infection phase is also characterized for showing low levels of HBsAg loss, which means that 
seroconversion of HBV’s antigen is minimal and is extremely difficult to spot on in patient’s serum 
1,45. Nonetheless, in 20%-30% of the inactive HBsAg carriers, spontaneous reactivation of hepatitis B 
may occur, which can lead to a disease progression and development of liver damage and 
decompensation 4. As HBV infection progresses, patients are likely to enter the HBeAg-negative CHB 
stage. Here, the lack of HBeAg in patients’ serum is characteristic, as well as fluctuations in HBV 
DNA levels, which might be correlated to an increase of ALT in the liver. The aforementioned phase 
is associated with low rates of spontaneous disease remission, perhaps since nearly all the patients 
within this phase demonstrate to have HBV variants accommodated within the precure/basal core 
promoter regions, leading to an impairment/abolishment of HBeAg manifestation. 
The last official phase in chronic HBV infection is called the HBsAg-negative phase but can 
also be denominated by “occult HBV infection”1 (Figure 1.4). The latter denomination relies on the 
fact that this stage is hypothesized to occur during all the previous HBV infection phases mentioned, 
though its diagnostic time point is not fully understood. Furthermore, this stage is characterized for 
showing no detectable antibodies for HBsAg in patients’ serum, positive antibodies for HBcAg (anti-
HBcAg) and normal ALT levels. Also, the majority of patients in this late HBV infection stage show 
undetectable traces of cccDNA) in the serum, although it is normally detected upon liver histological 
exams. HBsAg loss and seroconversion in this stage is correlated to disease progression into more 
extreme pathologies such as cirrhosis or HCC, since this HBV antigen is known to mediate HBV 
progression. Nonetheless, CHB patients’ survival rate is increased if HBsAg loss takes place before 
liver flares and cirrhosis outbreaks. However, in cases where patients show signs of cirrhosis or HCC 
but HBsAg loss is insignificant, it is possible that HBV reactivates, leading to a possible death. 
Table 1.1 Phases of chronic HBV infection. 
Legend: ALT, alaninaminotransferase; IU, international units; NA, nucleos(t)ide analogues; PEG-IFN, pegylated 
interferon alfa; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; LHBs, large hepatitis B surface protein; 
anti-HBc, antibodies to hepatitis B core antigen; HBcrAg, hepatitis B core-related antigen; RNA, ribonucleic acid; 
DNA, deoxyribonucleic acid.The risk for disease progression and the need for treatment is indicated by colour shading: 
red: high risk for disease progression / treatment required, yellow: low risk for disease progression / monitoring 
required, green: no disease progression / no action required. aMonitor in case of cirrhosis or immunosuppression. 
9 
 
1.2.1 T-Cell exhaustion  
Innate and adaptive immunocyte activation is regulated by a set of inhibitory surface receptor-
ligand pairs or checkpoint inhibitors46. It is well established that the presence of anti-viral T cells 
contributes to the eradication of acute infections, restrains the resurgence of latent viral infections and 
controls the viral loads during chronic infection, as these cells are crucial elements of the adaptive 
immune response47. Typically, naive T cells recognize antigen peptides presented via their T-cell 
receptor (TCR) and become activated, being liable to clonal expansion as well as differentiation into 
potent effectors48. When in a differentiated effector state, T cells show high cytotoxic levels, produce 
effector cytokines such as IFNγ and TNFα and express chemokine and homing receptors, which 
allows them to migrate to peripheral tissues and infection sites48–50. However, the host immune system 
fails to respond if there is a continuous TCR stimulation due to the persistence of high levels of 
antigens, leading T cells to enter a state nominated T cell exhaustion51,52. Fundamentally, T cell 
exhaustion is characterized by the endurance of high levels of antigens, that leads to a repeated T cell 
dysfunctional state and an increase of distinct inhibitor receptors (IR), a gradual depletion of effector 
cell functions translated by the loss of effector cytokine secretion levels (IL-2, IFNγ and TNFα), as 
well as a change of these cells metabolism and transcriptional profile 51,53–55. Also it is well-
established that exhausted T cells are characterized by the upregulation of surface markers such as 
PD-1, TIM3 and LAG3, investigated during the course of this project.  
1.3 Treatment Strategies  
Hepatitis B virus (HBV) remains a major healthcare challenge, and according to the World 
Health Organization (WHO), hepatitis viral infection is still the eight most frequent cause of mortality 
worldwide56,57). HBV is estimated to affect approximately 400 million people around the globe, and 
despite the existence of a prophylactic vaccine, there is still no definitive curative treatment for the 
more than 240 million people globally that are considered chronically infected with HBV57. CHB 
patients show a higher risk of death due to an inherent tendency to develop other severe pathologies, 
including liver cirrhosis and HCC8,57 . Prophylactic vaccination against HBV contains the envelope 
protein S and is either produced by processing of HBsAg retrieved from HBV carriers’ plasma, or 
from the yeast specie Saccharomyces cerevisiae, holding a recombinant DNA plasmid that also 
expresses the S protein58–60. Currently, there is another type of prophylactic vaccine, which 
encompasses the S and M envelope proteins obtained from genetically engineered ovary cell lines58–60. 
Even though HBV infection can be prevented by a recombinant yeast-derived prophylactic vaccine, 
the treatment is mostly available in developed countries and is mainly administered to infants and 
newborns. It is still extremely difficult for some undeveloped countries individuals to be granted 
access and acquire this preventive treatment, mainly due to its limited availability and high cost. 
Nonetheless, it appears that 184 of the 196 countries in the world are able to get a safe and effective 
prophylactic vaccine, at least for children8). In compliance with the number of chronically infected 
HBV patients globally and high mortality rate, the formulation of new and more efficient therapies is 
necessary. Also, efforts are being made by the scientific community to develop different therapeutic 
vaccines to substitute the prophylactic treatment, which can endure the clearance of circulating 
HBsAg and convert these to a state of recognition by antibodies of HBsAg, also called HBsAg 
serocoversion28,57.  
1.3.1 Nucleos(t)ide analogues and Interferon-Based therapies 
Currently, there are two treatment therapies approved for CHB patients: nucleos(t)ide 
analogues (NUCs) and IFN-based therapies such as pegylated interferon-α (PEG-IFNα)56,57. Despite 
demonstrating very interesting results among hepatitis B infected patients, unfortunately these 
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treatment regiments are still far from a satisfactory cure and complete eradication of the virus. When 
used separately, these two therapies work in distinctive manners. NUCs therapy impact positively on 
adaptive immunity61, suppressing viral replication by directly targeting virion synthesis61,62. However, 
this therapeutic drug does not successfully eliminate the nuclear persistence form of the virus genome, 
cccDNA, from all liver infected hepatocytes56,57. This eventually leads to an HBV infection rebound 
and hepatic flares upon treatment withdrawal56,63,64. For chronically infected HBV patients, NUCs 
treatment is considered life-long, representing an immense financial liability and latent systemic drug 
toxicity56,57,63. Another concern about using NUCs as a therapy against HBV infection is the possible 
appearance of drug resistance mutants in chronic patients due to its prolonged use65. Thus, these drugs 
can also be nominated as antiviral inhibitors, acting on HBV reverse transcriptase activity and 
disturbing its viral life cycle66. There are some NUCs available for clinical treatment, such as 
lamivudine (LAM), adefovir, entecavir (ETV), telbivudine and tenofovir (TDF)8,67. Although the use 
of NUCs show some contradictory effects, this antiviral therapy has shown to be effective as a 
functional cure. This kind of treatment provides the normalization in ALT levels, suppression of HBV 
DNA in patients, histological improvements and decreased liver inflammation and fibrosis8. As for 
HBeAg and HBsAg, it is hypothesized that NUCs treatment leads to a possible loss and 
seroconversion of both HBV specific antigens, but more studies should be performed in the clinics8. 
Besides using NUCs as a controlled treatment against CHB infections, it is currently very 
common to combine this medication with an IFN-based therapy57. IFN-based therapies, also called 
cytokine-mediated therapies, are new treatment strategies known for the enhancement of the immune 
system through the production of interferon-stimulated genes (ISGs) and their cytotoxic activity in 
killing HBV infected cells66,68. This therapeutic approach includes PEG-IFNα, and together with 
NUCs is the best line of attack against HBV infection, with particular attention for CHB patients66. In 
contrast to NUCs antiviral treatment, PEG-IFNα therapies currently show a higher efficacy response 
on the innate immune response61,69,70. Despite this, PEG-IFNα treatment and other IFN-based 
therapies can only grant an HBV cure to 10-15% of the treated patients57. Nonetheless, this treatment 
is strongly recommended for chronically infected HBV patients with no medical history of liver 
diseases, since PEG-IFNα is associated with severe side effects, including flu-like symptoms and the 
occurrence of hepatic flares57,66,71,72. Interferon α (IFNα) drugs are typically administered 
subcutaneously/intramuscularly on CHB patients, and lead to a decline of HBV DNA serum levels 
and viral replication rate. Consequently, this causes a reduction in HBV transcription, as well as 
enhancer activity in the host genome65,66,73. Also, IFNα therapy results in a decay of HBV virions, 
DNA polymerase, as well as HBcAg levels linked to HBV virions due to an inhibition of its reverse 
transcriptase activity65,66,74. The use of PEG-IFNα compared to standard IFNα has resulted in a 
significant reduction of HBV DNA and ALT levels in CHB66,75. Interestingly, IFNα was recognized 
as an up-regulator of APOBEC3A/C3B proteins, causing cystidine deanimation and degradation of 
cccDNA, without affecting the host genome3,66,76. These two drug treatment strategies are often 
combined, demonstrating higher reduction in HBV DNA serum levels, inhibition of HBV replication 
and lower ALT levels. However, even when combined, these treatments are unable to eradicate 
cccDNA from all infected cells, and it is very common for patients to experience a rebound of the 
viral load and ALT levels increase upon withdrawal of the medication. This might be due to the 
increase of cccDNA persistence as main cause and drug-resistance to the medication, hence it is 
considered a life-long treatment61,65,66. 
1.3.2 Therapeutic Vaccination 
Since HBV is capable of hampering adaptive and innate immune responses, it is of the utmost 
importance to find a new therapeutic approach that boosts the immune system and further enhances 
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the efficacy of the current antiviral therapeutic regimen58. The development of therapeutic vaccination 
is meant to activate the immune system in infected patients, in order to fight against, control, or 
ideally eliminate the established infectious pathogen57. In CHB patients, the objective is to reinforce 
the immune system to a point in which cccDNA clearance from HBV infected hepatocytes is 
achieved. Many studies have been published on the development of therapeutic vaccination against 
the HBV58. For the past 20 years, several clinical trials have been made regarding numerous 
therapeutic vaccination strategies, but the end results are far from excellent and cccDNA clearance is 
still impossible to accomplish57. Nonetheless, the scientific community is working to develop a 
therapeutic vaccine that can grant a definitive cure for CHB patients, instead of a functional one 
obtained with the available antiviral treatments. To the best of our knowledge, recombinant peptide-
based vaccines77–85, DNA-based vaccines86–88, viral vector-based vaccines89,90 and cell-based vaccines 
91,92 are being studied and are presently the most promising therapeutic vaccination approach57,58.  
In a simplified manner, the primary attempts to develop a therapeutic vaccine for HBV were 
peptide-based vaccines, and Pol S and co-workers were the first conducting a HBV therapeutic 
vaccination trial to test the efficacy of this vaccine nature in CHB patients58,77. This kind of 
therapeutic vaccination is easily produced and induces high titers of HBV-specific antibodies. Despite 
the efforts, peptide-based vaccines still show weak cellular immunity responses and require adjuvant 
and continuous administrations58,93. However, it seems that there is a substantial decrease in serum 
HBV DNA levels and viral replication, but no significant diminished in HBsAg levels in most of the 
patients tested58,77. Still, there is evidence that peptide-based vaccines for HBV will activate T cells 
responses, reduce HBV viral load and quicken HBeAg seroconversion frequency in CHB patients58,94. 
Another peptide-based vaccine approach involves the combination of recombinant HBV core particles 
(HBcAg) with HBsAg58,95. The combination of recombinant HBsAg with anti-HBs antibodies to form 
an antigen-antibody immune complex (IC) became a motivating method for developing therapeutic 
HBV vaccination58. Noteworthy, it is thought that these ICs may improve the chance of HBsAg being 
captured by antigen presenting cells (APCs), therefore enhancing the immunogenic effects of the 
vaccine and inducing more potent HBs-specific T cell responses58,96.  All peptide based vaccines so 
far have failed to induce sustained HBV-specific T cell responses in CHB patients. Though, with all 
the clinical trials performed so far, the medical community suggests that repetitive adjuvant 
vaccination might result in an inflammatory environment and stimulate pre-existing T cells in the 
liver58,81. This hypothesis is based on T cell responses detected upon therapeutic vaccination due to an 
effect registered on pre-existing T cells, indicating that patients with active liver inflammation may 
benefit more from therapeutic vaccination58,81,82.  
On the other hand, DNA-based vaccines encoding HBV envelope proteins are also under 
investigation as a therapeutic vaccination against HBV chronically infected patients57,97,98. This 
vaccination type induces humoral and cellular immune responses, including CD8+ and CD4+ T cell 
responses58,99. It seems that patients’ immune response after DNA-based vaccines administration is 
similar to that of individuals whose HBV infection was cleared. Furthermore, since HBV-specific 
IFN-γ-secreting T cells show upregulated levels upon treatment with this vaccination regimen, this 
strategy is promising, since it induces effective but transient T cell responses58,88,99,100. However, 
DNA-based vaccines fail to achieve HBeAg and HBsAg seroconversion, and they are not able to 
induce a consistent T cell response with reduction of viremia levels in chronic HBV patients57,97,98.  
Viral vector-based vaccines are another therapeutic vaccination approach to cure HBV, as 
these vaccines foundation is based on live attenuated viruses capable of broad stimulation and 
sustained immune responses58. In particular, adenoviral and modified vaccinia virus Ankara (MVA)-
based vectors have been tested in clinical trials, since these vaccines have an extensive stimulation 
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Entry Inhibitors
Interaction with sodium (Na+) - Taurocholate Cotransporting Polypeptide (NTCP) and 
decreases viral infection rate i.e Myrcludex
Silencing & Eliminating cccDNA 
cccDNA targeting through use of antiviral cytokines, blockade of RcDNA or via epigenetic 
regulation possibly leads to viral DNA degradation and elimination from infected hepatocytes i.e 
CRISPR/Cas9  and histone deacetylase (HDAC) inhibitors
Secretion Inhibitors Inhibition of HBsAg secretion i.e nucleic acid polymers
HBV Polymerase Inhibitors 
Promote the inhibition of the reverse transcriptase mechanism by heapatitis B polymerase and help 
in suppressing viral expansion
Core Allosteric Modulators (CpAM)
These agents stimulate the inhibition of nucleocapsid assembly, during hepatitis B life cycle, which 
incapacitates pgRNA encapsidation and results in the capture of viral RcDNA
Silencing RNA 
Prevent HBV replication by using HBV-specific small molecules that interfere and silence RNA 
resulting in reduced cccDNA levels in infected hepatocytes i.e RNA interference (RNAi)
Immune Stimulation 
Induce a stimulatory effect in the immune system. Agents for immune stimulation include pattern 
recognition receptor (PRR) agonists, Toll-like receptor 7 (TLR7, GS-9620), as well as TLR1/2, 
retinoic acid inducible gene I (RIG-I), and stimulator of interferon genes (STING)
Immune Modulation & Cytokines 
Innate cells have been identified for their role in immune tolerance. For example, NK cells 
demonstrate to have a regulatory role upon HBV-specific T cells via upregulation of a death 
receptor and myeloid derived suppressor cells have been shown to influence the adaptive 
immune response. On the other hand, the modulation of innate-adaptive interactions could 
also hold therapeutic promise, as cytokines such as TNFα, IL-2 and IL-12 have been implicated 
in HBV replication inhibition in vitro.
Checkpoint Inhibitors 
HBV-specific T cell are exhausted and overexpress inhibitory molecules such as programmed 
death-ligand 1 (PD-1), TIM3 and LAG3. However, in case of these molecules blockade as shown 
potential in vitro, with special attention in hepatocellular carcinoma medical conditions. 
T cell Therapies 
Increasing the number of HBV-specific T cells by autologous infusion of T cells expressing 
chimeric antigen receptors (CARs) or by engineering T cells to overexpress human leukocyte 
antigen (HLA)-restricted HBV-specific T cell receptors (TCRs).
Viral Targets
Immune Targets
range in immune responses like T cell-mediated immunity57. Nevertheless, vaccination strategies 
should combine different viral vector-based vaccines with other vaccination therapies like DNA-based 
vaccines, and recombinant antigens57,90. Finally, a vaccine strategy called cell-based vaccination was 
developed based on the role of innate immunity in HBV infection, as it aims to stimulate pattern 
recognition receptors (PRR). The objective is to induce a stimulatory response on different immune 
regulators like toll-like receptors (TLRs) and APC receptors (e.g. dendritic cell, or DC, receptors), 
which in turn can stimulate specific CD4+ and CD8+ T cells and direct them at HBV-specific infected 
cells58,101.  
New and more compelling therapeutic vaccination strategies have been developed and 
entering clinical trials recently (Table 1.2). However, these likely require new potent vaccine 
components and schemes that could induce more effective humoral and cellular immune responses. 
Besides this, it is necessary to include checkpoint inhibitors or other similar strategies that could 
overcome T cell exhaustion in chronic HBV infected patients, as well as lowering HBV specific 
antigen levels as a preventive action for T cell attrition in patients with low antigen loads57. 
 
1.4 Mucosal-associated Invariant T Cells: What are they? 
From an immunological point of view, the liver is considered one of the most important 
organs in the human body102. This aspect is supported by the fact that, even after being continuously 
exposed to non-self-food and microbial-derived products from the gut, the liver remains sterile and 
tolerogenic in homeostasis103. Nonetheless, in situations where the intestinal mucosal defenses are 
Table 1.2. New therapeutic strategies against chronic HBV infection. These strategies aim to target either a viral target, 
or modulate immune system components to overcome the viral infection. Adapted  from Gill, Upkar S and Kennedy, Patrick 
T.F, 201.   
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Figure 1.4 MAIT cells developmental stages, phenotype and frequency in the thymus, cord and adult peripheral 
blood. Adapted from Dias Joana, 2017. 
ruptured, or in presence of a systemic infection, this organ acts as a second ‘firewall’, through its 
enrichment with innate effector cells, which rapidly respond to infections or tissue damage102,103.  
Mucosal-associated invariant T (MAIT) cells are described as the most abundant subset of 
unconventional and innate-like T cells in humans104. MAIT cells are evolutionary conserved among 
different species and seem to be highly abundant in human mucosal tissues, peripheral blood and 
liver104. Also, there are evidence suggesting that MAIT cell can recognize microbial riboflavin 
metabolites (Vitamin B2) secreted by numerous bacteria and fungi species presented via the non-
polymorphic major-histocompatibility complex (MHC) Class-I related molecule (MR1)105,106. Due to 
the strong evolutionary conservation of this molecule (MR1) and the lack of riboflavin metabolite 
antigens variety, it is proposed that these cells are homogenous in their responses against several 
microbes that hold the biosynthesis pathway for riboflavin metabolites104–106. These T cells subset are 
defined by the expression of a semi-invariant αβ TCR) combined with a specific segment (Vα7.2) and 
high expression levels of the C-type lectin receptor CD161. These two receptors are well-established 
for describing, define and isolate MAIT cells in healthy humans.  However, it seems that recent 
studies showed that the IL-18 receptor α subunit (IL-18Rα), in combination with the TCRVα7.2 
marker, can be used to define MAIT cells in humans107–109. It is known that MAIT cells demonstrate 
higher tendency to accumulate at the infection sites, providing a protective role in some experimental 
infection models104. 
1.4.1 MAIT cells Development and Tissue Distribution  
In resemblance to other T cells subset like NK T cells, MAIT cells development starts in the 
thymus110,111, where these cells undergo a pre-selection by MR1-expressing CD8+CD4+ thymocytes112. 
Using transgenic mouse models and thymic organ cultures, Seach and colleagues were able to 
determine that MR1-expressing double positive thymocytes  have a vital role in MAIT cells selection 
mechanisms during their maturation development113,114. Also, other cells types such as thymic B cells 
and DCs are apparently redundant in MAIT cells selection in the thymus112. MAIT cells phenotype 
shows differences, depending on these cells’ location in the human body, as well as their 
developmental stage. When in the thymus and cord blood, MAIT cells exhibit a naive phenotype, 
characterized by being CD45RA+CD45RO- 111,115,116. On the other hand, peripheral blood MAIT cells 
are CD45RA-CD45RO+CD28+CCR7-CD62L-, which marks these cells as effector memory 
cells110,111,115. Nevertheless, Koay and colleagues proposed that MAIT cells maturation and 
development consists on a three-stage pathway, and is based on the expression of two markers in the 
thymus, CD161 and CD27 (Figure 1.5) 117.  
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In stage 1, in thymus, CD161-CD27- MAIT cells would be predominantly CD8+CD4+ or 
CD4+ only, whereas in stage 2, besides the latter described, MAIT cells could also be CD8+ only. 
Nonetheless, in stage 2 MAIT cells could be defined for being CD161-CD27+, characterizing this 
development stage in the thymus. Lastly, during stage 3, MAIT cells are CD161+CD27+, in the 
thymus as well as mostly CD8+ and CD8-CD4- in the thymus. However, MAIT cells in the latter stage 
are rare in the thymus, while abundant of cord and peripheral blood, which suggests that MAIT cell 
functional maturation occurs after these cell are translocated out of the thymus117. Besides this, MAIT 
cells are known for expressing the CD8αβ co-receptor exclusively in the thymus and cord blood116,117, 
while adult peripheral blood MAIT cells show evidence of CD8αβ or CD8αα expression (Figure 
1.5)111,116,117. Due to their effector memory phenotype, human peripheral blood MAIT cells are 
referenced as expressing different transcriptional factors such as PLZF, RORγt115,118,119, as well as T-
bet, Helios, and Eomes at low, intermediate and high levels, respectively118. These transcription 
factors are known for having a role in effector function, proliferation and activation in CD8+ T 
cells120–122. Furthermore, adult peripheral blood MAIT cells also express receptors for IL-12, IL-23, 
and IL-7 115,123,124, adding up to IL-18R, a well-established MAIT cell receptor. The NK cell receptor 
NKG2D, the T cell activation antigen CD26, and the multidrug resistance protein 1 (MDR1) are also 
described as being expressed by MAIT cells at different degrees115,125. It is strongly suggested that 
peripheral blood MAIT cell population tends to gradually expand with age126–128 and reaches a 
frequency ten times larger than initially seen in the thymus and cord blood117. MAIT cell populations 
range between 1 and 10% of the total circulating T cells111,115, although their frequency is associated 
to a high variability among individuals. Also, the frequencies of CD8+ and CD4+ MAIT cells show a 
tendency to inversely decrease and increase with age, respectively127,128. 
Adult peripheral blood MAIT cells are known to express a very distinct mixture of chemokine 
receptors which moderate their cellular trafficking to the peripheral tissues102. Indeed, MAIT cells 
prefer to home to the peripheral tissues, mainly due to the expression of CCR6 and CXCR6, liver-
homing receptors, as well as gut-homing integrin αβ47 and intermediate levels of CCR9, which is also 
expressed by T cells102,115,129. These receptors have an interesting function in lymphocyte migration to 
the gut. Human MAIT cells percentage is enhanced in the liver, constituting approximately 15% to 
50% of the hepatic T cells, staging as the most predominant T cell subset population expressing the 
markers CD161 and CD56115,123,130–132. Despite being considered the largest T cell subset and 
preferably allocated within the gut, MAIT cells present highly variable frequencies, according to 
which peripheral tissue they are encountered in102,104,132. MAIT cells have been found in several 
compartments of the small intestine, ileum, duodenum and jejunum, as well as within the large 
intestine, colon and rectum102. MAIT cells are also abundant in peripheral blood (≈1-10% of T cells) 
in which they are representative of a homogenous subset of CD4- T cells known to express the 
TRAV1-2 chain together with the CD161, CD26 or IL-18Rα markers 104,111,115,116. The presence and 
expression of chemokine receptors, such as CXCR6 and CCR5, illustrates these cells ability to transit 
to the lungs (≈2-4% of T cells)115,132. There is also evidence of the presence of MAIT cells in the 
stomach (≈2.5% of T cells). More recently it was discovered that MAIT cells have a small frequency 
in the endometrium and cervix (≈1-2% of T cells), and partially in the human skin. Transcripts for 
MAIT cells T cell receptor were also detected in other human organs, including kidneys, the ovaries 
and prostate 133. Although MAIT cells are widely distributed among the human tissues, studies show 
traces of these cells in the lymphoid tissues, but in a low frequency115. This aspect may be related to 
the lack of expression of CCR7 and CD62L, two receptors known to have an important function in 
lymph node homing132,134,135. Since MAIT cells are widely distributed within the human body and are 
highly frequent in the liver, these cells might be a new approach for HBV, as well as other liver 
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diseases as a possible new therapeutic approach, since MAIT cells can sustain exhaustion and show 
activation in adverse environments.  
 
1.4.2 Antigen presentation to MAIT cells 
1.4.2.1 - MAIT Cell TCR  
In 1993, while evaluating CD4-CD8- human T cells TCR repertoire, Porcelli uncovered the 
presence of two invariant TCRα chains sequences - Vα24-Jα18 and Vα7.2-Jα33136. These TCRα 
chains were characterized based on one Vα gene coupled to one Jα within the CDR3α loop region in 
the TCR and are currently notated as TRAV10 and TRAV1, respectively 106,137,138. Later, these 
invariant TCR sequences were shown to be characteristic of NK T cells and MAIT cells, two innate-
like subsets of canonical T cells110,139. Nowadays, it is well-established that, besides being relatively 
evolutionary conserved among mammals, MAIT cells’ TCR is also considered semi-invariant, which 
is strongly related to MAIT cells attributes regarding the adaptive and innate immune 
system104,108,113,140. Furthermore, the majority of human MAIT cells display the canonical TCRα chain 
defined by a Vα7.2-Jα33 rearrangement110,133,141. However, it is now known that a minority of these 
cells TCRα chain can represented by different rearrangements - Vα7.2-Jα12 or Vα7.2-Jα20 
102,132,133,141. Human MAIT cells TCRα preferentially pair-wise with TCRβ-chains Vβ2 or Vβ13.2, 
indicating lack of TCR diversity113,133. Nonetheless, this MAIT cells feature can be seen as 
advantageous in recognition and response initiation upon encounters with different pathogens113,114. 
1.4.2.2 – MR1 
MR1 is a non-polymorphic gene located on chromosome 1 in humans and was first sequenced 
in 1995102,132,142. Currently, this gene is well-established as an antigen-presenting molecule and is 
ubiquitously expressed in all cells138,140. Nonetheless, in a steady state, endogenous surface MR1 
expression has been difficult to detect with anti-MR1 staining on non-transfected MR1 
cells108,132,140,143–146. Interestingly, the MR1 molecule is highly conserved among mammals, displaying 
an increased homology with classical MHC class I molecules in humans and mice regarding their α1 
and α2 domains 106,132,140,142,147,148. So far and through alternative splicing, four human MR1 isoforms 
have been characterized and are notated as MR1A to MR1D106,132,147. The A isoform resembles the 
full-length protein originally discovered with 341 amino acids and all the structural characteristics of 
the classical MHC class I molecules106,132. These features include a leader sequence or signal peptide, 
three extracellular domains (α1 and α2 domains which form the ligand-binding pocket containing 
conserved residues of MHC-I molecules and the α3 domain that interacts with riboflavin residues), a 
transmembrane domain and a short intracytoplasmic domain with unknown trafficking function so 
far106,132,149–151. As for the remaining human MR1 isoforms all seem to be non-functional, since they 
lack some of the structural domains preserved in the full-length protein106,152. However, the MR1B 
isoform despite lacking the α3 domain it can still function as an antigen-presenting molecule due to 
the conservation of the transmembrane domain106,153. This isoform is expressed on the cell surface 
forming homodimers and consequently activating MAIT cells in the presence of bacterial species, 
despite absence of β2m (riboflavin)153,154. In vitro studies performed on MAIT cells activation and 
MR1 blockade have given insight on MR1 and suggested that MR1 antigen presentation is β2m-
dependent but TAP-independent110,114,146. Currently, it is widely accepted that MR1 presents lipid-
based and vitamin B-based antigens143. This observation was proved in crystallography studies where 
MAIT cells exhibited reactivity in the presence of bacterial species that could synthesize riboflavin 
(Vitamin B2) or similar precursors due to MR1105,114,143,149. Vitamin B2 metabolites would bind to MR1 
an activate MAIT cells 105,149. Structurally, MR1 and MHC-I are similar both forming a heterodimer 
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with B2m and with α1 and α2 domains having a two α-helices sitting atop a 7-strand antiparallel β-
sheet rearrangement143,149. Furthermore, the MR1 structural groove consists of two distinctive sections 
– A’pocket and F’pocket143. There is a direct alignment of the A´pocket with aromatic and polar 
residues, which potentiates the binding of pyrimidine, lumazine and pterin-based antigens143. Upon 
bacterial infections the capacity of MR1 to sequester the antigens above mentioned is increased due to 
the presence of a Lys residue (K43) at the base of the A’pocket and forming a Schiff-base (covalent 
bond) with the carbonyl group of the antigen itself143. In a curious manner, this covalent bond is 
characterized as common feature of MR1. In opposition to the A’pocket, the F’pocket in the MR1 
groove is much trivial and appears to be perfectly lined with primarily polar residues143,149,155,156. To 
the best of our knowledge, there are not physiological ligands characterized yet and the significance 
of this region is not fully understood. Despite the structural similarities between MR1 and MHC-I 
molecules, MR1 trafficking is way distinct and its intracellular location is still a debatable subject 
among the scientific community132,143. Presently, it is strongly suggested that most of the pre-
synthesized MR1 is confined in the ER, in the absence of bound ligands and adopting an incompletely 
folded state, meaning no β2m association132,140,143,146,157. However, there are reports suggesting that 
MR1 besides the ER is also present in late endosomes and lysosomes which facilitates association 
with β2m146,158. Nonetheless, it is known that soluble ligands are favourite in binding to MR1 when in 
the ER157. The increment in ligand availability and the presence of a Lys residue (K43), previously 
referred, prompts MR1 to become completely folded due to association with β2m covalently 
bounded132,140,157. After the MR1-β2m-ligand is created, MR1 cell surface expression levels 
increase132,140,157–159. This complex is internalized and degraded via endocytosis in late endosomes and 
lysosomes, where only 5% of the total MR1 present is recycled to cell surface and promoting new 
ligand exchange actions132,143,157,158. All this process is in concordance to what is known about fixed 
APCs like MR1 and their role in MAIT cells activation, when in presence of ligand-producing 
microbes108,132,160. Still, there are a few questions answered regarding MR1 and its antigen 
presentation role in MAIT cells108,160. Also, it is still unclear in which way ligands reach the ER and 
why several ligands are incapable to induce MAIT cell activation effectively despite binding to 
MR1114. 
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Figure 1.6 Overview of TCR recognition of peptide and metabolite presenting molecules. The top panels represent 
cartoon illustrations, indicative of the crystal structures of the ternary complexes: a) TCR-HLA-B and (b) MAIT TCR-5-OP-
RU-MR1, respectively. The middle panels show in detail view of the antigen (Ag) binding site in MHC and MHC-like 
(MR1) molecules. The bottom panels indicate the molecular surface of MHC-I and MR1, alongside their bound Ags. Black-
filled circles indicate the center of mass of the Va and Vb domains. CDR loops color codes: CDR1a, teal; CDR2a, pink; 
CDR3a, purple; CDR1b, red; CDR2b, orange; and CDR3b, yellow. Adapted from Awad, Wael; Le Nours, Jérôme; Kjer-
Nielsen, Lars et al 2018. 
1.4.2.3 - MR1 ligands and MAIT cell agonists and antagonists 
The nature of the MR1 ligands was discovered and characterized by Kjer-Nielsen and 
colleagues, in which the authors proposed the first MR1 ligand capable of inducing MAIT cells 
activation132,140,149. Furthermore, it was postulated that MR1 can present riboflavin (Vitamin B2) 
precursors, as well as folic acid synthesis pathways derivatives140. Curiously, depending on the level 
of MAIT cell activation in the presence of MR1 ligands, the latter can be differentiated in agonists 
and antagonists 148. Starting with MAIT cell agonistic compounds, these derive from the riboflavin 
biosynthesis pathway, characteristic of plants, bacteria and fungi, and are denominated as ribityl 
lumazines149,161,162. Some examples of ribityl lumazines MR1 ligands are: reduced 6-hydroxymethyl-
8-D-ribityllumazine (rRL-6-CH2OH), 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH) and 
6,7-dimethyl-8-D-ribityllmazine (RL-6,7-diMe)149. Further analysis on MR1 ligands was performed, 
as well as MAIT cell activation which led to the identification of different antigens (pyrimidines) that 
could work as MAIT cell agonists upregulating MAIT cell surface expression and activation rate. The 
most potent MAIT cell activatory ligands found to date are 5-(2-oxoethylideneamino)-6-D-
ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-Dribitylamonouracil (5-OP-RU) 
105,140,143. These pyrimidic antigens are generated from a non-enzymatic condensation process between 
5-amino-6-D-ribitylaminouracil (5-A-RU), identified by Corbett and colleagues as a key intermediate 
for MAIT cell activity and an early intermediate of the riboflavin synthesis pathway, with 
methylglyoxal and glyoxal byproducts105,113,132,140,143. Furthermore, since 5-A-RU contains a free 
amine that is susceptible to condensation reactions with metabolic byproducts and 
methylglyoxal/glyoxal are formed during metabolic pathways (for example glycolysis) in microbes 
and humans the end-products above mentioned are in constant production105,113,143,163. Despite being 
highly potent MAIT cell agonistic compounds, 5-OE-RU and 5-OP-RU are unstable and susceptible 
to condensation and consequent transformation in bicyclic ribityl lumazines105,113. However, when 
captured by MR1, these antigens are stabilized and function in a more potent manner in MAIT cell 
activation105,113,149,157,164. Besides MAIT cell agonistic MR1 ligands, there are also other MR1 ligands 
that despite upregulating MR1 cell surface expression lack the talent to activate MAIT cells. These 
compounds are described as MAIT cells antagonists, since they inhibit MAIT cell activation and are 
in constant competition with MAIT cells agonists for the MR1 binding pocket113,132. The first 
molecule identified as an MR1 ligand and MAIT cell antagonist was a non-stimulatory folic acid 
(vitamin B9)-related metabolite 6-formylpterin (6-FP)143,149,155,165. 6-FP is spontaneously produced due 
to the photodegradation of folic acid and is continuously bound to MR1.  
Furthermore, instead of promoting MAIT cell activation similar to 5-OE-RU and 5-OP-RU, 
6-FP inhibits or modulates MR1-mediated activation113,114,133,166. Following the identification of 6-FP, 
other pterin-based antigens were described such as acetyl-6-FP (Ac-6-FP) and two other variants of 6-
FP (2-acetylamino-4-hydroxy-6-formylpteridine dimethyl acetal and 2-acetylamino-4-hydroxy-6-
formylpteridine)132,140,155,165. These synthetic compounds were characterized as MAIT cell antagonists 
that inhibit MAIT cells activity, although are able to bind to MR1 and upregulate its cell surface 
expression levels113,114,143,157,165. Upon discovery, identification and characterization of MAIT cells 
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ligands, it became possible to generate MR1 tetramers with loaded with MAIT cells agonistic and 
antagonistic compounds, allowing specific detection and study of human MAIT cells in disease 
environments such as HBV like in this project105,141,155,167,168. Recently, it was identified a new panel of 
MR1 ligands which resembles a cocktail mix of drugs, drug metabolites and drug-like molecules. 
There are some examples of these new compounds like diclofenac (DCF) and salycylates that 
upregulate MR1 expression and at the same time promote the up or downregulation of MAIT 
cells132,143,169. Due to legal restrictions, commercial recombinant IL-12 and IL-18 were used to mimic 
the natural in vivo activation of MAIT cells in the liver, since these cytokines are produced by liver 
dendritic cells and monocytes during immune activation. 
Figura 1.7 a) MR1-related Vitamin B2 and Vitamin B9 metabolite Ags chemical structures. Pterins: 6-formyl pterin (6-
FP) and acetyl-6-formyl pterin (Ac-6-FP); Pyrimidines: 5-(2- oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU), 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-(1-methyl-2-oxopropylideneamino)-6-D- ribitylaminouracil 
(5-MOP-RU); Lumazines: -hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH), reduced 6-hydroxymethyl-8-D-
ribityllumazine (rRL-6-CH2OH) and 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe). b) Condensation reaction between 
bacterially produced riboflavin biosynthesis intermediate 5-amino-6- D –ribityaminouracil (5-A-RU) with the reactive 
byproducts of metabolism glyoxal and methylglyoxal. There is a consequent production of the potent antigens 5-OE-RU and 
5-OP-RU. These rapidly circularize to form ribityllumazines, which are far less potent than the pyrimidine antigens. . 
Adapted from Awad, Wael; Le Nours, Jérôme; Kjer-Nielsen, Lars et al 2018.  
1.4.2.4 MAIT cell TCR recognition of MR1-ligand complexes 
Previously, it was described that both MAIT agonists (5-OE-RU and 5-OP-RU), as well as 
antagonists such as 6-FP and Ac-6-FP binding mechanism to MR1 occurs105,113,114,140,143,149. The 
process itself takes place due to a covalent bond via the formation of a Schiff base between the ligand 
and the K43 residue within the MR1 structure105,149,155. Besides demonstrating a powerful link 
between MR1 and its ligands, also indicates that MR1 trafficking is directly influenced and triggered 
by the formation of a Schiff base and consequent molecular alterations, which allows MR1 cell 
surface expression increment113,132,157. In concordance with the statement above, several reports 
mention that the ribityl lumazine RL-6-Me-7-OH and DCF establish contact with the MR1 molecule 
but lack the strength to induce upregulation of MR1 cell surface expression, since no Schiff base is 
formed upon binding105,113,143. Furthermore, it is nowadays accepted that a few MAIT cell activating 
ribityl lumazines and pyrimidines resemble a MAIT cell antagonistic ligand (6-FP)105,132,149,170. 
However, within their structure, these ligands possess an extra ribityl moiety which promotes direct 
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contact between them and MAIT cells TCR132,170,171. Nonetheless, this is only possible due to the 
existence of a hydrogen bond between the ribityl moiety and a determinant residue (Y95) in the CD3α 
loop in MAIT cells TCR 105,170,172. 
1.5 MAIT cells Effector Functions 
1.5.1 – Cytokine Production  
MAIT cells upon activation, besides producing pro-inflammatory cytokines173 they also 
respond to microbial stimulation, riboflavin-producing microbes, which response is translated in the 
upregulation of activation markers such as CD69 and CD25 (IL-2Rα chain)106,132,160,174–176. On the 
other hand, microbes that lack the riboflavin synthesis pathway149,173, like Escherichia faecalis, can 
still activate MAIT cells due to the presence of IL-12 and IL-18 markers as described below in MR1-
dependent/independent MAIT cell responses107,130,132. As it happens during T cells stimulation and 
activation, also in MAIT cells there is a presence of Th1115,173,177,178 and Th2 cytokines 
families115,132,179,180 , which may influence the activation rate of these cells, as well as increase or 
decrease specific cytokines expression. These cells are well-described for their function within the 
immune system, where they seem be responsible for cell-mediated immunity and strong antibody 
production181. The goal of these T helper cells is to provide phagocyte-dependent and independent 
protective responses against different kinds of pathogens106. 
It has previously been reported that peripheral blood MAIT cells produce high levels of IFN-ү 
and TNF-α, these two pro-inflammatory cytokines being part of the Th1 cytokine 
family123,132,141,159,160,173,178. On the other hand, a subset this cytokine family, Th17 cytokines, appear to 
be expressed in a lower or inexistent degree115,131,174. Cytokines such as IL-17A and IL-22 are 
included in this cytokine family and its expression may depend on the MAIT cell population tissue 
localization analyzed173,177. Despite this, upon stimulation with strong stimuli such as PMA and 
ionomycin115,131,132,173, peripheral blood MAIT cells these cells start secreting IL-17A, even though at 
lower levels than liver MAIT cells131,132,152. Also, in comparison to Th1 and Th17 cytokines, the 
production of Th2 cytokine family, which includes IL-4, IL-5, IL-9 and IL-13 cytokines, as well as 
IL-10, a known T cell regulatory (Treg) cytokine are likely expressed by peripheral blood and liver 
MAIT cells in a minimal degree131,132,179,180. 
As mentioned previously, when MAIT cells are stimulated with PMA/Ionomycin, specific 
cytokines show an upregulated expression, compared to unstimulated samples. Thus, superantigens182 
, can also be used as potent stimuli to induce MAIT cells activation and cytokine production by these 
cells. The latter are exotoxins secreted by bacterial species that cross-link TCRs in T cells, as well as 
MHC class II molecules on APCs132,182. Therefore, MAIT cell activation pattern becomes enhanced 
and the release of pro-inflammatory mediators increases132,183,184. As an example, it is described that 
MAIT cells in adipose tissues can indeed secrete high levels of IL-10173  or that it is possible to detect 
IL-2 expression levels in liver and peripheral blood MAIT cells but only after 
PMA/Ionomycin115,131,132,141 or superantigens stimulation132,182. It appears to exist an involvement by 
MAIT cells in cross-talk mechanisms with other cells types, like APCs, and this might be an 
explanation to why activated MAIT cells produce granulocyte-macrophage colony stimulating factor 
(GM-CSF) and why MAIT cells can work as mediators of survival, activation and differentiation of 
other cellular types or T cells subsets 132,185,186. 
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1.5.1.1 – Degranulation and Cytotoxicity  
As one of the hallmarks of MAIT cells is to recognize infected target cells and kill them, it is 
reasonable that being a subset of T cells, these cells have the same effector functions106,132,173. 
However, MAIT cells might have evolved in such a manner that they could improve this ability by 
secreting different cytokines, as well as regulating their cytotoxicity role. This cellular mechanism 
takes place for the most part via granule exocytosis and it is built on the effector cells elements that 
facilitate the elimination of the target cells173. 
Subsequently to microbial stimulation, besides producing a various number of cytokines, 
MAIT cells are also described as key players in degranulation and being able to kill infected target 
cells132. While evaluating MAIT cells degranulation capability and killing rate it was discovered that 
peripheral blood MAIT cells present specific cytokines that lead to the death of infected target 
cells106,140,176,187. Therefore, holding a significant and possible new cell based therapeutic approach 
based on its effector functionality, despite effector MAIT cells expressing programmed cell death 
protein 1 (PD-1), a known exhaustion marker188. Peripheral blood MAIT cells, ex vivo, are able to 
express (once activated) granzyme A (Grz A), residual levels of granzyme B (Grz B), low levels of 
perforin (Prf) and granulysin (Gnly), which levels are variable, probably due to inner-donor variability 
or intrinsic fluctuation in this specific cell type115,132,140,173,176,187. The above cytokines mentioned 
might influence MAIT cells ability and function upon the presence of infection and allow these cells 
to directly encounter infected cells and to kill them. Prf is a pore-forming protein that consents the 
discharge of granzymes and Gnly molecules to the cytoplasm132,189. The latter cytotoxic effector 
molecules are recognized for their direct link to cytotoxic CD8+ T cells173. Therefore, imposing 
enough influence on MAIT cells and enabling these cells to induce apoptotic mechanisms on infected 
target cells132,140,189. Lastly, Gnly is an antibacterial protein recognized for killing intracellular bacteria 
by disrupting their membranes132,189,190. This indicates that MAIT cells contain a readily available pool 
of cytotoxic molecules (Prf/Grz A/Gnly) that can be rapidly released upon degranulation132. After 
activation, MAIT cells are subjected to a degranulation mechanism where CD107 A, a type-I 
transmembrane protein familiar for its function in degranulation in lymphocytes, is upregulated. In 
contrast, while activated, MAIT cells undergo a Grz A and Gnly expression downregulation. 
Nevertheless, when stimulated in a MR1-dependent manner in vitro, MAIT cells are able to lyse 
bacteria-infected epithelial cells176  and E. coli-infected THP1 cells 173,187,191, as well as S. flexinirii 
infected HeLa cells expressing endogenous levels of MR1106,176. This suggests that MAIT cells 
improve their degranulation and cytotoxicity effector functions, upon stimulation. Also, further 
studies are needed to compare if MAIT cells transduced with HBV TCR produce as much 
Prf/GrzA/Gnly as MR1-dependent activation, for greater clarity in the efficacy of TCR transduced 
MAIT cells. 
 
1.5.1.2 – Proliferation 
The Ki-67 marker/protein is a well-described marker strongly associated with cellular 
proliferation192. Proliferation of pathogen specific immune cells are a vital step in controlling 
infection, and is one of the first functions lost during T cell exhaustion. Furthermore, clonal 
proliferation is a force-multiplier for the immune response, especially in rapid pathogen growth  
Despite the apparently inexistence of basal levels of Ki-67 expression ex-vivo, peripheral blood MAIT 
cells are still able to proliferate in vitro upon microbial response115,177,187. This response might be 
strongly related to their response to riboflavin, vitamin B2, and other bacterial products149. As 
mentioned previously, upon in vitro stimulation MAIT cells increase their proliferation ability due to 
an upregulated expression of the Ki-67 marker177. Nonetheless, MAIT cells seem to keep their 
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cytolytic profile, whereas displaying high GrzB and Prf expression levels, known for their role in 
degranulation and cytotoxicity in MAIT cells effector functionalities106,132,187. 
 
1.5.1.3 – MR1 – dependent/independent MAIT cell responses  
One parameter that influenced the insight about MAIT cells was the discovery of its ligands, 
provided as a possible explanation to MAIT cells unresponsiveness when stimulated by bacteria that 
lack riboflavin metabolites, but becoming actively functional when presented to MR1 molecules 
inducing MAIT cells activation149. MR1 is a non-polymorphic gene located on chromosome 1 in 
humans142, similar to the CD1 gene193, and outside of the MHC located on chromosome 6 132,194. As 
MR1 is expressed ubiquitously and different cell types, such as DCs 109,195, B cells178 and 
macrophages123 can behave as APCs, it became easier to evaluate MAIT cells effector functionalities, 
since these cells function in a similar manner132,154. Also, scientific studies on these cells led to the 
conclusion that MAIT cells activation upon microbial stimulation is directly correlated to TCR 
antigens and MR1 interactions, which are considered MR1-dependent MAIT cell responses148,196 
(Figure 1.6). Cytokine production (IFNγ and TNFα), degranulation, cytotoxicity, proliferation are 
examples of effector functions associated to MR1-dependent TCR interactions123,131,176,178,187,197. 
Besides these, upregulation of GrzB and Prf, as well as production of IL-22118,187, and the IL-10 
cytokine, a family member and known marker for cellular inflammatory response, are responsible for 
MAIT cell activation in a MR1-dependent manner. Another criteria used to define MR1-dependent 
TCR MAIT cell responses is based on these cells response to microbial response, in particular to 
bacteria which display the riboflavin biosynthesis pathway such as Escherichia coli107. Nonetheless, 
there are bacterial species, for example Escherichia faecalis, that lack this pathway and are not able to 
induce an MR1-dependent activation response on MAIT cells106,107,130,132. In resemblance to other 
innate-like cells such as NK T cells, MAIT cells can also be directly activated by lymphokines in 
response to an infection in an MR1-independent manner106,107,173,198. As an example, in vitro studies 
using cells infected with Mycobacterium bovis Bacillus Calmette–Guérin (BCG) have shown to 
induce solely MR1-independent MAIT cell activation responses173. Also, MAIT cells are known for 
expressing IL-12R and IL-18R receptors123,124,160, and when stimulated with innate-like cytokines, IL-
12 and IL-18, they induce MAIT cells activation responses in a MR1-independent manner and 
without TCR signaling influence107,132. Supporting this fact, Ussher and colleagues107 performed 
experiments regarding MAIT cells cytokine-mediated activation and reported that MAIT cells could 
produce IFNγ after TCR blocking and in culture with IL-12 and IL-18173. Besides IL-12 and IL-18 
there is evidence of other cytokines such as IL-15 and IL-7 being able to activate MAIT cells in a 
MR1-independent process106,173,199. IL-15 appears to partake in a synergistic relation with IL-12 and/or 
IL-18, which translates the activation of peripheral blood MAIT cells even without microbial 
stimulation132,199. In addition, IL-15 directly potentiates IFNγ secretion, cytolytic activities (GrzB 
production) and induces MAIT cells expression of the early activation marker CD69 through the same 
mechanisms after sub-optimal TCR triggering106,182,200,201. Furthermore, IL-7 is implied in MAIT cell 
effector functions and is yet considered an extra marker to bear in mind in MR1-independent MAIT 
cell responses to innate cytokines148,196. Le Bourhis L and colleagues176 reported that MAIT cells from 
the liver highly express IL-7R, hence IL-7 potentiates TCR-dependent secretion of Th1 cytokine and 
of IL-17A173,176. This innate-like cytokine is also directly correlated with an augmented expression of 
GrzB, Prf and several transcription factors (PLZF, RORүt, T-bet, Eomes and Helios), which are of 
extreme importance effector molecules in MAIT cells stimulatory activation mechanisms202. 
Curiously, IFNγ, TNFα and IL-17A, important during bacterial infections, expression after IL-7 
stimulation seems to be nonexistent152,176. MAIT cells are indeed a very remarkable T cell subset that 
undergoes cytokine mediated activation and not only can respond to bacterial infection, while this 
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Figure 1.8 MAIT cells activation in a TCR-dependent or –independent manner. TCR engagement triggers secretion 
of mainly IFNγ and TNFα by MAIT cells. Although MAIT cells express CD161, IL-17 production can also be achieved 
upon PMA/ionomycin stimulation. MAIT cells can also secrete cytotoxic effectors and kill infected cells. These cells 
secretion profile is strongly supported by their role in immune defense against pathogens. MAIT cells effector functions 
can be modulated through different pathways. CD161 triggering can be acknowledged as one of the modulators of MAIT 
cells effector functions, since its expression regulates consequently decreases the amount of IFNγ and TNFα produced, but 
not the level of cytotoxic molecules secreted. Among other cytokines, IL-12, IL-18, IL-23, and IL-15 that are produced for 
example by infected cells, can modulate the cytokine secretion proﬁle. As for MAIT cells activation through TCR-
independent mechanisms, IL-12 and IL-18, secreted by liver and blood monocytes appear to have a pivotal participation in 
TCR-independent MAIT cells activation. Adapted from Franciszkiewicz et al 2016  
capacity seems to allow them to respond to certain viral infections. Regarding viral infections, MAIT 
cells are suggested to be indirectly activated due to a cytokine-mediated stimulation mainly caused by 
the secretion of IL-12 and IL-18 by parenchyma or hematopoietic cells106,182,203. Supporting this 
statement, several  reports with IL-12, IL-15 and IL-18 blocking experimental procedures showed that 
IFNγ production by MAIT cells in viral infections such as dengue virus, influenza virus and Hepatitis 
C virus (HCV) is directly affected and depends on IL-12 and IL-18, IL-18 alone, and IL-18 and IL-15, 
respectively 132,182,203. In vitro studies using TLR agonists suggest that MAIT cells are activated 
independently of microbe or virus stimulation, as well as in a MR1-independent manner107,130. For 
example, agonists for TLR3, TLR4 (lipopolysaccharide, LPS) and TLR8 (single-stranded RNA40) 
indirectly through APC’s activate peripheral blood MAIT cells and induce IFNγ production via IL-12 
and IL-18 stimulation 107,109,130,132. 
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1.5.1.4 - Regulatory Aspect of MAIT cells effector functions 
As described in this chapter, it is strongly suggested that MAIT cells are involved in a give-
and-take relationship with other cell types, as seen in studies performed in MAIT cell activation using 
APCs204. Also, microbes and innate cytokines stimulations seem to regulate MAIT cells activation 
responses through different mechanisms and mediators205. In one single study, it was reported that 
MAIT cells can be actively induced merely by the presence of innate cytokines such as IL-12 and IL-
18 and when combined with TCR stimulation, MAIT cells show an increased stimulatory response201. 
However, it seems that MAIT cells are not functionally activated upon TCR stimulation alone201. 
MAIT cells are also characterized for expressing numerous membrane molecules such as CD161, 
NKP30 and NKG2D106. These membrane molecules function as immune-modulators and prevent 
inflammatory responses to commensal riboflavin biosynthesis-competent microorganisms 115,132,141. 
Interestingly, only CD161 triggering mechanism has been studied176,206 and depending on which 
cellular type this lectin-like membrane receptor is expressed it was concluded that CD161 can be 
inhibitory or exert an activator function106,207. This was proved in studies using NK and CD8+ T cells 
208–210. Currently, it is suggested that MAIT cells responses can be modulated on CD161 expression. 
However, this modulation is quite controversial, since different studies report different results. On one 
side, CD161 presence seems to downregulate the expression of activation markers and cytokine 
production, without affecting MAIT cells cytolytic effector functions201, whereas other studies report 
an increase in cytokine production176.  
In any case, most of the science performed regarding MAIT cells effector functions uses 
human peripheral blood mononuclear cells (PBMCs), instead of liver and mucosal tissues samples, 
where these cells can be found at a higher percentage106. Therefore, it would be of the utmost interest 
to increase the number of studies on MAIT cells, sourced from more disease relevant organs as 
mentioned previously. 
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Chapter 2 – Objectives 
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The main goal of this project is to phenotypically characterize MAIT cells. Here, our 
focus is to compare MAIT cells isolated from PBMCs from both healthy and CHB patients and 
to perform a comparative analysis that could be indicative of a potential role of MAIT cells as a 
new immunotherapeutic approach for infectious diseases such as HBV. The specific goals of the 
project are the following: 
• To address whether there are differences in the phenotype of MAIT cells in the 
peripheral blood from healthy versus CHB patients. For this, we will evaluate the 
percentage of total MAIT cells, as well as the percentage of CD4+, CD8+ and CD56+ 
MAIT cells through flow cytometry analysis. 
 
• To investigate whether there are functional differences within MAIT cells isolated 
from healthy versus CHB patients. For this purpose, we will analyze the percentage of 
MAIT cells that are positive for 1) checkpoint inhibitors PD-1, TIM3 and LAG3, 2) 
activation markers CD25, CD38, CD69 and HLA-DR and 3) pro-inflammatory cytokines 
IFNγ, TNFα and IL-2. As in the previous objective, we will employ flow cytometry for 
this comparative analysis. Additionally, we will evaluate the cytokine and chemokine 
expression profile of these MAIT cells when in presence of APCs. To achieve this, 
isolated MAIT cells will be combined with a B lymphoblast cell line (HMy2.CIR) which 
mimics the activity of APCs, and a CD8+ cytotoxic T cell Luminex Kit will be performed 
using these cells. 
 
In parallel, we will also perform a serum screen to evaluate the performance of 
commercially available serums in immunological assays . In the scope of this objective, we 
will use ELISpot, ICS and proliferation assays in PBMCs form different healthy patients, in 
order to find the serum that provides the lowest background levels and highest signal 
amplification in each of these assays. Results will be directly compared to a currently in use in-
house serum, and the chosen serum will be used in further experiments performed in our lab.  
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3.1 Human Samples 
3.1.1 Healthy Donors 
Buffy coats of healthy patients were provided by Belgium Red Cross with the proper patients consent 
and according the Belgium law for the use of human primary materials.  
3.1.2 CHB Patients 
All patient samples were collected by Caprion Biosciences (Montreal, Canada), with the written 
informed consent of all patients and according to all legal regulations for the handling of human 
primary materials. In Table 3.1, an overview of the patient chronic status can be found. They were all 
chronic HBV patients based on high levels of HBsAg and no detectable levels of HBs antibodies. All 
patients are currently on treatment.  
Table 3.1. Overview Patient Disease status 
 
3.1.3 Isolation of Peripheral Blood Mononuclear Cells 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from buffy coats through a density 
gradient centrifugation by using LymphoprepTM (Axis-Shield, Cat. 1114547) (Figure 3.1). After 3 
washes with medium, cells were counted on GUAVA (using GUAVA ViaCountTM Flex Reagent) or 
on MoxiFlo ORFLO (using Moxi Cycle Viability Reagent, Cat. MXA055). Cells were cryopreserved 
in the presence of 10% Dimethylsulphoxide (DMSO) (Sigma - Life Science, Cat. D2650) and 90% 
heat-inactivated fetal calf serum (FCS) (GIBCO, Cat. 1865043), and aliquoted in cryovials. 
Subsequently, the vials were placed in freezing boxes, filled with 100% isopropanol (Mister Frosty), 
and placed at -80⁰C (at least overnight) to slowly freeze the cells. After that, vials were transferred to 
the liquid nitrogen (-175ºC) tanks for long-term storage until usage in subsequent assays.  
 
 
 
3.1.4 Thawing of the PBMCs 
The cryovials were thawed by transferring them directly from liquid nitrogen to a water bath (37ºC). 
The cells were washed 3 times with RPMI-1640 medium (Lonza, Cat. 12-702F) supplemented with 
10% fetal calf serum (FCS) (GIBCO, Cat. 1865043) and 1% L-Glutamine (Sigma - Life Science, 
200mM, Cat. G8541) to remove all the cryoprotectant DMSO and allowing cell recovery from the 
freezing process to prevent reduction in viability in following biological assays. 
Subject ID Chronic Hepatitis B HBsAg QT Anti-HBs HBeAg Anti-HBe Anti-HBc HBV DNA ALT
HBV 1 Y 5564.57 0 Reactive Non-Reactive Reactive < 20 19
HBV 2 Y 5019.49 0.13 Non-Reactive Reactive Reactive < 20 44
HBV 3 Y 7327.7 Non-Reactive Reactive Non-Reactive Reactive 303 28
Chronic HBV Donors
Figure 3.1.. Overview of steps in isolation of Peripheral Blood Mononuclear Cells 
(PMBCs). Murphy, K., Travers, P., Walport, M., & Janeway, C. 
(2012). Janeway's immunobiology (8th ed.). New York: Garland Science.  
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3.2 Mucosal-Associated Invariant T cells (MAIT cells) 
3.2.1 Flow Cytometry 
Flow cytometry is a well-established laser-based technique used to count, sort and phenotype 
different cell subpopulations within an heterogenous cell population (Figure 3.2). Using a panel of 
specific antibodies, each conjugated with a distinct fluorescent dye, fluorochrome, different cell 
subpopulations can be distinguished based on a combination of colors emitted by the cells upon 
excitation with multiple lasers in the flow cytometer. Cell populations are also distinguished based on 
their size (Forward-Scatter), granularity (Side-Scatter). The labeled samples go through a liquid 
stream where they are passing through a laser beam. This excites the fluorochromes which will emit 
light at a certain wavelength.  
 
This technique enables us to quantify and evaluate specific cell populations functionalities 
based on activation markers, cytokine secretion and proliferation parameters, among others. In the 
context of this project, flow cytometry was used to identify, characterize and compare mucosal-
associated invariant T (MAIT) cells between healthy and chronically infected hepatitis B patients. For 
this purpose, cellular surface and intracellular markers were used that would allow us to explore the 
phenotypic profile of MAIT cells between healthy and chronic HBV patients. Besides the lineage 
markers to define the MAIT cells, this evaluation was done based on 3 antibody panels: 1) pro-
inflammatory cytokine production, 2) activation markers and 3) checkpoint inhibitors (Table 3.2). 
Processed PBMCs were stained with LIVE/DEAD staining carried out using Fixable Viability 
Dye 660 (eFluorTM) (ThermoFisher, Cat. 65-0864-14) dissolved in PBS (Dulbecco’s Phosphate 
Buffered Saline, Sigma-Life Science, Cat. D8537) and applied to all samples as a viability marker. 
This LIVE/DEAD stain mechanism is based on the reaction of a fluorescent reactive dye with cellular 
proteins (amines). The dye is incapable of penetrating into live cells membranes. However, this 
reactive dye can permeate membranes from dead cells irreversibly, staining amines, located both on 
the interior and exterior of the membrane.   
Surface antibodies were diluted in Horizon Brilliant™ Stain Buffer (BD Bioscience, Cat. 
563794) per BD instruction for Horizon Brilliant stain buffer (Panel 1-3). This buffer prevents 
conjugation of the BV dyes.  Afterwards samples were incubated in the dark at 4ºC for 30 minutes. 
After washing the samples and prior to the addition of intracellular antibodies (Panel 1), cells were 
Figure 3.2. Flow Cytometry Technique Principle Overview - Murphy, K., Travers, P., Walport, M., & Janeway, C. 
(2012). Janeway's immunobiology (8th ed.). New York: Garland Science. 
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fixed with CytofixTM (4.21% formaldehyde w/w and saponin) (BD Bioscience, Cat. 555028) in the 
dark at 4ºC for 20 minutes to crosslink, stabilize and fix the cell membrane. Brefeldin A (GolgiPlugTM 
BD Bioscience, Cat. 555029) was added to block intracellular protein transport processes so that 
cytokines can accumulate in the Golgi complex and are prevented to be secreted.  
Further on, these samples were washed with Perm/WashTM buffer (BD Bioscience, Cat. 
554723) containing saponin (diluted 10x in distilled H2O) to permeabilize the cell membranes. 
Intracellular staining antibodies for panel 1 were diluted in Perm/WashTM buffer and added to the 
cells following an incubation in the dark at 4ºC for 30 minutes. 
 
Table 3.2. Antibodies used during flow cytometry experiments 
 
ArC™ Amine Reactive Compensation Beads (ThermoFisher Scientific, Cat. A10346, Lot 
1703807) were incubated and used as a compensation control for live/dead stain. BD™ CompBeads 
Positive Control (BD Bioscience, Cat. 51-90-9001229) and BD™ Negative Control (BD Bioscience, 
Cat. 51-90-9001291) Compbeads incubated with a single antibody were used as compensation 
controls for all fluorochromes, except for the IL-2 and TCRVα antibodies. BD™ CompBeads Anti-
Rat/Hamster Ig, κ (BD Bioscience, Cat. 51-90-9001189) and UltraComp eBeads (eBioscienceTM, Cat. 
01-2222-42), were used for IL-2 and TCRVα antibodies, respectively. Every experimental procedure 
regarding flow cytometry, MAIT cells marker’s expression were performed by plating 1 million 
PBMCs in each well, already supplemented with FCS serum. Afterwards cells were incubated and 
stimulated for 8 hours at 37ºC. 
All data acquisition was executed on a BD Biosciences LSR FortessaTM flow cytometer with a 
5-laser configuration (355-, 405-, 488-, 561-, and 639-nm lasers). The data generated was processed 
with BD FacsDiva v.8.0.1, Cytobank Janssen, FlowJo v. 10 and TIBCO Spotfire software. 
Fluorescence Minus One (FMO) control staining was integrated within the experiments to establish 
the gating strategy. 
Marker Fluorochrome Clone Vendor Catalog AB
Volume per Sample 
(µL)
Staining
CD3 AF 488 UTCH1 BD 557694 M 5 Surface
CD56 BB700 NCAM 16.2 BD 745894 M 5 Surface
CD161 BV421 DX12 BD 562615 M 5 Surface
TCRVα7.2 APC-Vio770 REA179 Milteny 130-100-179 ? 10 Surface
Marker Fluorochrome Clone Vendor Catalog AB
Volume per Sample 
(µL)
Staining
CD4 Bv650 RPA-T8 BD 563795 M 5 Surface
CD8 BUV395 RPA-T4 BD 740563 M 5 Surface
IFN-g PECF594 B27 BD 562392 M 5 Intracellular
TNF-α PE-Cy7 MAb11 BD 560678 M 5 Intracellular
IL-2 BUV737 MQ1-17H12 BD 564446 R 5 Intracellular
Marker Fluorochrome Clone Vendor Catalog AB
Volume per Sample 
(µL)
Staining
CD25 BUV395 M-A251 BD 740290 M 5 Surface
CD38 BV711 HIT2 BD 563965 M 5 Surface
CD69 PE-Cy7 L78 BD 335792 M 5 Surface
HLA-DR PECF594 G46-6 BD 562304 M 5 Surface
Marker Fluorochrome Clone Vendor Catalog AB
Volume per Sample 
(µL)
Staining
PD-1 (CD279) BUV737 EH12.1 BD 565299 M 5 Surface
TIM-3 (CD366) BV711 7D3 BD 565566 M 5 Surface
LAG-3 (CD223) BUV395 T47-530 BD 745640 M 5 Surface
үDTCR PECF594 B1 BD 562511 M 5 Surface
Antibodies Common To Each Panel
Panel 2 - Activation Markers
Panel 3 - Checkpoint Inhibitors
Panel 1 - Pro-Inflammatory Cytokines
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Figure 3.3. Gating strategy used to identify and characterize MAIT cells within PBMC’s samples 
3.3 Gating Strategy of Mucosal-Associated Invariant T (MAIT) cells:  
A gating strategy was developed to identify MAIT cells within the PBMC population and 
characterize them phenotypically, while using MAIT cells specific marker, CD161 and TCRVα7.2. 
Initially, the PBMCs samples were gated for lymphocytes, single cells and living cells. Afterwards, 
and within the living cell population, the samples were gated on the CD3+ T cells. Within this 
population, MAIT cells were gated and identified by using two different markers: CD161 and 
TCRVα7.2 (Figure 3.3). All other markers (Table 3.2) were gated after, as phenotypic markers for 
MAIT cells. 
 
PBMCs were stimulated with IL-12p70 (Human IL-12p70 Recombinant Protein, 
ThermoFisher, Cat. 14-8129-62) and IL-18 (Recombinant Human IL-18-1F4 Protein, R&D Systems, 
Cat. 9124-IL-010), used as activation stimuli for MAIT cells. Polyclonal stimulus phytohemagglutinin 
(PHA) stimulation (Sigma, Cat. L4144) stimulation and anti-CD3/CD28 BD Beads (Gibco, 
ThermoFisher DynabeadsTM Human T-activator CD3/CD28, Cat. 11453D) were used as positive 
controls, while DMSO stimulus (Sigma - Life Science, Cat. D2650) and unstimulated samples were 
used as negative control.  
3.4 Isolation of MAIT cells 
3.4.1 Isolation of MAIT cells with Microbeads Separation Kit 
PBMCs were thawed and counted as previously mentioned (See 3.1.4 Thawing of the 
PBMCs). The PBMC culture was rested overnight at 37ºC, in a 5% CO2 incubator to let the cells 
recover from the thawing process. On the following day, the cells were isolated using two different 
cell markers (CD161 and TCRVα7.2), as well as two distinct multisort microbeads separation kits: 
anti-PE Multisort Kit (MiltenyiBiotec, Cat. 130-090-757) and anti-APC Multisort Kit 
(MiltenyiBiotec, Cat. 130-091-255). These kits are commercially available and are used for sorting 
different cell populations according to specific surface markers due to an indirect magnetic labeling 
system. Then, these cell suspensions go through a MACS-MS column to be sorted. Alongside with 
the separation kits mentioned above, additional experiments included a Dead Cell Removal Kit 
(MiltenyiBiotec, Cat. 130-090-101) as a complementary kit, which allows the removal of dead cells 
during beads cell isolation. The separation was performed in FACS tubes and the cell suspension was 
stained with two different antibodies, anti-CD161 (PE, BD Bioscience, Cat. 556081) and anti-
TCRVα7.2 (APC, MiltenyiBiotec, Cat. 130-100-177). Along the isolation procedure, samples were 
taken at different timepoints, transferred to a 96-well plate and stained with LIVE/DEAD Fixable 
Viability Dye 780 (eFluorTM) (ThermoFisher, Cat. 65-0865-14) and anti-CD3 (Alexa Fluor 488, BD 
Bioscience, Cat. 557694). Anti-CD56 (BB700, BD Bioscience, Cat. 745894) was used as a control 
measurement. All data acquisition was performed on a BD Bioscience LSR FortessaTM flow 
cytometer.  
3.4.2 FACS Cell-Sorting 
PBMCs were thawed and counted as previously described (See 3.1.4 Thawing of the 
PBMCs) as an initial viability check to confirm the quality of PBMC samples (>70% viability). 
Following this, the PBMC cell suspension was centrifuged, diluted in PBS (Dulbecco’s Phosphate 
Buffered Saline, Sigma-Life Science, Cat. D8537), stained LIVE/DEAD viability using Fixable 
Viability Dye 660 (eFluorTM) (ThermoFisher, Cat. 65-0864-14) and incubated in the dark at 4ºC for 
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30 minutes. Afterwards, cells were stained for anti-CD3, anti-CD161 and anti-TCRVα7.2 (Table 3.2) 
and incubated in the dark at 4ºC for 30 minutes. MAIT cells were sorted from the PBMC population 
using a BD Bioscience FACS Aria1TM cell sorter. Differing from the preciously used FACS 
FortessaTM this cell sorter is equipped with 3 lasers (405-, 488- and 633-nm) wavelengths. 
Importantly, since it is a time-consuming process (cells might die), sorted MAIT cells were directly 
transferred to RPMI-1640 medium (Lonza, Cat. 12-702F) supplemented with 50% % fetal calf serum 
(FCS) (GIBCO, Cat. 1865043) and 1% L-Glutamine (Sigma - Life Science, 200mM, Cat. G8541) via 
an automatic process to improve the cells’ viability. The sorted cell suspension was put at 37ºC in a 
5% CO2 incubator for overnight resting. 
3.5 Functional Assay – C1R Cell line 
3.5.1 Cell Culture 
The B lymphoblast cell line, HMy2.CIR [C1R, HMy2.C1R] (ATCC® CRL1993™), was 
cultured in IMDM (1x) – Iscove’s Modified Dulbecco’s Medium (GIbco, Cat. 12440-053) 
supplemented with L-glutamine and 25mM HEPES and 10% FCS as mentioned by ATCC 
instructions. Cells were split every 2 to3 days and seeded with a concentration between 2*105 and 
1*106 cells per mL of medium, according to the manufacture instructions. After passage 3, a 
mycoplasma test sample was taken from the cell line suspension to check for possible mycoplasma 
contaminations.  
3.5.2 Stimulation of Sorted MAIT cells in combination with B Lymphoblast cell line 
The B lymphoblast cell line, HMy2.CIR [C1R, HMy2.C1R] (ATCC® CRL1993™), 
performing as antigen presenting cells (APCs), and MAIT cells, previously sorted (See 3.4 Isolation 
of MAIT cells), were stimulated in 3 different ratios, 2:1, 5:1 and 10:1 d for 20 hours at 37ºC with 5% 
CO2 with different stimuli. These included PHA (Sigma, Cat. L4144), lipopolysaccharide (LPS, 
InvivoGen, Cat. tlrl-eklps), two concentration levels (0.5 and 0.25%) DMSO (Sigma - Life Science, 
Cat. D2650) and two different concentrations (25μM and 50μM) of Diclofenac, an MR1 agonist. The 
next day supernatant was collected and frozen at -80ºC for Luminex assay read out. Cells were also 
checked for activation markers using flow cytometry technology. 
3.5.3 Flow cytometry 
Samples were stained for LIVE/DEAD viability marker, common markers and activation 
markers (See 3.2.1 Flow Cytometry and Table 3.2). Due to the presence of an B lymphoblast cell 
line an extra antibody was used, CD20 (FITC, BD Bioscience, Cat. 345792), to exclude B cells from 
the flow cytometry analysis. As CD20 antibody used FITC fluorescence channel necessary for 
detection, CD3 fluorescence channel was switched to PerCP-Cy5.5 (BD Bioscience, Cat. 557694). All 
data acquisition was performed on a BD Bioscience LSR FortessaTM flow cytometer. 
3.5.4 Luminex 
Luminex is a multi-analyte profiling based technology that enables the detection and 
quantification of numerous secreted proteins (cytokines and chemokines) by testing one single 
sample. This immunoassay instrumentation displays high efficiency levels, and dynamic range for the 
number of analytes that can be tested in one sample. Luminex sample reader is composed by two 
lasers (Green – 532nm and Red – 635-nm), that when combined with different labeled beads 
(magnetic/polystyrene) can generate a combination of 80 individual color combinations. The Luminex 
sample reader also contains a fluidic and real-time digital quantification signal processing. These 
color-coded beads are pre-coated with analyte-specific capture antibodies, one per bead, for the 
molecules of interest. This leads to the capture of analytes of interest by these analyte-specific capture 
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antibodies. Phycoerythrin (PE)-conjugated streptavidin is also added and will bind to the biotinylated 
detection antibodies. Following the addition of specific biotinylated detection antibodies, they will 
bind to the analytes of interest forming what is commonly called as antibody-antigen sandwich.  
When the analytes are crossed by the laser beams, they are analyzed and quantified based on the 
conjugation between the specific antibodies – beads complex formed. However, this technology has 
the disadvantage of not being able to discriminate the cell type or cell population that produced a 
specific cytokine/chemokine (Figure 3.4).  
For this project, this assay was employed to quantify and evaluate the type of cytokines and 
chemokines expressed by sorted MAIT cells upon stimulation (Table 3.3). For that purpose, we used 
a CD8 cytotoxic T cell Luminex Kit (Milipore, previously qualified by Janssen Lab). Undiluted 
supernatant from the functional assay performed with the B lymphoblast cell line and sorted MAIT 
cells (See 3.4 Isolation of MAIT cells) were tested with, following the protocol instructions from the 
Luminex kit. 
 
Table 3.3. List of cytokines and chemokines tested with the Luminex protocol.  
 
Cytokines and Chemokines IL-10 GrzA 
GM-CSF CD137 IFN-ү IL-2 IL-4 
IL-13 GrzB sFAS MIP-1α MIP-1β 
IL-5 IL-6 sFASL TNFα Perforin 
 
Figure 3.4. Luminex Principle Overview – From https://www.rndsystems.com/resources/technical/luminex-assay-principle 
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Figure 3.5. Overview of ELIspot technique. Murphy, K., Travers, P., Walport, M., & Janeway, C. 
(2012). Janeway's immunobiology (8th ed.). New York: Garland Science. 
3.6 Serum Screen 
A serum screen assay was performed to test 11 different serums commercially available. The 
objective of this screen was to choose the serum that would provide the lowest background and 
increase the signal for human PBMC samples upon stimulation, specifically on low responder donors. 
Test serums (Table 3.4) were evaluated using 3 different assays (Elispot, Intracellular Staining and 
Proliferation assay), and compared with a reference serum. 
Table 3.4. List of Serums tested in the Serum Screen 
 
3.6.1 ELIspot 
Enzyme-linked immunospot (ELISPOT) is a high sensitivity assay that provides 
measurements on the frequency of cytokine-secreting cells at single-cell level (Figure 3.5). Upon 
stimulation with antigens of interest, samples are stimulated on an ELISPOT plate. These are 
previously coated with capture antibodies against specific cytokines. The capture antibodies will bind 
to the cell surface and after an incubation period cells are removed, while the secreted molecules of 
interest remain. These can be detected by adding a cytokine specific detection antibody. The detection 
antibody is biotinylated and accompanied by a streptavidin-enzyme conjugate, or directly coupled to 
the enzyme. Finally, a substrate solution is added (BCIP/NBT-plus) is added to the plate, which will 
reveal a circle of bound cytokines, surrounding the position of each activated cell of interest (spot). 
Each spot will correspond to an individual cytokine-secreting cell which grants a quantification of the 
cytokine level within the cellular type analyzed, immediately after secretion.   
In the scope of this project, the ELISPOT assay was performed due to its high sensitivity. The aim of 
this project is to compare healthy and chronic HBV patients. This assay was used on the serum screen 
to find the best serum with the lowest background possible, as well as exclude potential false positives 
results.  
Human IFN-γ ELISpotPRO kit (Cat. 3420-2APT-10) was purchased from MABTECH. The kit 
uses PVDF plates pre-coated with a monoclonal antibody for IFN-γ (Cat. mAb 1-D1K) and one-step 
detection via alkaline phosphatase (ALP)-conjugated monoclonal antibody (Cat. mAb 7-B6-1-ALP). 
 
Serum Type Company Reference Number EU/mL Heat Inactivation 
1. Human AB Serum Seralab SM-612-HS 0.6 no 
2. Human AB Serum Seralab SM-512-HS 0.3 no 
3. Fetal Bovine Serum (FBS) VWR Seradigm life Science 89510-194 0.2 no 
4. Fetal Bovine Serum (FBS) Biowest S1810-050 0.2 no 
5. Fetal Bovine Serum (FBS) Hyclone SV30160.02 0.2 no 
6. Fetal Bovine Serum (FBS) Sigma F7524-500ML 0.2 no 
7. Human AB Serum Sigma H6914-100ml 5 no 
8. Fetal Bovine Serum (FBS) Life technologies 1190005 0.5 yes 
9. Fetal Bovine Serum (FBS) Life technologies 1190018 0.5 yes 
10. Fetal Bovine Serum (FBS) Life technologies 10082-147  yes 
11. Fetal Bovine Serum (FBS) Seralab EU-000F 0.311 no 
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BCIP/NBT-plus was used as the substrate for the ALP-conjugated detection mAb. PBMCs were 
isolated from healthy donors’ buffy coats (See 3.1.3 Isolation of Peripheral Blood Mononuclear 
Cells). ELIspot plates were blocked with RPMI-1640 medium (Lonza, Cat. 12-702F) supplemented 
with 1% L-Alanyl-L-glutamine (Sigma, Cat. 68541). The following antigens were added first at 
appropriate concentrations: PepMixTM CEF pool stimulus (JPT, Cat. PM-CEF-E, at 2µg/mL), 
consisting of 32 individual peptides, corresponding to a HLA class I-restricted T-cell epitope from 
CMV, EBV, and Flu viruses (JPT 2µg/mL). A monoclonal antibody against CD-3 (mAb CD3-
2/OKT3) was used as a positive control for cell viability and functionality of the assay. DMSO 
(Sigma - Life Science, Cat. D2650) was used as negative control. From previous studies on Janssen 
Lab, certain patient samples, were stimulated with individual CEF peptides (Table 3.5). All dilutions 
were made in RPMI-1640 medium (Lonza, Cat. 12-702F) supplemented with 1% L-Alanyl-L-
glutamine (Sigma, Cat. 68541). PBS (Sigma, Cat. D8537) was used for washing of the plates. All 
wells contained 200,000 cells in a volume of 150μL medium. The plates were incubated overnight at 
37ºC with 5% CO2 circulation and wrapped around aluminium foil to avoid evaporation. On the 
following day, the ELISpot plates were read on CTL ImmunoSpotTM plate reader, according to 
MABTECH protocol instructions. Counting of spots and quality control was done with CTL 
ImmunoSpotTM. GraphPad Prism 7 was used to visualize the results. 
Table 3.5. List of individual CEF peptides used. EBV derived peptides are shown in green (numbers 6 and 19), and CMV 
derived peptides are shown in blue (numbers 7 and 32). 
 
3.6.2 Intracellular Staining to confirm ELISpot Results 
PBMCs were isolated, thawed and counted (See 3.1 Human Samples). Each sample tested is 
composed of 1*106 PBMCs per well. Samples were stimulated for 6 hours at 37⁰C with PepMixTM 
CEF pool stimulus, individual CEF peptides (Table 3.6) and DMSO as a negative control. The 
intracellular staining protocol used during this assay was the same as before (See 3.2.1 Flow 
Cytometry). However, the antibody panel used was changed to a different set of fluorophores, 
rendering a slightly different experiment. LIVE/DEAD Fixable Viability Dye 780 (eFluorTM) was 
used as a viability check marker in all samples. All healthy donors’ PBMCs were tested for 
intracellular pro-inflammatory cytokine expression, including IFN-ү, TNF-α and IL-2. PBMC 
samples were also evaluated for the percentage of canonical T cells, CD3+, CD4+ and CD8+ T cells. 
Isotypes antibodies for IFN-ү, TNF-α and IL-2 were also used as quality controls. All data acquisition 
was performed on a BD Bioscience LSR FortessaTM flow cytometer. 
Index JPT-# Sequence 
Amount 
(mg) 
Volume DMSO 
[mL] 
6 28167_06 H-GLCTLVAML-OH 1.1 0.55 
7 28167_07 H-NLVPMVATV-OH 1.6 0.8 
19 28167_19 H-RPPIFIRRL-OH 2.1 1.05 
32 28167_32 H-TPRVTGGGAM-OH 2.5 1.25 
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Table 3.7. Antibodies used in the proliferation assay in serum screen. 
 
3.6.3 Proliferation Assay 
PBMCs were thawed and counted. Afterwards, a total amount of 600,000 of PBMCs were 
placed in each well of a 48 well plate. The cells were stimulated with PepMixTM CEF peptide pool 
stimulus, individual CEF peptides (Table 3.5) and DMSO as a negative control, and incubated at 
37⁰C with 5% CO2 for 6 days. All the tested serums (Table 3.4) were added to each well for every 
donor, respectively. After 6 days of stimulation/incubation, cells were stained for LIVE/DEAD 
viability using the Fixable Viability Dye 780 (eFluorTM) and incubated for 30 minutes at 4ºC. All 
samples were stained for surface markers anti-CD14 (BV510, BD Bioscience, Cat. 563079), anti-CD8 
(BV421, BD Bioscience, Cat. 562428), and anti-CD3 (PE-CY7, BD Bioscience, Cat. 557851). 
Samples were also stained for KI67, a known proliferation marker (FITC, BD Bioscience, Cat. 
556026) (Table 3.7). At least one sample for each one of the tested donors was stained for an FMO 
for the proliferation marker Ki-67 as a staining control. After staining, samples were incubated for 30 
minutes at 4ºC and the read out performed on a BD Bioscience LSR FortessaTM flow cytometer. 
  
 
  
Table 3.6. List of cytokines and isotype markers 
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4.1 Optimizing flow cytometry panel for MAIT cell analysis in human PBMC 
The first goal of this project is to determine phenotypically differences in MAIT cells in 
healthy versus chronical HBV patients. New antibody panels were designed and optimized, and a 
gating strategy was placed based on fluorescent minus one (FMOs). To achieve this, PBMC 
populations were stimulated with CD3/CD28 beads and Leukocyte Activation Cocktail (LAC), which 
were used as positive controls, since they overstimulate and induce unspecific activation of PBMCs 
and MAIT cells. These experiments were performed on all the flow cytometry antibody panels 
described in the Materials and Methods section.  
Since using LAC, a PHA based, positive stimuli, results were strong but unspecific. It was 
necessary to find other stimuli that would stimulate and activate MAIT cells with higher specificity. 
For this purpose, based on other experiments described in the literature152,199, out-titration experiments 
were performed using recombinant cytokines IL-12 and IL-18. The activation of MAIT cells as 
response to IL-12 and Il-18 was measured with the previously described antibody flow panels (See 
Materials and Methods). Both stimuli were tested in several concentrations and at different time 
points (6 and 24 hours) with the aim of finding optimal or define the sub-optimal concentrations that 
could increase the activation level of MAIT cells without reaching toxic levels. The addition of 
Brefeldin A was tested at different time points, without observing any significant differences in MAIT 
cell activation (data not shown). 
We performed two sets of experiments using IL-12 and IL-18 as single stimuli. First, we 
tested 3 different concentrations for each stimulus: IL-12 was evaluated at 50, 10 and 2ng/mL, and IL-
18 at 100, 50 and 10ng/mL. There was no dose depended response observed (data not shown). This 
could indicate that, at higher stimuli concentrations, the percentage of MAIT cells activated reaches a 
maximum level remaining equal. Hence, even if the concentration of the stimuli is increased, the 
percentage of MAIT cells that are activated remains the same. Lower concentrations of IL-12 and IL-
18 were tested to identify a sub-optimal concentration for both single stimuli. The concentrations used 
were 1, 0.25 and 0.0625ng/mL for IL-12 single stimulation and 5, 1 and 0.5ng/mL for IL-18 stimuli. 
After optimizing the panels for the evaluation of MAIT cells in human PBMCs, we decided to use 
three different concentrations for both IL-12 (10, 1 and 0.25ng/mL) and IL-18 stimuli (50, 10, 
1ng/mL). 
4.2 MAIT cell phenotyping (% population in PBMC) 
4.2.1 Surface markers (CD4/CD8 and CD56) within the MAIT cell population in donor 
PBMC 
PBMCs from each donor were stimulated with different doses of IL-12 and IL-18. PBMCs 
were sained with different cellular markers to identify MAIT cells. MAIT cells were gated and their 
frequency measured for the percentage of CD4+, CD8+ and CD56+ MAIT cells. As shown in Figure 
4.1, the percentage of MAIT cells was evaluated within the CD3+ T cell population for both sample 
groups (healthy versus chronic HBV patients). The results show that there is no clear difference 
between healthy controls and HBV chronically infected patients. After stimulation, the same 
frequency was observed independently of the stimuli concentrations of either IL-12 or IL-18. We 
observed a clear donor variability in both groups, which might influence our comparative analysis. 
Still, our results are consistent to what is documented on the literature, 1 to 10% of PBMCs 
population are indeed MAIT cells. The total number of MAIT cells was compared with the 
unstimulated control samples obtaining the same results, and equal to the unstimulated control 
samples (Figure 4.1).   
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Figure 4.1 Quantification of MAIT cells within the CD3+ T cell population (indicated in % from total CD3+ T cells). MAIT 
cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 (0.25/1 
and 10ng/mL) and IL-18 (1/10 and 50ng/mL). MAIT cells from 3 Healthy Control Patients and 3 Chronic HBV patients 
were tested 
The percentage of CD4+ and CD8+ MAIT cells in healthy and chronic patients were 
evaluated (Figure 4.2). Healthy patients showed similar frequencies of CD4+ MAIT cells 
independently of the stimuli used, ranging from 0 to 10%. Donor HC3 showed higher levels upon 
stimulation with IL-18 at 50ng/mL, compared to the other two donors.  On the contrary, when 
evaluating the chronic HBV patients, higher variation on the frequency CD4+MAIT cell was 
observed. Two of the donors, HBV1 and HBV3, seemed to contain higher levels of these cells 
compared to HBV 2. Additionally, when healthy and chronic HBV donors were compared, the 
percentage of CD4+ MAIT cells was around three times higher in the latter independently of the 
stimuli concentration.  
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Figure 4.2 Quantification of CD4+ within the MAIT cell population (indicated in % from total MAIT cells). MAIT cells 
stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 (0.25/1 and 
10ng/mL) and IL-18 (1/10 and 50ng/mL). MAIT cells from 3 Healthy Control Patients and 3 Chronic HBV patients were 
tested 
Next, the percentage of CD8+ MAIT cells (Figure 4.3) was analysed. It was clear that no 
change existed among the healthy patients after stimulating conditions and that the majority of MAIT 
cells in the periphery were CD8+ effector cells. The percentage of CD8+ MAIT cells for all donors 
ranged between 80 and 100%. On the contrary, the chronic HBV donors presented different 
frequencies of CD8+ MAIT cells. HBV 2 donor showed similar percentage of CD8+ MAIT cells to 
that observed on healthy patients. However, donors HBV1 and HBV3 showed lower population 
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frequency of CD8+ MAIT cells, around 60%. No increase in MAIT cell frequency were expected, due 
to the limited time of stimulation, 24 hours. 
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Figure 4.3 Quantification of CD8+ within the MAIT cell population (indicated in % from total MAIT cells). MAIT cells 
stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 (0.25/1 and 
10ng/mL) and IL-18 (1/10 and 50ng/mL). MAIT cells from 3 Healthy Control Patients and 3 Chronic HBV patients were 
tested 
According to the literature, there is a MAIT cell sub-population that is positive for CD56 152. 
Thus, the data was analysed for CD56+ MAIT cells. In Figure 4.4, the results for the percentage of 
MAIT cells that are CD56+ are shown. When comparing both groups, the levels of CD56+ MAIT cells 
were similar between healthy controls and chronic HBV patients. One large deviation in donor HC3 
was observed. when stimulated with IL-18 at the highest concentration of 50ng/mL almost 50% of 
MAIT cells were CD56+. Also, the unstimulated CD56+ MAIT cells samples show a baseline of 20% 
and in the lower IL-18 stimulation the results remain similar. 
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Figure 4.4 Quantification of CD56+ within the MAIT cell population (indicated in % from total MAIT cells). MAIT cells 
stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 (0.25/1 and 
10ng/mL) and IL-18 (1/10 and 50ng/mL). MAIT cells from 3 Healthy Control Patients and 3 Chronic HBV patients were 
tested 
4.3 Ex vivo MAIT cell activation 
4.3.1 Checkpoint Inhibitors  
MAIT cell population was evaluated for its checkpoint inhibitory marker expression level. 
The following checkpoint inhibitors assessed: PD-1, TIM3 and LAG3, as previously mentioned (See 
3.2.1 Flow Cytometry). The results obtained for these markers are illustrated on Figure 4.5, Figure 
4.6 and Figure 4.7. MAIT cells from chronic HBV patients showed higher PD-1 expression levels 
than those observed for HC donors (Figure 4.5). Indeed, even if we take into consideration the high 
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background levels present in the unstimulated samples, and the variability among donors upon IL-12 
and IL-18 stimulation, all the chronic HBV donors expressed PD-1 in more than 55% of the cells. On 
the contrary, only HC2 seemed to be positively activated amongst the HCs, with around 60% of the 
cells expressing PD-1 when stimulated with IL-12 at 10ng/mL. Also, it is important to mention that 
despite the high background levels, all donors responded in a positive manner, demonstrating a dose-
response curve upon IL-12 stimulation. However, when analysing the results for IL-18 stimulation, 
only donor HC2 responded to the stimulus, showing high percentage of PD-1+ MAIT cells at a 
concentration of 50ng/mL compared to baseline levels. As for the chronic HBV donors, both HBV2 
and HBV3 increased PD-1 expression in a dose-dependent manner. Also, we observed that HBV3 
reaches its PD-1 expression peak at 10ng/mL of IL-18 and, when the concentration of this stimulus 
increases, this donor decreased its PD-1+ expression levels. The differences among HC and HBV 
donors might happen due to presence of the PD-1 marker itself, hence in a case where there is no 
apparent infection, PD-1 can function as an activator, and upon a chronic infection it can have an 
inhibitory effect. 
 
Figure 4.5 Quantification of PD-1+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). MAIT 
cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 (0.25/1 
and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy Control 
Patients and 3 Chronic HBV patients were tested 
The expression of another MAIT cells checkpoint inhibitor, TIM3 was also evaluated and 
compared between healthy and chronic HBV donors (Figure 4.6). The results shown in figure 4.6 
demonstrate a high variability among donors of each group, but still suggest a positive response from 
the cells upon stimulation. On the left side, HC2 showed a dose-response activation upon stimulation 
with IL-12, and the highest values of TIM3 expression, with more than 30% of MAIT cells expressing 
this checkpoint inhibitor at a stimulus concentration of 10ng/mL. As for HC1 and HC3 donors, 
although they seem to have responded positively when stimulated with IL-12, their results varied. 
HC1 already displayed its maximum TIM3 expression at 0.25ng/mL, while HC3 seemed to increase 
the level of expression for this marker only at 1ng/mL.  In addition, when stimulated with IL-18, all 
HCs responded in a positive manner. However, HC1 and HC2 reached the maximum percentage of 
MAIT cells expressing TIM3 at a concentration of 1ng/mL, whereas HC3 showed a similar effect to 
that observed upon IL-12 stimulation, reaching the maximum level of expression (10% of the cells 
were positive for this marker) at 10ng/mL of IL-18. All the results obtained were compared with the 
unstimulated samples, which give an input on the background expression levels. 
 On figure 4.6 right graph, it is shown that CHB patients have slightly higher baseline TIM-3 
expression than HC, which is not as evident as in PD-1 expression. Two of the donors, HBV1 and 
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HBV3, stand out in the group for both stimuli, since their response was not dependent on the 
concentration used for each stimulus, and the concentration that led to higher expression levels of 
TIM3 was not the same for both donors. HBV1 showed little response to the lowest concentration 
used. However, when increasing concentrations (to 1 ng/ml for IL-12 and to 10 ng/ml for IL-18), this 
donor expressed 3 times more TIM3, in comparison with the lowest concentration. We also noticed 
that, after reaching this peak of TIM3 expression (30% of the cells expressing the marker) for both 
stimuli, expression levels decreased with increasing concentrations, suggesting that above a certain 
concentration of stimulus cells might die or be unable to further express this marker. The same was 
observed for donor HBV3. However, in this case, the maximum levels of expression were seen 
already at the lowest concentration of both stimuli, 0.25 and 1ng/mL for IL-12 and IL-18, 
respectively. Here, the maximum percentage of MAIT cells expressing TIM3 was approximately 
35%. Regarding HBV2 donor, MAIT cells seemed to be expressing TIM3 when stimulated with IL-
12, but no differences in their response were seen between different concentrations of stimulus. 
However, when analysing the same donor upon IL-18 stimulation, HBV2 does not upregulate TIM3 
as much as HBV chronic, but seem to have similar levels to healthy volunteers.  
 
Figure 4.6 Quantification of TIM3+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). MAIT 
cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 (0.25/1 
and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy Control 
Patients and 3 Chronic HBV patients were tested 
The percentage of MAIT cells expressing the checkpoint inhibitor LAG3 was also assessed. 
The first thing we noticed when analysing the results displayed in Figure 4.7. was that there is a much 
lower percentage of MAIT cells expressing LAG3, in comparison to the previously evaluated 
markers, PD-1 and TIM3. Also, HC donors did not show a clear response to any of the used stimuli. 
Therefore, no significant increase in the expression of the LAG3 marker was observed for these 
donors, independently of the concentration of stimuli used, and in comparison, to the unstimulated 
samples. Nevertheless, upon stimulation with IL-12 at a concentration of 10ng/mL, HC2 
demonstrated an increase in the percentage of MAIT cells expressing LAG3, reaching almost 2%. On 
the other hand, all the healthy control appeared to be unresponsive to IL-18 stimulation. Additionally, 
the response and expression of the inhibitory marker LAG3 was also assessed in chronic HBV 
patients. The variability among donors was evident, as well as the lack of response both HBV2 and 
HBV3 upon stimulation with IL-18. Nonetheless, with regards to IL-12 stimulation, the percentage of 
MAIT cells expressing LAG3 increased with increasing concentrations of the IL-12 stimulus. Despite 
this, all donors responded differently. MAIT cells from this donor HBV1 reached peak expression of 
LAG3 at 1ng/mL (around 8%). At the maximum concentration tested of IL-12, a drop in LAG3 
expression levels was observed. HBV2 donor showed a dose-response to IL-12 stimulation in the first 
two concentrations of stimulus, but once it reached the maximum expression levels of LAG3 (at 
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1ng/mL of IL-12), the percentage of MAIT cells expressing LAG3 (around 1.5%) remained equal to 
that observed at the highest concentrations of IL-12suggesting that this donor reached a plateau phase. 
Finally, HBV3 donor positively responded to stimulation with different concentrations of IL-12, 
increasing the percentage of MAIT cells expressing LAG3 in a dose-dependent manner. This donor 
reached the maximum levels of expression at 10ng/mL of IL-12 (approximately 6% of MAIT cells 
expressed the marker). As stated before, only HBV1 was shown to be responsive to IL-18 stimulation, 
and the results were similar to the ones obtained with IL-12 stimulation. HBV1 reached the maximum 
level of expression of LAG3 at a concentration of 10ng/mL, whereas the lowest concentration used 
showed the same result as the unstimulated sample. MAIT cells from CHB patients have 3-4 fold 
higher maximum LAG-3 expression than HC, and peaking already at 1ug/mL IL-12/18 stimuli, 
suggesting a much higher sensitivity to checkpoint upregulation and possibliy entering an exhaustive 
state  
 
Figure 4.7 Quantification of LAG3+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). 
MAIT cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 
(0.25/1 and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy 
Control Patients and 3 Chronic HBV patients were tested 
4.3.2 Activation Markers 
Are MAIT cells still able to be activated in chronic HBV? To answer this question, the 
expression level of different activation markers - CD25, CD38, CD69 and HLA-DR - were measured 
on MAIT cells. Figure 4.8 shows the results for CD25+ MAIT cells. A clear difference was observed 
between HC and chronic HBV patients. Chronic HBV patients demonstrated higher expression of the 
activation marker CD25. The healthy patients tested do not show a dose-response for CD25 activation 
after 24 hours stimulation. The same activation pattern was expected from the chronic HBV patients. 
Despite reacting in a similar manner upon stimulation with IL-12 and IL-18 at different 
concentrations, donor HBV3 presented a different activation response. This donor displayed a steep 
dose-response in the number of CD25+ MAIT cells upon stimulation with different concentrations of 
IL-18. At this concentration, approximately 30% of the cells expressed CD25. Regarding HC donors, 
HC1 and 3 showed almost no CD25+ MAIT cells. On the opposite, HC2 contains MAIT cells that 
express CD25, maybe responding in a dose-dependent manner for the IL-12 stimulus. However, it is 
not easy to perceive, due to the exclusion of some data points (HC2 and HBV3) for the entire 
antibody panel. The values excluded lacked viability percentages above 70%, minimum required to be 
used in immunological assays.  
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Figure 4.8. Quantification of CD25+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). 
MAIT cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 
(0.25/1 and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy 
Control Patients and 3 Chronic HBV patients were tested 
CD38, a well-established late activation marker, was also tested (Figure 4.9). When 
comparing HC versus chronic HBV donors, the first observation was the difference in the frequency 
of CD38+ MAIT cells. HBV patients clearly presented higher CD38 expression levels, even though 
there was high variability between the donors. When stimulated by different concentrations of IL-12 
and IL-18, HBV1 exhibited no changes in CD38 expression levels. Upon stimulation with IL-12, 
HBV2 responded in a dose-response manner, showing the highest CD38 expression levels at 10ng/ml 
of stimulus. At this concentration, around 60% of MAIT cells were positive for CD38 expression. 
Though this donor still demonstrated CD38 expression upon IL-18 stimulation, it seems that at the 
two highest concentrations there was no change in CD38 expression levels perhaps due to a saturation 
effect. Donor HBV3 does not show a dose-response increase of CD38 after stimulation with IL-12, 
which might be influenced by the exclusion of the values for the highest IL-12 concentration used. 
However, after stimulation with IL-18, this donor responded in a dose-depended manner, reaching the 
highest CD38 expression levels at 50ng/mL of IL-18 (~30% of CD38+ MAIT cells). Contrarily, HC 
donors did not show an increase in CD38 expression after stimulation with any of the stimuli. For 
instance, donors HC1 and 3 displayed no change in CD38 expression levels, when compared to the 
unstimulated samples. Nevertheless, HC2 donor reacted positively upon stimulation with IL-12 at 
10ng/mL, while IL-18 seemed to induce effect at a concentration of 10ng/mL.  
 
 
Figure 4.9. Quantification of CD38+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). 
MAIT cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 
(0.25/1 and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy 
Control Patients and 3 Chronic HBV patients were tested 
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Simultaneously, early activation markers CD69 and HLA-DR were investigated on MAIT 
cells (Figure 4.10 and Figure 4.11). The first observations, MAIT cells showed higher background 
levels in the unstimulated samples. After stimulation, variability among donors was observed.  
As shown in Figure 4.10, all the HC donors reacted to IL-12 stimulation and demonstrated a 
dose-response curve to this stimulus. A dose-response pattern was shown after IL-18 stimulation in 2 
out of 3 donors. Donor HC2 only shows one value point for the IL-18 stimulation, while the other two 
points were removed due to a low viability frequency (< 70%). HC1 showed the highest CD69 
expression levels among the healthy controls, in which around 80% of MAIT cells expressed CD69, 
even though we observed a slight decrease on CD69 expression levels at the highest concentration of 
IL-18 stimulus. HC3 still responded to stimulation with IL-18 but at lower levels, only 60% of MAIT 
cells expressed CD69. The percentage of MAIT cells expressing CD69 in HC2 can be considered 
null, since the background in the unstimulated sample was high and comparable to after IL-18 
stimulation, although only one value is shown in the graph (stimulation at 10 ng/mL of IL-18). On the 
other hand, HBV donors showed a few differences. For example, donor HBV2 showed a large 
deviation, compared to the other two chronic HBV donors in expression of CD69 by MAIT cells. 
However, donors HBV1 and HBV3 were the ones that responded to stimulation in a dose-response 
manner, even though one value point was excluded for donor HBV3. Also, when comparing the 
background levels for healthy and chronic HBV patients, 2 out of 3 HBV donors demonstrated lower 
background levels than the healthy controls. The highest percentage of MAIT cells expressing CD69 
was observed after stimulation with 1ng/mL for IL-12 and 10ng/mL for IL-18. With regards to HBV2 
donor, despite demonstrating the highest percentage of MAIT cells expressing CD69 (almost 100%), 
this donor did not show a dose-depended response after stimuli due to the high background levels. 
Finally, donor HBV3 only reacted to stimulation with 10ng/mL of IL-12. This donor did not react to 
all the other stimuli concentration tested, since CD69 expression levels were below the background 
levels. 
 
Figure 4.10. Quantification of CD69+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). 
MAIT cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 
(0.25/1 and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy 
Control Patients and 3 Chronic HBV patients were tested 
In Figure 4.11 is showed the results for the percentage of MAIT cells expressing the HLA-
DR activation marker in healthy and chronic HBV donors. Within the HC patients tested, the HLA-
DR expression levels seemed to be similar. Still, healthy donors reacted positively after stimulation 
with both IL-12 and IL-18, since levels of HLA-DR expression were higher than the background 
levels. When looking at each stimulus separately, all HCs show to have a dose-response after IL-12 
stimulation with a maximum HLA-DR expression at 10ng/mL (35 to 55% of MAIT cells). On the 
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other hand, when stimulated with IL-18, the expression levels of HLA-DR remained similar between 
all HC individuals, independently of the concentration of stimuli used, which is around 20 to 40%.  
Regarding the chronic HBV donors, variability among donors and the background levels were 
higher than healthy controls. HBV1 showed no activation when stimulated with IL-12 and IL-18 at 
different concentrations. In contrast, HBV2 showed a dose-response for both stimuli. Upon IL-18 
stimulation, this donor response was identical to donor HBV3 with a maximum of 60% expression at 
50ng/mL of IL-18. When the PBMC were stimulated with IL-12, HBV3 exhibited an increase in 
HLA-DR expression, with almost 80% of the MAIT cells expressing this marker at the highest 
concentration for IL-12, 10ng/mL. Even considering the variation within the donors, both healthy and 
chronic HBV donors responded similarly to IL-12 and IL-18.  
 
Figure 4.11. Quantification of HLA-DR+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). 
MAIT cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 
(0.25/1 and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy 
Control Patients and 3 Chronic HBV patients were tested 
4.3.3 Pro-Inflammatory Cytokines 
To investigate whether MAIT cells are still functional in chronic hepatitis B patient’s, 
cytokine production (Il-2, IFN-g, TNF-a) after stimulation of MAIT cells with IL12 or IL-18 was 
measured (See 3.2.1 Flow Cytometry). Figure 4.12, Figure 4.13 and Figure 4.14  show the levels of 
expression of pro-inflammatory cytokines IFNγ, TNFα and IL-2. Figure 4.12 compares % of MAIT 
cells that express IFNγ in healthy donors (left) and HBV donors (right). No apparent reduction of 
IFNγ production in MAIT cells correlated to chronic HBV infection was observed. Despite showing 
higher expression levels of IFNγ, upon IL-18 stimulation only 1 out of 3 donors in each group (HC2 
and HBV2) show up to 15% of IFNγ+ MAIT cells, while the remaining donors for each group did not 
seem to respond to the stimuli. These donors demonstrated a clear dose-response upon IL-12 
stimulation, showing almost 16 times more IFNγ expression at the highest concentration (10ng/mL), 
in comparison to the unstimulated control samples. HBV3 demonstrated the highest level of IFNγ 
expression upon IL-12 stimulation at 1ng/mL, while increasing the concentration of this stimulus led 
to a saturation point of IFNγ expression by MAIT cells. 
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Figure 4.12. Quantification of IFNγ + MAIT cells within the PBMC population (indicated in % from total MAIT cells). 
MAIT cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 
(0.25/1 and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy 
Control Patients and 3 Chronic HBV patients were tested 
The percentage of TNFα and IL-2 cytokine expression was also evaluated within the MAIT 
cell population (Figure 4.13 and Figure 4.14). As seen with IFNγ, the results between HCs and 
chronic HBV patients the expression levels of TNFα and IL-2 were similar 
In general, all donors displayed MAIT cells expressing TNFα ranging from 0 and 1% (Figure 
4.13) and lower than the results observed for the expression of IFNγ. MAIT cells from sample HBV1 
were observed to have an unusual TNFα expression, with background values at 1.6% and much lower 
TNFα after stimulation with IL-12/18 except at 10ng/mL IL-12. The high background of TNFα in 
sample HBV1 makes it difficult to deduce changes in TNFa functionality of this sample. 
 
Figure 4.13. Quantification of TNFα+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). 
MAIT cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 
(0.25/1 and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy 
Control Patients and 3 Chronic HBV patients were tested 
IL-2 cytokine expression levels by MAIT cells was also measured (Figure 4.14). As 
illustrated below, there were no major differences in the IL-2 expression pattern between HC and 
chronic HBV patients. Also, the levels of IL-2 expression are so diminished that the production of this 
cytokine by MAIT cells was almost inexistent. Furthermore, the different concentrations used for each 
of the stimulus did not seem to increase or decrease the number of MAIT cells that express IL-2. 
Despite this, it is important to mention that, within the HC donors, HC3 demonstrated a positive 
reaction upon stimulation with IL-18 at 50ng/mL, whereas sample CHB donor HBV1 shows a larger 
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IL-2 population in the control conditions, than in stimulated conditions, making functional evaluation 
of IL-2 response very difficult. 
 
Figure 4.14. Quantification of IL-2+ MAIT cells within the PBMC population (indicated in % from total MAIT cells). MAIT 
cells stimulation for 24 hours with IL-12 and IL-18 recombinant innate cytokines at different concentrations: IL-12 (0.25/1 
and 10ng/mL) and IL-18 (1/10 and 50ng/mL) and CD3/CD28 Beads as positive control. MAIT cells from 3 Healthy Control 
Patients and 3 Chronic HBV patients were tested 
4.4 MAIT cell isolation with beads 
While evaluating the expression of different cellular markers on MAIT cells, we tested two 
different methods to isolate these cells within a PBMC population: Bead Isolation and Cell Sorting 
(See Materials and Methods). The isolation of MAIT cells was necessary to carry out functional 
assays together with a lymphoblast cell line - HMy2.CIR [C1R, HMy2.C1R]. This allowed us to 
assess MAIT cells ability to be activated in the presence of an antigen presenting cell line, and address 
whether MAIT cells express similar or different cytokines and chemokines as the ones previously 
described (See Introduction). First, we followed a beads sorting protocol from Miltenyi Biotech, 
using two specific known markers for MAIT cells, TCRVα7.2 and CD161, to evaluate their viability 
after the isolation process. In figure ZX, some of the steps of this isolation are depicted. Based on 
these results, we concluded that the experimental procedure did not work completely. Before sorting 
MAIT cells, more than 90% of the PBMC population was viable. However, when assessing the 
percentage of MAIT cells double positive for TCRVα7.2 and CD161, we observed that almost none 
(3.74%) of the MAIT cells isolated were viable, meaning that cell death occurred along the procedure. 
Thus, we decided to include an extra step on the experimental procedure using a dead removal kit 
(See 3.4.1 Isolation of MAIT cells with Microbeads Separation Kit). The aim was to remove the 
highest percentage possible of dead cells that could influence the viability of isolated MAIT cells. 
However, even with this extra step, the percentage of viable MAIT cells within the PBMC population 
before bead sorting (4.74%) was much higher than after sorting, whereas the percentage of viable 
MAIT cells double positive for TCRVα7.2 and CD161 was almost inexistent within the 4.74%, 
representing the total MAIT cell population within PBMCs. 
Figure 4.15. Overview of bead sorting of MAIT cells using two different beads marker: TCRVα7.2 and CD161 
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Figure 4.16. Overview of Cell Sorting of MAIT cells from PBMC population from a healthy donor 
The next step was to use a cell sorter (See 3.4.2 FACS Cell-Sorting) instead of beads 
isolation protocols. Figure 4.16 illustrates an example of MAIT cells sorting within a PBMC 
population obtained from a healthy donor. This procedure provided better results, as shown by the 
purity percentage of MAIT cells after sorting (99.3%). The same monoclonal antibodies used in the 
bead isolation experiment were applied in this technique, as these are known specific cellular markers 
used in the identification of MAIT cells. Figure 4.16 represents the viability percentage of the initial 
PBMC population, as well as the purity percentage of MAIT cell within that population. 
 
 
 
 
 
 
 
Sorted MAIT cells were tested in a functional assay together with HMy2.CIR [C1R, HMy2] 
cell line. Cells were stimulated and evaluated using Luminex technology as previously mentioned 
(See 3.5.4 Luminex). Unfortunately, the cytokine assay did not pass qualification, since MAIT cells 
showed activation patterns even before being co-cultured with the cell line or stimulated (data not 
shown). Also, it seemed that the viability of MAIT cells was low when these cells were sorted and 
stimulated for a certain period of time. This might be one reason for the inability to observe 
expression of cytokines/chemokine upon stimulation on Luminex. 
4.5 Serum screening for PBMC culture media 
A serum screen for PBMC culture media was performed using three different assays 
(ELIspot, Proliferation assay and ICS), in which 11 different serums coupled to healthy donors were 
tested (See 3.6 Serum Screen).   
4.5.1 ELIspot 
Six healthy donors were assessed for their response, translated by the number of spot forming 
cells, upon stimulation with CEF pool peptides, individual CEF peptides and DMSO (See 3.6.1 
ELIspot). In Figure 4.17, the results obtained for the ELISPOT assay are shown. Human donors can 
be classified as low, intermediate or high responders, depending on the scientific assay they are tested 
for. Since the overall objective of this project was to compare healthy patients against chronic HBV 
patients, the latter known to have week responses when tested in assays such as ELISPOT, ICS and 
Proliferation assays, in this experiment we used intermediate and low responder donors. DMSO was 
used as a negative control and we confirmed this control worked when compared to the results from 
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the positive stimulation with CEF pool peptides or with individual peptides, as shown in Figure 4.17 
and in Figure 4.18. Serum 10 was also used as control, since this serum was used for all the 
immunological assays performed in house. Also, due to the high sensitivity of the ELISPOT assay, a 
cut-off line was placed on 50 spots forming cells (SFCs) per million PBMCs, whereas values below 
this threshold were considered not accurate to take conclusions in the context of this technique. 
When stimulated with a pool of 32 CEF peptides, screen donor 1611 (shown in Figure 
4.17.A) responded in a similar manner to all the serums tested. There was small variability with this 
donor amongst the 11 serums tested, and results ranged between 500 and 1000 SFCs per million 
PBMCs. Still, serums 1, 2, 4, 6, 7, 8 and 10 exhibited the best results among all the serums. Notably, 
serum 1 reached approximately 1000 SFCs per million PBMCs. The same pattern can be observed for 
screen donors represented by figures Figure 4.17.B, C and D, where there was not a substantial 
difference among the serums tested. Although the differences are not obvious between distinct 
serums, it is possible to highlight some serums that showed the best results. For instance, figure 
Figure 4.17.B shows a screen donor that reacted poorly to CEF pool stimulation, and in which serums 
2, 7 and 8 were the ones leading to a signal amplification above 50 SFCs, as the number of SFCs 
obtained were between 60 and 80. Similarly, in Figure 4.17.C, serums 2, 7 and 8 performed better, 
showing approximately 500 SFCs per million PBMCs. In addition, in figure Figure 4.17.D, serums 3, 
4 and 8 were the ones that better amplified the response signal from this donor upon stimulation with 
CEF pool peptides. All the other serums tested on this donor were below the cut-off line, including the 
in-house used serum (serum 10). 
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Figure 4.17. Quantification of spots forming cells in 1 million PBMCs in healthy donors A) DN 1611, B) DN 1620, C) DN 
1626 and D) DN 1625 upon stimulation with a pool of CEF peptides.  
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Using the same assay, two screen donors were stimulated with individual CEF peptides, either 
peptides 19 and 32 (Figure 4.18.A) or peptides 6 and 7 Figure 4.18.B). These individual CEF 
peptides were chosen based on previous studies done with these donors and these CEF peptides as 
stimuli, showing signal amplification of the cellular markers tested here. Stimulation with CEF 
peptides 19 and 32 showed similar results among all the serums, even though the number of SFCs was 
slightly higher for CEF peptide 32 (approximately 400 SFCs per million PBMCs in all the serums) 
compared with CEF peptide 19 (200 SFCs per million PBMCs). Thus, results for this donor were not 
conclusive, and it is difficult to assess which serum was the best. With regards to donor 868, 
stimulation with CEF peptides 6 and 7 showed interesting results. Upon stimulation with CEF peptide 
6, only serum 8 showed an increase in signal above the cut-off line. Nevertheless, upon stimulation 
with CEF peptide 7, almost all serums improved the signal, specially serums 1, 2, 7, 8, 9 and 10 which 
exhibited more than 1000 SFCs per million PBMCs. 
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Figure 4.18. Quantification of spots forming cells in 1 million PBMCs in healthy donors A) DN 5943 upon stimulation with 
CEF peptides 19 and 32 and B) DN 868, upon stimulation with a CEF peptides 6 and 7.  
4.5.2 Intracellular Staining (ICS) 
Based on previous experiments performed in our lab group, we tested particular donors 
previously used in the assays above mentioned in combination with different serums, with the aim to 
evaluate their CD8+ T cells expression levels of IFNγ, TNFα and IL-2. 10 serums were used in these 
assays for all donors. DMSO and CEF isotypes were integrated in the assay as background level 
controls. Also, donors were stimulated with either CEF pool peptides or individual CEF peptides, 
depending on the donor (Figure 4.19). 
Screen donors DN 1611 and DN 1626 (Figures 4.19.A and B) demonstrated low background 
levels, meaning that without being stimulated, their CD8+ T cells do not express IFNγ, or express it in 
a very low percentage. Even though the results from negative controls demonstrate that the assay 
worked, when stimulated with CEF pool peptides, these donors reacted in a positive manner, but still 
presented low levels of IFNγ expression by CD8+ T cells. On screen donor DN 1611, serums 2, 4, 5, 9 
and 10 seemed to slightly improve the signal and amplify the levels of expression of IFNγ by CD8+ T 
cells, reaching almost 3% of cells expressing this marker. Despite showing lower levels of IFNγ+ CD8 
expression, screen donor DN 1626, also reacted upon stimulation. For this screen donor, serums 3, 4, 
8 and 9 showed the best results, as with these serums around 0.5% of the CD8+ T cells expressed 
IFNγ. Screen donors DN 5943 and DN 868, which were stimulated with individual CEF peptides as 
previously described, showed different responses (Figures 4.19.C and D). When stimulated with 
individual CEF peptides (19 and 32), screen donor DN 5943 reacted poorly and the expression levels 
of IFNγ by CD8+ T cells were low. Nevertheless, CEF peptide 32 stimulation seemed to improve the 
results. However, if we compare the expression signal upon stimulation with this peptide to the high 
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background levels (DMSO condition), the expression of IFNγ becomes almost null. In this case 
serums 6 and 7 showed the best results. The values obtained for the stimulation of CEF peptide 19 
were very similar amongst all the serums and comparable to the DMSO values (Figure 4.19.C). 
Regarding donor DN 868, it was harder to evaluate IFNγ expression levels by CD8+ T cells and 
distinguish which of the serums led to an amplification of IFNγ cellular expression. In this donor, 
stimulation with CEF peptide 6 resulted in similar expression levels between the different serums 
used, but once again these were comparable to the values obtained from the DMSO stimulation. 
However, when stimulated with CEF peptide 7, serums 2, 3, 8, 9 and 10 granted an amplification of 
the expression levels of IFNγ by CD8+ T cells. In these conditions, between 1 and 2% of the analysed 
CD8+ T cells expressed IFNγ. The exception was serum 10 (in-house serum), which obtained almost 
6% of IFNγ expression by these cells. This difference might result from a variability in the donor 
response to the serums tested, or even from assay variability, which influences the results. 
Furthermore, this donor seemed to have no activation in the presence of serums 4 to 7 (Figure 
4.19.D). 
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Figure 4.19. Quantification of IFNγ + CD8+ T cells within the PBMC population (indicated in % from total PBMCs) ) in 
healthy donors A) DN 1611 and B) DN1616 upon stimulation with a pool of CEF peptides, and in healthy donors C) DN 
5943 and D) DN 868 upon stimulation with CEF peptides 6 and 7.    
The expression of TNFα by CD8+ T cells was also evaluated for the same screen donors, as 
shown in Figure 4.20. For this analysis, the same number of donors, controls and stimuli were used 
and compared among each other. It is necessary to state that the DMSO control showed higher 
background levels (overall between 0.2 and 0.8%) in comparison to the previous experiment, where 
IFNγ levels were analysed. Donor DN 1611 demonstrated activation after being stimulated with the 
entire pool of CEF peptides (Figure 4.20.A). Despite showing DMSO values around 0.5%, this donor 
reached values of TNFα+ CD8+ T cells above 1.5%. Of note, serum 7 seemed to give the best results 
upon stimulation with the CEF pool (~3% of cells expressed the marker). On the other hand, screen 
donor DN 1626 did not respond well upon stimulation, showing low expression rates of TNFα, almost 
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equivalent to the DMSO control (Figure 4.20.B). Nonetheless, serum 8 reached TNFα expression 
percentage above 0.6%, demonstrating higher values than the other serums tested. This donor also 
demonstrated low TNFα expression levels upon stimulation with DMSO when serum 8 was used, 
suggesting that this serum presents the best results for this donor. As for screen donors DN 5943 and 
DN 868, the results varied mainly due to donor variability, stimulation with distinct individual CEF 
peptides and DMSO control values. As depicted in Figure 4.20.C, for donor DN 5943, only 3 serums 
(2, 7 and 10) demonstrated increase in the expression of TNFα upon stimulation. However, serum 2 
and 3, presented results within the same range as the DMSO stimulation condition for both individual 
CEF peptides stimuli, meaning that no activation or increase in TNFα expression occurred in these 
two serums. On the other hand, although serum 10, did not seem to increase the levels of TNFα 
expression by CD8+ T cells when stimulated with CEF peptide 19, upon stimulation with CEF peptide 
32 the values of TNFα expression improved, and approximately 1.5% of the cells were shown to 
express it. Lastly, screen donor DN 868 responded well to the CEF peptide 7, but not to the CEF 6 
peptide. Stimulation with CEF 6 peptide resulted in similar TNFα expression levels among the 
different serums (0.3% – 0.5% of TNFα+ cells), but these were comparable to the values obtained 
upon stimulation with the DMSO control. When stimulated with CEF peptide 7, serums 2, 3, 8, 9 and 
10 responded well, and more than 1% of the CD8+ T cells were also TNFα+. Like previously 
observed, no response was obtained with serums 1 and 4 to 7. Furthermore, the in-house serum 
(serum 10) was the serum candidate that showed better results upon stimulation for this screen donor 
(approximately 5% of the cells expressed TNFα upon stimulation with CEF peptide 7). 
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Figure 4.20. Quantification of TNFα + CD8+ T cells within the PBMC population (indicated in % from total PBMCs) ) in 
healthy donors A) DN 1611 and B) DN1616 upon stimulation with a pool of CEF peptides, and in healthy donors C) DN 
5943 and D) DN 868 upon stimulation with CEF peptides 6 and 7.    
The last intracellular marker evaluated in this serum screen was IL-2, and once again by its 
expression was assessed in CD8+ T cell within a PBMC population (Figure 4.21). All the stimuli, 
controls and number of serums tested here were the same used as the ones previously described for 
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the evaluation of IFNγ and TNFα expression patterns by CD8+ T cells. Results indicate that the levels 
of IL-2 expression in this cell subset by are much lower when compared with IFNγ (Figure 4.19) and 
TNFα (Figure 4.20). However, it was still possible to distinguish IL-2 expression levels among the 
donors, and some serums potentiated an increase in IL-2 expression, when compared with the DMSO 
control values, which were very low in this experiment. For instance, all the serums seemed to 
amplify IL-2 expression in the same spectrum (0.2% to 0.5% for the cells expressed the marker) in 
screen donor DN 1611, upon stimulation with the CEF peptide pool. Although there was some 
variation between the responses to the different serums, this might be justified by a variation within 
the serums content. The same happened in screen donor DN 1626, where the results were similar 
among all the serums, even though IL-2 expression occurred at a lower range compared to donor DN 
1611. Because of these overall lower levels, and due to the variation between serums, we concluded 
that practically all serums enhanced the signals obtained from this donor. As for screen donors DN 
5943 and DN 868, which were stimulated with CEF individual peptides, their response to the presence 
of different serums was not distant from what we have seen for the other donors. Screen donor DN 
5943 showed similar results for the two individual peptides among all the serums used (around 0.1% 
of IL-2+ cells). On the other hand, screen donor DN 868 demonstrated a good response to CEF 
peptide 7 with serums 2, 3, 8 and 10. The latter is the in-house used serum, and showed the best 
results upon stimulation with this peptide, with around 0.5% of the cells expressing IL-2. Also, no 
response was obtained by serums 1 and 4 to 7, where no IL-2 expression was observed, and the same 
holds true upon stimulation with the CEF 6 peptide.  
Figure 4.21. Quantification of IL-2 + CD8+ T cells within the PBMC population (indicated in % from total 
PBMCs) in healthy donors A) DN 1611 and B) DN1616 upon stimulation with a pool of CEF peptides, and in healthy 
donors C) DN 5943 and D) DN 868 upon stimulation with CEF peptides 6 and 7.   
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4.5.3 Proliferation Assay 
In complementarity to the ELIspot assay, a proliferation assay was performed using some of 
the donors used in the previous experiments, and included 10 different serums previously tested. In 
this experimental procedure, all donors’ PBMCs were stimulated with CEF pool peptides (Figures 
4.22.A and B), and two of the donors were stimulated with individual CEF peptides (Figures 4.22.C 
and D). DMSO and Ki67 proliferation marker were also used, due to their well-stablished 
functionality as negative control and proliferation cell marker, respectively. FMOs for the Ki67 
marker were also prepared for all donors as a negative control for the assay. In this assay, the 
percentage of CD8+ T cells within PBMCs was evaluated based on the expression of the Ki67 cellular 
marker, i.e. based on these cells ability to proliferate after 5 to 7 days. The negative control, DMSO, 
showed the expected results for all the tested donors and serums (Figures 4.22.A, B, C and D). 
However, there were some exceptions: serum 10 on figure Figure 4.22.A, serum 9 on Figures 4.22.C 
and serum 4 on Figures 4.22.D responded in a relatively high manner, demonstrating high percentage 
of background in comparison to the other serums tested. 
In Figures 4.22.A and B, there is a clear amplification of Ki67 signalling by CD8+ T cells 
when stimulated. Serums 3, 4, 6, 9 and 10 (20 to 30% of cells express Ki67) for screen donor DN 
1611 and serums 3, 4, 5, 6, 8 and 9 (20 to 40% of Ki67 expressing cells) for screen donor DN 1626 
presented the best proliferation results for these donors. In particular, we noticed that serum 4 granted 
the best results among all tested serums for donor DN1626, reaching values of Ki67 expression by 
CD8+ T cells of above 40%. 
As for screen donors DN 5943 and DN 868, these were stimulated with individual CEF 
peptides, both 19 and 32 in the case of DN 5943, or 6 and 7 for DN 868. Screen donor DN 5943 
proliferation levels seemed to be higher (10 to 20% of the cells expressed Ki67) compared to screen 
donor DN 868. In this donor, we observed that there was signal amplification in serums 3, 4, 5, 6 and 
8, independently from the CEF individual peptide used as stimulus. Serum 10 was discarded for this 
donor’s results, since both background levels and FMO percentage levels were too high. On the 
opposite, screen donor DN 868, showed very low levels of proliferation and this donor did not seem 
to be stimulated by any of the individual CEF peptides tested. It also did not present signalling 
amplification with any of the serums used. Only serum 3 and 6 show proliferative response for this 
donor upon stimulation with CEF peptide 7, where approximately 20 and 30% of the CD8+ T cells 
expressing the Ki67 marker, respectively. However, when stimulated with CEF peptide 6, no response 
was obtained for any of the serums tested. 
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Figure 4.22. Quantification of CD8+ T cells based on the proliferation marker Ki67 (indicated in % from total 
PBMCs) in healthy donors A) DN 1611 and B) DN1616 upon stimulation with a pool of CEF peptides, and in healthy 
donors C) DN 5943 and D) DN 868 upon stimulation with CEF peptides 6 and 7.   
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The aim of this thesis project was to characterize immunologically MAIT cells in chronically 
infected HBV patients in comparison to MAIT cells from healthy donors. For that purpose, MAIT 
cells from healthy and chronic HBV patients were evaluated and compared for their phenotypic 
signature and their functionality, when stimulated with IL-12 and IL-18 recombinant cytokines. In this 
project, three main questions were addressed: 1) Do MAIT cells show phenotypic differences in 
healthy and chronic HBV patients?, 2) Are MAIT cells still functional in a chronic HBV infected 
patients? and 3) Can MAIT cell be used as a new immunotherapeutic approach for HBV cure? 
The experimental procedures and consequent results obtained in this project gave us a better 
understanding about MAIT cells and how to address the questions previously made, as well as to give 
input on the next experimental steps to perform using MAIT cells. 
Gating Strategy, FMO’s  
A gating strategy was successfully set up for MAIT cells according to these cells specific 
markers, CD161 and TCRVα7.2. MAIT cells were gated on a lymphocyte population and used on 
subsequent assays (See Materials and Methods section). The gating strategy used within this project 
is in compliance to gating strategies used by other research groups152. At the same time, we 
successfully optimize the different antibody panels used in this project by performing FMO’s 
experiments. This qualifies this gating strategy for every antibody used in the identification of our 
MAIT cells populations and subpopulations, as the FMO controls ensure any spread of the 
fluorochromes into the channels of interest, properly identified. The aim was to obtain accurate results 
and with the smallest deviation possible when characterizing MAIT cells phenotype and functional 
ability. 
IL-12/IL-18 out titration experiments 
It is known that MAIT cells are activated in a TCR dependent manner due to the presentation 
of pyrimidine intermediates such as 5-OE-RU or 5-OP-RU105,106,149,211,212. These can also be 
denominated as bacteria-born small compounds, derived from the riboflavin synthesis pathway, which 
is present in bacteria such as Escherichia coli149. However, MAIT cells can also be activated in a 
TCR-independent manner when stimulated with innate cytokines IL-12 and IL-18213,214. This occurs 
because MAIT cells express interleukin receptors correspondent to the cytokines IL-12R and IL-
18R107,123,160,200. Some reports describe that is possible to activate MAIT cells through their stimulation 
with other innate cytokines, such as IL-15 and IL-7200,215,216 which we did not have time to test in our 
study. In the scope of this project, MAIT cells were stimulated IL-12 and IL-18 recombinant 
cytokines (See Materials and Methods). Thus, it was necessary to perform out-titration experiments 
where these cytokines were used in different concentrations (See  Materials and Methods and 
Results). We tested different dilutions of recombinant cytokines IL-12 and IL-18 stimuli, using 
healthy patients PBMCs. Out of the 6 dilutions for each stimulus, we found that the concentrations 
0.25, 1 and 10ng/mL, and 1, 10 and 50ng/mL covered the optimal range for MAIT cell stimulation for 
IL-12 and IL-18, respectively. Also, the stimuli concentrations chosen allowed a better evaluation of 
MAIT cells activation range and functionality, based on the measurement of specific cellular markers 
expression in a dose-dependent stimulation manner. 
Surface Markers  
MAIT cells were evaluated for their total percentage in healthy and chronic HBV patients, 
based on two specific cellular markers for these cells, CD161 and TCRVα7.2217,218 (See  Materials 
and Methods and Results). MAIT cells were stimulated with IL-12 and IL-18 recombinant 
cytokines at different concentrations, as these cytokines activate MAIT cells213,214. Also, these cells 
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were tested for their phenotypic signature as an approach to understand if the frequency of CD4+, 
CD8+ and CD56+ MAIT cells differs among the two groups tested - healthy and chronically infected 
HBV patients.  
The results obtained in this project suggest that the frequency of total MAIT cells in healthy and 
chronic HBV patients is similar after stimulation with IL-12 and IL-18 (Figure 4.1). In our study We 
show that total population of MAIT cells were similar between healthy and chronically infected 
patients, but also that there is no difference in the percentage of MAIT cells responding to IL-12/18 
stimuli. Therefore, we are confident that this study is comparing the same MAIT cell populations 
between the two patient groups. Also, we observed that after 24 hours stimulation with IL-12 and IL-
18, the percentage of total MAIT cells did not increase within the two groups. One of the reasons why 
the total number of MAIT cells remains identical among healthy and chronic HBV patients might be 
that 24 hours stimulation might not be sufficient to induce MAIT cells replication cycle that can show 
differences between the two groups tested, since the conditions used were not suppressive. 
Nonetheless, HBV infection apparently does not promote MAIT cells death, which from a therapeutic 
development perspective is a positive remark for using these cells in the future as a therapy for HBV. 
Also, by limiting the stimulation time of MAIT cells (24 hours) we were able to restrict the number of 
variables used in this project and can directly compare healthy and chronic HBV patients. However, it 
is important to mention that the percentage of total MAIT cells in each donor individually presents 
variation, which suggests variability upon stimulation with IL-12 and Il-18 recombinant cytokines. 
This variable needs to be taken into account when working with human samples, in this case PBMCs. 
Some reports174,175,219–221 indicate that the frequency of total MAIT cells (CD3+ CD161+ TCRVα7.2+) 
decreases during human viral infections such as human immunodeficiency virus (HIV) infections or 
co-infections like HIV/ M. Tuberculosis221,222. However, our results show the contrary in regards to 
hepatitis B patients and are supported by Boeijen and colleagues223, where the same results were 
obtained with regards to the total MAIT cells percentage when these cells were sorted using specific 
cellular markers, CD161 and TCRVα7.2. At the same time, flow cytometry analysis of our samples 
confirmed that MAIT cells are a subset of innate-like T cells214, showing a CD3+ CD161+ TCRVα7.2+ 
phenotype after IL-12 and IL-18 stimulation. Also, confirmed that the percentage of MAIT cells 
within the peripheral blood is comprised between 0 and 10%115,212,224. Despite these facts, we could 
argue that the variation in healthy and CHB MAIT cells baseline is high, but demonstrate an overlap 
when analysing their frequency. However, due to a low number of patients tested and consequent poor 
statistical data, it is not entirely correct to make this claim. For example, donor HBV1 shows less 20% 
CD8+ and 4% CD56+ MAIT cells expression percentages than healthy volunteers, and donor HBV3 
presents the same pattern for CD8+ MAIT cells expression.  Therefore, further studies are needed to 
reproduce these results in bigger cohorts in the future, which would allow a statistical and 
comprehensive analysis of the levels of MAIT cells between healthy and HBV chronic donors.  
We further investigated whether MAIT cells present a similar phenotypic signature as their 
parental population. As MAIT cells are known to be CD3+ lymphocytes, we evaluated whether these 
cells could be CD4+ and CD8+, since this is the case with conventional T cell subpopulations. 
Importantly, while in the presence of a viral infection, as Hepatitis B infection, the existence of an 
active and sustained multi-epitope-specific CD4+ and CD8+ T cell response is necessary in order for 
the immune system to respond effectively225. However, in a situation of a chronic infection such as 
HBV, there is a failure in innate and adaptive response to clear the infection, which leads to an 
increased persistence by the virus within the host225,226. Subsequently, we tried to understand whether 
there are differences in the percentage of CD4+/CD8+ MAIT cells between healthy patients and 
chronically infected HBV patients (Figure 4.2 and Figure 4.3). These results are supported by 
Wakao and colleagues212, as the authors state that in healthy humans MAIT cells are mainly CD8+, 
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with a smaller percentage being CD4+. Regarding chronic HBV patients, our results suggest the same, 
since exists a higher percentage of CD8+ MAIT cells in comparison to CD4+ MAIT cells, which 
strongly indicates that these cells could be used as a new therapeutic approach. CD8+ T cells primary 
function is its cytotoxic function for clearing viral infection. MAIT cells in peripheral blood are 
mainly CD8+ and that would mean that in chronic viral infections, like HBV specific T cell 
exhaustion, if we could transfect an HBV specific TCR to MAIT cells, possibly these could be used 
for HBV viral clearance and HBV specific hepatocytes killing.    
The frequency of CD4+ MAIT cells was measured and the results obtained indicate a slightly higher 
population in chronic HBV patients, when compared to health and after stimulation. Nonetheless, 
CD4+ MAIT cells frequency is inversely related with their homologous population, CD8+ MAIT cells. 
2/3 of chronic HBV donors (HBV1 and HBV3), responded positively to both stimuli, reaching 
frequencies approximately two-fold higher than the frequencies we had observed in the healthy 
patients. Furthermore, while quantifying the frequency of CD8+ MAIT cells from the both healthy and 
chronic HBV patients, it is possible to identify an increase in percentage, in both groups and in 
comparison to CD4+ MAIT cells, previously discussed. Interestingly, chronic HBV patients (HBV1 
and HBV3) show that 60% of the total MAIT cells tested in these donors are indeed CD8+ MAIT cells 
and that there is a percentual decrease, when comparing to healthy patient’s data. The sudden increase 
in CD4+ MAIT cells frequency after stimulation and consequent decrease of CD8+ MAIT cells 
frequency in chronically HBV infected patients, in contrast to healthy patients, could be directly 
related to the presence of a chronic viral infection211. In cases of HBV infection, CD4+ T cells227 
support antiviral response signalling against the virus, whereas CD8+ T cells role in focus on killing 
infected hepatocytes. Assuming a state of chronic HBV infection, in which the human immune system 
is continuously subjected to a state of latent infection CD8+ T cells normally become exhausted, 
losing the capacity to act upon infected hepatocytes. MAIT cells, as one of T cells subset, show the 
same pattern in chronic HBV where CD4+ and CD8+ MAIT cells frequency is inversely related, 
curiously higher, and lower than healthy patients MAIT cells, respectively. Based on our results, and 
assuming that our observations regarding the total percentage of CD3+ MAIT cells are correct, and 
that CD4+ or CD8+ MAIT cells derive from CD3+ MAIT cells, is normal that if one subpopulation 
frequency shifts, the other automatically tends to compensate and change. In addition, the fact that 
patients are continuously infected may also influence the results, since the immune system might be 
exhausted. Importantly, when MAIT cells were stimulated with IL-12 and IL-18, CD4+ MAIT cells 
frequency slightly increased, whereas CD8+ MAIT cells frequencies remain identical, within each 
group. 
MAIT cells were also evaluated for their frequency of CD56 expressing cells, as shown in 
Figure 4.4. This surface marker was tested in healthy and chronically HBV infected patients using the 
same experimental procedure as for the other surface markers, described before. Here, we tried to 
understand the extent of MAIT cells that are CD56+, and to address if any differences appear when in 
a chronic viral infection environment. The results obtained suggest that CD56+ MAIT cells are present 
both in healthy and chronic patients (between ≈10 and 35%, respectively). However, there was an 
exception, healthy donor HC 3, when stimulated with IL-18 at 50ng/mL showed almost 50% of 
CD56+ MAIT cells. Still, no differences were observed when comparing the results for the two groups 
tested, even though all donors were prone to inherent variability, more patients’ samples are needed to 
increase the statistical power of our results and possibly a net change in percentage that could 
normalize this variability and minimize its influence in our data. In resume, we concluded that MAIT 
cells phenotype, retrieved from human PMBCs, is also characterized by the surface expression of 
CD56, i.e., these cells are CD56+.  
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Based on the results obtained from human PBMCs, we could conclude that MAIT cells 
display a phenotypic signature characterized by the presence of two surface markers, CD4 and CD8. 
Therefore, independently of their frequencies, which may vary from donor to donor, we concluded 
that MAIT cells contain separate CD4+, CD8+ and CD56+ populations which were previously 
observed by Sandberg and colleagues152. 
Ex Vivo MAIT cell Activation 
Next, we evaluated MAIT cells for their expression of different molecules divided in three 
panels: 1) Checkpoint inhibitors, 2) Activation Markers and 3) Pro-Inflammatory Cytokines (See  
Materials and Methods and Results). Thus, in the scope of this project (See Objectives), we 
compared the activation state of MAIT cells retrieved from healthy patients and chronic patients 
infected with HBV. HBV chronic infection is characterized by a sustained level of T cell 
exhaustion228. For that purpose, MAIT cells were stimulated with IL-12 and IL-18 recombinant 
cytokines in three different concentrations each and evaluated for their expression levels of the 
following checkpoint inhibitors: PD-1, TIM3 and LAG3. There are several reports describing high 
levels of expression and the function of inhibitory receptors within an exhaustion environment in 
chronic viral infections228–230. In this project, we assessed MAIT cells for the extent of their 
exhaustion pattern and level. In Figure 4.5, the results obtained for MAIT cells expression of the 
checkpoint inhibitor marker PD-1 firstly show that MAIT cells retrieved from chronic HBV patients 
express higher PD-1 levels in comparison to MAIT cells isolated from healthy patients, with donor 
HBV2 reaching almost 80% of PD-1+ MAIT cells. These results are in accordance to what is 
described in the literature, hence the percentage of PD-1+ expressing MAIT cells in chronic HBV 
patients was expected to be higher than healthy controls due to the consistent viral infection and 
potentially higher MAIT cells exhaustion levels231,232. For instance, these results are supported by a 
study from Yong and colleagues232, where the authors evaluated MAIT cells from chronic HBV 
patients with and without DNA viremia and compared them with MAIT cells from healthy patients. In 
this study, the authors show an increase in the levels of PD-1 expressing MAIT cells in chronic HBV 
patients in comparison to healthy controls232. Also, MAIT cells have been shown to be dysfunctional 
in chronic patients infected with the human immunodeficiency (HIV) virus 175,211 and co-infection of 
HIV and tuberculosis221,224, correlated with PD-1 expression levels increment. Our results indicate that 
MAIT cells, when stimulated increase the rate of PD-1 expression and at the highest concentration of 
IL-12 (10ng/mL) the frequency of PD-1+ MAIT cells reaches its highest value. In addition, these 
results suggest that, besides expressing PD-1, MAIT cells from chronic HBV patients are functional 
and may be resistant to exhaustion, based on IFNγ+ MAIT cells results, discussed below. On one of 
the healthy patients, donor HC 1, this specific value was excluded from the results due to a low 
viability level and therefore failed our qualification criteria for using this sample (viability above 
70%) (Figure 4.5). Based on our results MAIT cells from chronic HBV patients, these individuals 
present higher expression of PD-1 when stimulated, leading to an increase in these cells exhaustion 
state. However, upon the same stimulation parameters healthy patients MAIT cells also express PD-1, 
but at a lower degree of infection. This occurrence might happen, since PD-1 is also an activation 
marker, hence present at both test groups, with or without stimulation. Moreover, due to these cells’ 
tissue localization on mucosal sites such as the liver and the amount and diversification of bacterial 
species within the same. Remarkably, PD-1 expression by MAIT cells in this organ is always present. 
Furthermore, all samples from both groups were compared to unstimulated samples (See Materials 
and Methods) which showed that the baseline level of PD-1 expression was comprised between 20% 
and 60%, meaning that without stimulation, MAIT cells from healthy and chronic HBV patients 
already express this checkpoint inhibitor. 
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Besides PD-1 checkpoint inhibitor, there are two other regulatory factors that are directly 
involved in immune dysfunction, TIM3 and LAG3. Therefore, the expression of these checkpoint 
inhibitors by MAIT cells was also studied46,226. TIM3 is known as a regulatory molecule expressed on 
T cells226. Upon chronic infection and T cells exhaustion, this inhibitory surface marker seems to be 
overexpressed and expressed at higher frequency233–235. Interestingly, some reports state that a 
blockade of TIM3 expression enhances cell proliferation and cytokine production46,236. Thus, this 
checkpoint inhibitor is seen as promising target for immunotherapy for infectious diseases and 
cancer46,237. 
In Figure 4.6, the results for MAIT cells expression of TIM3 checkpoint inhibitor are 
displayed. As shown for PD-1+ MAIT cells expression, chronic HBV patients MAIT cells also 
demonstrate higher TIM3 expression percentages (30, 10 and 40% for donors HBV1, HBV2 and 
HBV3, respectively), in comparison to the baseline expression in healthy volunteers. However, the 
results for TIM3 are not as conclusive as for PD-1 expression, due to the fact that donor variability 
and variation upon IL-12 and IL-18 stimulation is higher than previously observed. When assessing 
the two groups tested, it is clear that only one of the healthy patients tested, donor HC2, demonstrated 
an increase in TIM3 expression by MAIT cells, reaching a percentage of 30% TIM3+ MAIT cells 
upon stimulation with IL-12 at 10ng/mL. Donors HC1 and HC2 expression levels were not conclusive 
due to variation upon stimulation with IL-12 and IL-18 at different concentrations. On the other hand, 
chronic HBV donors HBV1 and HBV3 showed a positive response upon stimulation with these 
cytokines, where TIM3 expressing MAIT cells reached frequencies of 30 and 40%, respectively, and 
in comparison to healthy patients (below 5%) baseline expression. Donor HBV2 responded in a 
similar manner to the healthy patients HC1 and HC2. However, we could speculate that, upon 
stimulation with IL-12 recombinant cytokine, donor HBV2 responded positively, although at a lower 
extent compared to the other chronic HBV donors. In this donor, around 10% of the analysed MAIT 
cells expressed TIM3. Also, the results show that chronic HBV patient’s response may vary 
depending on the stimuli concentration used, suggesting susceptibility upon stimulation. However, 
this variation might not be only associated to chronicity, since healthy volunteers demonstrate the 
same pattern, as well as strong individual variability. 
Previously, Yuan Liu and colleagues indicated that CD4+ and CD8+ HBV-specific T cells 
showed an increase of TIM3 expression levels46,238. Despite having a low N value of donors in this 
project, our results suggest that the frequency of MAIT cells expressing TIM3 increases upon 
persistence of a viral infection (HBV). Overall, our data suggests that MAIT cells isolated from CHB 
patients PBMCs show higher expression frequencies of TIM3 in comparison to the healthy patients. 
The same appears to result in other chronic viral infection like HIV and HCV, where overexpression 
of TIM3 CD4+ and CD8+ T cells was associated to a progressive state of T cell dysfunction and 
consequent exhaustion 46,236,239–241. These results are also in compliance to another research study from 
Yong and colleagues 232, where the authors showed an increase on TIM3+ in Vα7.2 cells in chronic 
HBV patients in comparison to their healthy controls. 
Lastly, the frequency of LAG3+ expressing MAIT cells was evaluated on the same donors 
(See Materials and Methods and Results). LAG3 molecule is a member of the immunoglobulin 
family and carries a negative regulatory role in T cell exhaustion by suppressing T cells function242. 
Some reports give special attention to this checkpoint inhibitor function and involvement in T cells 
regulation243–245. Also, its role in effector T cells and Treg cells puts this marker in a position of 
potential target modulator for T cells regulatory mechanisms in autoimmunity, cancer and chronic 
infections such as HBV246. Our results regarding the comparative analysis of MAIT cells from healthy 
and chronic HBV patients, after stimulation with IL-12 and IL-18, shows discrepancies in the LAG3+ 
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frequencies among the two groups (Figure 4.7). Overall, chronic HBV patients, upon stimulation with 
cytokines IL-12 and IL-18 but depending on the stimulation concentration used, present 2 to 4 times 
higher LAG3+ MAIT cell frequencies than healthy patients, whereas only healthy donor HC2 
responds positively (2%) to one of the stimuli, IL-12 at 1ng/mL respectively. In 2/3 of the chronic 
HBV patients tested (HBV1 and HBV3), it seems that LAG3+ MAIT cells frequency progressively 
increases with IL-12 stimulation, whereas IL-18 recombinant cytokine only induces a positive 
stimulatory effect in chronic HBV donor HBV1. Importantly, chronic HBV donor HBV1 shows the 
highest LAG3+ MAIT cells frequency (approximately 8%) in both stimuli, when compared to the 
other chronic HBV patients, as well as healthy patients. Interestingly, regarding the highest 
concentration used in both stimuli (10ng/mL for IL-12 and 50ng/mL for IL-18), these concentrations 
seem to be too high for this donor, and potentially no more MAIT cells are available to express 
LAG3, suggesting that such higher concentrations led MAIT cells to a state of apoptosis and could 
explain the low sample viability in this donor after stimulation. Ye and colleagues demonstrated that 
CD8+ T cells in chronic HBV patients overexpress LAG3, in contrast to their healthy control values 
247. The same result was obtained in another report243, where the authors concluded that chronic HIV 
patients CD4+ and CD8+ T cells LAG3 expression levels are upregulated, almost four times, in 
comparison to the healthy volunteer’s samples. These two studies give sustain to our results, hence 
MAIT cells show the same response pattern as CD4+ and CD8+ T cells, since there is an 
overexpression of the checkpoint inhibitor molecule LAG3 in these cells. Also, our results suggest 
that upregulation of this molecule is mostly favoured when MAIT cells were stimulated with IL-12, 
both in healthy and chronic HBV patients. These findings could correlate to one report242, in which 
the author describes the same, although this study was directed at conventional T cells from patients 
with follicular lymphoma, and states that there is a relation between the increase of LAG3 expression 
with the progression of the disease. We can conclude that, not only MAIT cells express LAG3 
checkpoint inhibitor upon stimulation, but also that chronic HBV patients MAIT cells show 
upregulated LAG3+ frequencies, when compared to the baseline expression from healthy patients. 
This could indicate that MAIT cells in chronic HBV patients are exhausted up to a certain extent, 
depending on the severity of the disease228. MAIT cells are known for expressing checkpoint 
inhibitory molecules, previously mentioned, in HBV and other chronic viral infection. This is strongly 
correlated with T cell exhaustion and suggests that MAIT cells in chronic HBV patients are exhausted 
or at least show this phenotypic state up to a certain point. 
 Activation Markers 
Based on the fact that MAIT cells show expression of markers characteristic from exhaustion, 
we went further to understand if being exhausted meant no sign of being functional or whether these 
cells could still be activated when stimulated with IL-12 and IL-18 recombinant cytokines. For that 
purpose, we tested MAIT cells for different activation markers, 1) early activation markers – CD69 
and CD25 and 2) late activation markers – CD38 and HLA-DR (See Objective, Materials and 
Methods and Results Section). It is imperative to mention, that the designations “early” and “late” 
are solely based on how long cells, in this case MAIT cells, were stimulated for and the time point at 
which these markers started to be expressed by MAIT cells. The baseline CD25+ expression 
frequency on healthy patients MAIT cells is practically null in all donors, even upon stimulation with 
IL-12 and IL-18 recombinant cytokines (Figure 4.8). Nonetheless, healthy donor HC2 shows a 
positive response to both stimuli, displaying a maximum frequency of 10% of the total MAIT cells 
tested expressing CD25 activation marker. On the other hand, the data from chronic HBV patients 
suggests that MAIT cells are actively functional, since we observed an increase in CD25 expression. 
Donors HBV2 and HBV3 MAIT cells positively respond to IL-12 stimulation by expressing CD25, 
but at a low degree. As for IL-18 stimulation, it appears that donor HBV 3 was the only one showing 
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a positive activation, where CD25+ expressing MAIT cells percentage progressively increases with 
the stimuli concentration and reaches 30% at 50ng/mL (Figure 4.8). Thus, when comparing healthy 
and chronic HBV patients CD25+ expressing MAIT cells percentages, we can conclude that chronic 
HBV patients MAIT cells CD25 expression is upregulated, when compared to the baseline expression 
levels in healthy patients. Therefore, we can conclude that chronic HBV patients MAIT cells can be 
activated with IL-12 and IL-18 and demonstrate functionality based on CD25 expression. The 
previous statement is supported by Pushpa Hegde and colleagues, as the authors showed that 
peripheral blood MAIT cells from cirrhotic patients display an activated phenotype characterized by 
upregulation of CD25 expression marker, in comparison to the healthy controls 213. The authors 
reported that the percentual difference between cirrhotic patients and controls of almost four times 
higher in cirrhotic patients, but contrary to our project MAIT cells were stimulated with PMA/ 
ionomycin213. Also, the authors assessed the CD25 baseline expression, as well as MAIT cells CD25+ 
percentages after PMA/ionomycin stimulation. Our results suggest the same pattern, although it is 
necessary to increase the N value of the donors from each group to clarify our results, since despite 
the CD25 expression in MAIT cells from chronic patients is upregulated, when compared to healthy 
patients, the statistical difference between the two groups is tenuous. Nonetheless, several reports 
come to the same conclusion in other chronic viral infection such as hepatitis C (HCV) and HIV 
102,175,218,248.  
CD69 is a co-stimulatory receptor, as well as an early activation marker which function is 
correlated with the cytotoxic potential of lymphocytes, as well as cellular proliferation and cytokine 
production225,249,250. The role of this early activation marker in immune exhaustion is far less 
understood. However, since MAIT cells are found in systemic circulation and are enriched in the 
mucosa and liver, it is hypothesized that MAIT cells exhaustion could be in concordance to a 
reduction of CD69 in chronically infected HBV patients225. Also, this activation marker is known for 
being constitutively expressed by plentiful of cell types such as monocytes, NK cells, B cells and T 
cells225,251,252. In this project, we assessed whether the lack of effector cell function of exhausted 
MAIT cells could be a repercussion of reduced levels of CD69 in chronic HBV patients (See 
Objective). Our results show a clear downregulation of CD69+ MAIT cell percentages in chronic 
HBV patients, compared to the baseline expression from healthy patients’ MAIT cells (Figure 4.10). 
Healthy volunteers responded positively to both stimuli, and donor HC1 obtained the highest MAIT 
cell CD69 expression percentage, almost 80%, upon stimulation with IL-12 (at 10ng/mL) and IL-18 
(10ng/mL). As for chronic HBV patients, the results were disparate and variable. Thus, only donor 
HBV1 should be assessed in more detail, since almost 60% of the total MAIT cells analysed 
expressed the early activation marker CD69. As for the other chronic HBV patients, donor HBV2 
showed a similar response as healthy volunteers with no variation while stimulated with different 
stimuli concentrations and donor HBV3 only responded to IL-12 stimulation at 1ng/mL (Figure 
4.10). We could conclude that despite the downregulation in CD69+ MAIT cells frequency in chronic 
HBV patients, MAIT cells are still functional and show activation as MAIT cells from healthy 
patients, even though at a lower degree. There are a few reports supporting our results and consequent 
analysis, though in our case the number of donors tested in both groups is low173,175,225. For instance, 
Yong and colleagues225 assessed whether the decrease in number of cytokine-producing cells in 
chronic HBV patients, as well as cytokine levels produced in these patients, could be directly 
associated with the expression of CD69. The authors evaluated the expression level of this activation 
marker in MAIT cells through MFI and registered a reduction in CD69 expression levels by MAIT 
cells in chronic HBV patients in comparison to the healthy controls 225. This remark correlates 
perfectly with the results obtained within this project, since the percentage of CD69 expressing MAIT 
cells decreased in HBV patients in comparison to healthy patients. However, some reports suggest 
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that, when in the presence of an exhausted environment associated with several infectious diseases, 
such as dengue virus, influenza virus, HCV and Systemic lupus erythematosus (SLE), this early 
activation marker is overexpressed by MAIT cells109,211,253,254. 
Above, we described and discussed the percentual expression levels of early activation 
markers – CD25 and CD69 – by MAIT cells in healthy and chronic HBV patients. Accordingly, we 
also compared the frequency of MAIT cells that express late activation markers – CD38 and HLA-DR 
– between both groups. 
In this project we assessed MAIT cells CD38 expression and its impact in MAIT cells 
activation and function within a chronic infection such as HBV. The results obtained demonstrate that 
the baseline CD38 expression by MAIT cell from healthy patients is practically null, suggesting that 
this cellular marker is not accurate to conclude if MAIT cells are active or not in chronic HBV 
patients (Figure 4.9). However, healthy donor HC2 positively responded to IL-12 stimulation at 
10ng/mL and approximately 20% of the total MAIT cells for this donor have shown CD38 
expression. In contrast, chronic HBV patients MAIT cells CD38 expression is quite different, starting 
with the background levels, which are considered much higher in comparison to healthy patients and 
suggesting that a chronic HBV infection could influence CD38 expression and consequent MAIT cell 
activation and function. Furthermore, only donors HBV2 and HBV3 behaved in a dose-dependent 
manner in response to the increase in stimuli concentrations. Notably, chronic HBV donor HBV3 only 
showed this dose-response pattern upon stimulation with IL-18, where practically 40% of the total 
MAIT cells presented CD38 expression at the highest stimuli concentration. Chronic HBV donor 
HBV2 was responsive to both stimuli showing that almost 60% of the total MAIT cells tested express 
CD38. As for chronic HBV patient HBV1, its response to stimulation was null, since CD38+ 
expressing MAIT cells frequency was equal to the background level (Figure 4.9). We can conclude 
that despite the low N value of donors tested, the late activation marker CD38 is expressed by MAIT 
cells from both healthy and chronic HBV patients. Also, we could advocate that MAIT cells from 
chronic HBV patients are active, functional and show overexpressed frequencies of CD38, which 
could be directly associated to a continuous viral infection, since this marker is considered a late 
activation marker. Boeijen and colleagues also claim in one of their reports that chronic HBV patients 
MAIT cells present higher CD38 expression levels, when compared to healthy controls223. Here, the 
authors also suggest a direct relation between CD38+ MAIT cells increased frequencies to HBV 
disease progression, reaching it highest values in the inactive carrier phase. Another report evaluated 
the percentage of CD38+ expressing MAIT cells in other viral infection such as Dengue and Influenza 
A virus109. In this case, the authors describe a slight upregulation in the expression of CD38 by MAIT 
cells in both diseases after 10 days of infection. Thus, these results might suggest that MAIT cells 
from chronic HBV patients might be able to be activated in a chronically viral infected environment.  
Another late activation marker, HLA-DR, is constitutively expressed on the surface of B 
lymphocytes, monocytes and macrophages. This marker is well-described for being expressed at the 
late stages of activation on T and NK cells255,256. Also, the expression of HLA-DR on human T cells 
has been regarded primarily as a marker of activated T cells 257. Following the previous analysis on 
MAIT cells activation pattern, the frequency of HLA-DR+ MAIT cells was assessed. The objective 
was to get a better comprehension of this specific marker expression by MAIT cells and compare it to 
the previously tested activation markers in healthy and chronic HBV patients. The results obtained 
regarding the frequency of HLA-DR expressing MAIT cells in healthy and chronic HBV patients are 
similar (Figure 4.11). Nonetheless, there are results variations among donors from both groups, which 
can be directly related to the low number of donors and inter-donor variability, making it difficult to 
take solid conclusions. Based on HLA-DR+ expressing MAIT cells frequencies, our results 
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demonstrate that MAIT cells from healthy patients are functional and show activation when 
stimulated with both IL-12 and IL-18 recombinant cytokines. Also, in one of the healthy donors, HC2, 
we observed that more than 50% of the total MAIT cells tested expressed HLA-DR (Figure 4.11). It 
is true that the results for healthy and chronic HBV patients are similar for this marker, but it appears 
that chronic HBV patients MAIT cells show a slight upregulation of HLA-DR expression. For 
instance, chronic HBV donor HBV 2 responds in a dose-dependent manner to both stimuli as it 
reaches an HLA-DR+ MAIT cell frequency of 80%, way above HLA-DR baseline expression found in 
healthy patients. The same pattern can be found in donor HBV3, whereas donor HBV1 response to 
stimulation is considered null and below the background level. Hengst and colleagues demonstrated in 
an increase in MAIT cells HLA-DR expression in hepatitis C infected patients, when compared to 
healthy controls254. Even though their experimental procedures were directed at understanding the 
influence of different therapies used in HCV patients and how they could affect different markers, 
their results are in alignment with this project. Other two reports, one in Human T-lymphotropic virus 
type 1 (HTLV-1) infection and another in HBV, both indicate an upregulation in HLA-DR expression 
by MAIT cells in infected patients, compared to health controls232,258. Further analysis should be made 
on MAIT cells HLA-DR expression, starting by increasing the stimulation time above 24 hours, since 
our results suggest the same as the previous studies mention, but are still not clear. Nonetheless, we 
can conclude that MAIT cells from chronic HBV patients do express the late activation marker HLA-
DR, at a higher level than healthy patients MAIT cells, and are considered functional and active after 
being stimulated. Nevertheless, an upregulation in HLA-DR expression by MAIT cells in chronic 
infections could be an indicator of disease progression and state. As an extra remark, we were able to 
verify that in an exhausted environment, MAIT cells demonstrate an overexpression of several 
checkpoint inhibitory molecules, such as PD-1 and TIM3, which indicates that these cells present an 
exhausted phenotype. However, chronic HBV MAIT cells show activation and functionality in a 
chronic infection environment, as seen in this project by analysing different activation markers, upon 
stimulatory parameters. Nonetheless, not all activation markers evaluated on MAIT cells were 
expressed equally between both groups, and the fact that we observed a big inter-donor variation 
indicates the need to increase the number of samples analysed and repeat these experiments.  
Pro-inflammatory cytokines 
Under chronic viral infections or tumoral microenvironments, T cells activation mechanisms 
are downregulated as a feedback mechanism against the immune pathology, giving rise to a 
phenotype known as T cell exhaustion 259. Processes such as proliferative capability, cytotoxic activity 
and pro-inflammatory cytokine production are normally decreased in functional exhausted T cells and 
are considered intrinsic characteristics of these cells phenotypic signature 259. After showing that 
virally triggered MAIT cells are active, we went further with our analysis on MAIT cells to 
understand whether these cells can still show effector cell functions that may be significant to HBV 
chronic patients. MAIT cells were tested for different pro-inflammatory cytokines – IFNγ, TNFα and 
IL-2 – and their cytokine expression level was analysed and compared in healthy versus chronic HBV 
patients. IFNγ is the only type II interferon and it signals through the IFN-γ receptor (IFNGR). IFNγ 
production only takes place in specialized cells from the immune system, however their receptor 
(IFNGR) is present in most cells allowing this cytokine to bind all the major cell types and elicit a 
cellular response. Therefore, IFNγ is crucial in cellular immunity and establishes a bridge between 
innate and specific immune response pathways 260.We looked at pro-inflammatory cytokines in order 
to understand if MAIT cells are functional despite PD-1 and other checkpoint inhibitors upregulated 
levels. In addition, this project explored the concept that MAIT cells retain T cells functionality in a 
tolerizing environment.  Our results show that there is no upregulation of IFNγ expressing MAIT cells 
in chronic HBV patients in comparison to the healthy volunteers, which is concurrent with the 
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statement that MAIT cells have no TCR receptors and therefore cannot recognize HBV infected 
hepatocytes (Figure 4.12). MAIT cells from healthy patients seem to respond positively towards IL-
12 and IL-18 stimulation, but in a weak manner and showing low of IFNγ+ MAIT cells percentages. 
Only donor HC2 shows a dose-response pattern when stimulated with IL-12 reaching the highest 
percentage (15%) of IFNγ+ MAIT cell at 10ng/mL of stimulus. Likewise, only one chronic HBV 
donor (HBV2) shows a dose-response curve when stimulated with IL-12, reaching the same 
percentages of IFNγ+ expressing MAIT cells seen in healthy donor HC2. However, donors HBV1 and 
HBV3 MAIT cells demonstrate a slight increase in IFNγ expression when stimulated with 10ng/mL 
and 1ng/mL of IL-12, upon which around 5% of the total MAIT cells analysed express IFNγ. 
Nonetheless, these donors MAIT cells were also subjected to IL-18 stimulation, but overall responded 
insufficiently. Despite the low N value and high variability, our results suggest that IL-12 stimulation 
forces MAIT cells to secrete more IFNγ in donors from both groups, but in similar levels when 
compared against each other. Several studies have focused on quantifying the levels IFNγ expression 
on MAIT cells retrieved from patients with chronic viral infection such as HBV, HCV, HIV or other 
chronic liver pathologies that lead to a cirrhosis or hepatocellular carcinoma state213,218,232,248. A recent 
paper concerning MAIT cell exhaustion in HBV infection shows that IFNγ expression is upregulated 
in MAIT cells from healthy patients, compared to a poor expression level in chronic HBV patients232. 
The authors’ hypothesis is based on a relationship between the number of IFNγ+ MAIT cells and the 
disease state and progression. Also, Xiao and colleagues proved MAIT cells involvement in viral 
infections clearance and showed that in chronic HCV patients these cells are activated in a cytokine-
mediated manner, leading to an IFNγ upregulation214. In contrast to these and other reports 109,248,261, 
our results indicate that  MAIT cells from chronic HBV patients show a similar degree of IFNγ 
expression as MAIT cells from healthy volunteers (Figure 4.12). In concordance to our results, Hegde 
and colleagues, while measuring the percentage of IFNγ+ MAIT cells in healthy volunteer and 
cirrhotic patients, have found no significant differences in frequencies and activation response 
between the two groups213. MAIT cells show indeed effector cell function and production of IFNγ and 
there are references showing residual MAIT cells to be functionally active in HIV-infected patients, 
possibly contributing in mucosal inflammation by the release of pro-inflammatory cytokine such as 
IFNγ175,224,262. We can conclude that MAIT cells from chronic HBV patients have a similar activation 
and effector cell function as healthy MAIT cells. However, it is possible that IL-12 and IL-18 stimuli 
concentrations were not as optimal as we thought, since these recombinant cytokines are not only 
stimulators of MAIT cells but also influence IFNγ production by T and MAIT cells109,218,263. MAIT 
cells, contrary to normal CD8+ T cells, show IFNγ and TNFα functions, even though being PD-1 
positive, suggesting that MAIT cells are able to overcome exhaustion at a certain degree.   
Besides expressing IFNγ, MAIT cells also show evidence of secreting TNFα in several 
diseases, such as alcoholic liver disease (ALD), Scrub Typhus, HCV and HBV211,232,264–266. TNFα is 
known for being a pleiotropic cytokine involved in a range of physiological mechanisms that regulate 
inflammation, anti-tumoral responses and homeostatic control of the immune system267–269. This pro-
inflammatory cytokine is well-characterized for its protective endeavour against pathogens and as an 
effector cell product of CD4+ and CD8+ T cells or innate-like T cells such as MAIT cells, leading to 
the killing of infected cells267. The majority of the actions taken place by TNFα are mediated by the 
TNF receptor 1 (TNFR1), ubiquitously expressed by a large extent of cell types267,270–272. However, it 
is still unclear the role and effects of TNFα on T cells, though it is thought that this cytokine receptor 
is induced on T cells after activation267. Nevertheless, the expression levels of this cytokine in chronic 
HBV patients and healthy volunteers may be suggestive of a direct relation between MAIT cells 
exhaustion, activation and effector cell function upon infection. Therefore, in this project we aimed to 
understand the dynamics of TNFα pro-inflammatory cytokine expression in chronic HBV patients 
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(See Objective, Materials and Methods and Results Section). The results obtained regarding MAIT 
cells TNFα expression are considered similar for both groups (Figure 4.13). Only one healthy donor, 
HC1, positively responded to stimulation (IL-12) and shows an increment in TNF+ expressing MAIT 
cells frequency up to a maximum of 1% of the total MAIT cells evaluated. As for chronic HBV 
patients, MAIT cells show a slight TNFα expression increase, which also depends on inter-donor 
variability and stimulation concentration variations. Chronic HBV donors HBV2 and HBV3 act in a 
similar manner as healthy donors upon stimulation with IL-12, where it is observed that at the highest 
concentration MAIT cells express more TNFα. Furthermore, chronic donor HBV1 MAIT cells show 
approximately 3.5% TNFα expression, which is more than two times higher than the baseline 
expression in healthy patients and could be indicative of an increment in effector cell function by 
MAIT cells. Nonetheless, it is of the utmost importance to mention that the background expression 
levels for this donor were extremely high (almost 2%) and it should be noted that the number of 
TNFα+ MAIT cells was very low in both groups. Concerning IL-18 stimulation, no upregulated 
response in TNFα+ expression by MAIT cells was seen in both groups. There are several reports 
investigating MAIT cells’ TNFα expression in patients suffering from multiple infectious diseases 
218,232. Yong and colleagues performed a functional assay assessing the potential impairment of MAIT 
cells in IFNγ and TNFα production on chronic HBV patients232. The authors observed a decreased 
TNFα+ MAIT cells frequency in chronic HBV patients, which is suggestive to a direct connection to 
the high expression level of PD-1 in infected patients MAIT cells, leading to the functionally 
impairment of MAIT cells 232. Furthermore, in a report in HCV and antiviral therapy effect, it is 
shown a similar TNFα+ MAIT cells expression in HCV patients and healthy controls 218. These 
findings are supported by a study performed by Laidlaw and colleagues showing that TNFα secretion 
is another effector function of MAIT cells, depite the fact that the experimental feature is slightly 
different, since cells were not stimulated with IL-12 or IL-18 but different TNFα concentrations were 
measured266. Interestingly, in HCV this pro-inflammatory cytokine can have an antiviral role in 
inhibiting the spread of the virus211,266. In a study about Scrub Typhus disease the authors concluded 
that MAIT cells deficient TNFα expression in vitro reflects disease severity and demonstrated an 
increase in TNFα expression due to a consequent disease remission towards a healthy state265. Also, 
TNFα+ MAIT cells production impairment is related to elevated CD69 expression in this specific 
disease265. As a remark, our results show a downregulation of CD69+ MAIT cells percentages in 
chronic HBV patients, as well as poor production of TNFα. Nevertheless, chronic HBV patients are 
constantly on antivirals which may lead to a change in MAIT cells phenotype, as seen in cirrhotic 
patients subjected to long-term prophylactic antibiotic therapy213. In conclusion, our results are not 
enough to understand the degree of potential changes in TNFα expression by MAIT cells on chronic 
HBV patients, and to comprehend whether it may help clear the virus during a possible disease 
remission. However, our project is solely a piece of the puzzle, and these results should be optimized 
in the future by increasing the number of donors tested and by stimulating MAIT cells with IL-12 and 
IL-18 together. Despite this, our findings are still supportive of MAIT cells having a role in immune 
mechanisms and pro-inflammatory properties. 
MAIT cells exert its role in protective immunity against microbial infections through the 
production of effector molecules, such as IFNγ, TNFα and IL-2, and others like IL-17 and GrzB, 
which were not tested within this project255,273. We measured IL-2+ MAIT cells frequency in healthy 
and chronic HBV patients (Figure 4.14), since IL-2 is a pleiotropic cytokine, primarily produced by 
CD4+ T cells, although there is evidence of being secreted by activated dendritic cells (DCs), CD8+ T 
cells and NKT cells, though at lower levels273,274. Our results show limited IL-2 production by healthy 
and chronic HBV patients MAIT cells upon IL-12 and IL-18 stimulation, which might be influenced 
by inherent inter-donor variability in both groups. Upon IL-12 stimulation, the frequency of IL-2+ 
MAIT cells in healthy and CHB patients is considered disparate, since healthy patients do not 
72 
demonstrate any positive response or increase in frequency to situation, whereas chronic HBV 
patients, namely donors HBV 1 and HBV3 show an increase in IL-2+ MAIT cells percentage. 
Nonetheless, due to a high background level, chronic donor HBV1 response can have been 
misdirected and in contrast, this donor lacks a positive response to the stimulus. On the other hand, 
when evaluating MAIT cells from healthy and chronic HBV patients to IL-18 stimulation, the results 
are slightly different, since in both groups there are donors which respond positively and show an 
increase in IL-2+ MAIT cells frequency. In this case, two out of three healthy donors show a positive 
response to IL-18 stimulation and two out of three chronic HBV patients show the same response 
(Figure 4.14). Interestingly, healthy donor HC3 at the highest IL-18 concentration shows 1% of the 
total IL-2+ MAIT cells, which is way above the results obtained for all the chronic HBV patients. 
There is not much of a difference in our results, when comparing both groups, it is possible to see 
their response for the three IL-18 concentrations used is practically the same. As IL2+ MAIT cells 
analysis in this project was subjected to several variables, low number of donors, inter-donor 
variability and low cytokine expression, it is preposterous to assume differences between healthy and 
chronic HBV patients in IL2 expression. Thus, based on this cytokine expression alone, it is not 
possible to infer whether chronic HBV patients MAIT cells still demonstrate effector cell functions 
within this exhausted environment. Besides the data that we generated, there are a few reports 
debating IL-2 presence and expression by MAIT cells, as well as its possible role as novel therapeutic 
target for different diseases280. For instance, in 2014, Serriari and colleagues reported that in 
inflammatory bowel diseases like Crohn’s disease (CD) and Ulcerative colitis (UC), characterized by 
an immune response deregulation targeting the gut bacterial flora, MAIT cells activation during 
pathology could translate in a functional response281. The authors also claim that MAIT cells produce 
predominantly IFNγ, TNFα and IL-2, when stimulated in vitro, but when activated they might express 
more pro-inflammatory cytokines or change the set of effector molecules secreted281. In their report, it 
is also shown that IL2+ expressing MAIT cells frequency is lower in healthy patients, when compared 
to infected ones.  
In contrast, our results suggest similar but low IL2+ MAIT cells frequencies in both groups, 
which might make sense since IL2 expression is normally showed in low basal levels in resting T 
cells275. However, there is evidence showing that upon stimulation, T cells show an increase of IL-2 
expression, which might be correlated to CD25 activation marker expression255,282. Curiously, CD25 
is the alpha chain of the trimeric IL-2 receptor and it is expressed constitutively in the surface of 
several peripheral blood lymphocytes such as regulatory or memory T cells, making this relationship 
feasible255. In this project, we found that MAIT cells do express CD25, known for its role as an 
activation marker, and that chronic HBV patients show a slight upregulation of CD25+ expressing 
MAIT cells. Interestingly, we also found that chronic HBV patients MAIT cells seem to be more 
activated, and as a consequence show higher IL-2 production, although not confirmed for all donors. 
As a concluding remark, even though we observed that MAIT cells from chronic HBV patients 
overexpress exhaustion markers such as PD-1 and TIM3, these cells are still active, as confirmed in 
experiments where different activation markers were tested. As a consequently of this activation, 
MAIT cells are able to increase their frequencies of effector cell molecules like IFNγ, TNFα and last 
IL-2, although the outcome was dependent on the evaluated cytokine. 
Functional Assay – C1R and Isolated MAIT cells 
To evaluate whether MAIT cells are still functional or show an immune suppression similar 
to T cells in chronic HBV patients, we used two different procedures to isolate MAIT cells from 
human PBMCs (Figure 4.15 and Figure 4.16). The objective was to couple isolated MAIT cells 
together with a B lymphoblast cell line - HMy2.CIR [C1R, HMy2.C1R] –, which functions as an 
antigen presenting cell (APC) line, and surveys if this interaction results in an upregulation of MAIT 
cells function or in modifications in these cells’ activation pattern. Nonetheless, we unsuccessfully 
isolated MAIT cells from human PBMCs when using a magnetic beads isolation kit (Figure 4.15). As 
previously mentioned, MAIT cells can be identified and isolated with the help of two different 
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markers: CD161 and TCRVα7.2. However, and probably due to a lack of optimization of the 
protocol, we could not isolate MAIT cells, hence double positive MAIT cells for these markers were 
lost along the process and retained in the negative fraction of the columns, leading to a inexistent or 
decreased percentage of isolated MAIT cells in the end. Even when using a death cell removal kit 
upfront to try and compensate the amount of negative MAIT cells in the positive isolated fraction the 
result was the same as before. The major concern using this isolation technique was indeed the low 
cell viability associated to loss of cells during the entire experimental procedure and the presence of 
negative MAIT cells within the positive MAIT cells fraction. Therefore, we then used a cell sorter to 
separate MAIT cells from human PBMCs. Figure 4.16 shows a successful isolation of MAIT cells 
population (double positive for CD161 and TCRVα7.2) from human PBMCs with a purity of 99.3% 
after sorting.  
Once we isolated a sufficient amount of MAIT cells, these cells were put together with the 
HMy2.CIR [C1R, HMy2.C1R] cell line and tested for different cytokines and chemokines using a 
Luminex Kit (See Matherials and Methods and Results). This cell line is well-descrided as an 
antigen presenting cell (APC) line and able to promote the delivery of an MR1 agonistic compound 
(Diclofenac) to MAIT cells, known for activating these cells. However, the assay did not show the 
expected results since the expression levels of all the cytokines and chemokines tested with Luminex 
were almost inhexistent or null. The same observations were made when testing different ratios 
between the C1R cell line and sorted MAIT cells. Still, our results suggest that sorted MAIT cells 
together with the C1R cell line already show some degree of activation. Nevertheless, the presence of 
diclofenac does not show any enhancement of this activation state, and it is possible that the 
compound concentrations or the ratios applied were not optimal to allow an upregulation of MAIT 
cells’ activation.  
Serum Screening 
As a secondary objective within this project, we performed a serum screen for PBMCs culture 
media, where eleven different commercially available serums were tested in three different assays – 
Elispot, Proliferation and ICS – using previously described methods (See Materials and Methods 
Section). Since this project was mainly created to evaluate and compare healthy patients and 
chronically HBV patients, we first used the Elispot assay, due to its high sensitivity (Figure 4.17 and 
Figure 4.18). Here, we assessed the response of six healthy donors upon stimulation CEF pool and 
individual peptides, translated by the number of spot forming cells. As mentioned in the results 
section, the healthy patients used were classified as low and intermediate responders. Our aim was to 
find at least one serum that could amplify our donors signal, i.e., increase the number of spot forming 
cells in comparison to the negative controls used. The purpose of using solely low and intermediate 
responders was due to fact that chronic HBV patients are low responders, demonstrating very low to 
inhexistent response in assays such as Elispot. The results obtained were broad, suggesting that more 
than one serum could provide the maximum amplification signal. Nonetheless, serums 2, 7 and 8 
showed the best resuts, having in thought the controls and stimulation parameters used, as well as an 
increase in the number of spot forming cells in each donor tested. 
Additionally, we performed two different assays: ICS and proliferation assay (Figures 4.19-
4.22). Respectively, CD8+ T cells gated out of the human PBMCs donors were tested for their pro-
inflammatory cytokines – IFNγ, TNFα and IL-2 – expression rate, as well as spread ability regarding 
the Ki67 proliferation marker, while maintaining the same stimulus conditions as before. As T cell are 
known to express pro-inflammatory cytokines when in an exhaustion environment such as HBV, we 
sought to investigate which serum out of the eleven tested indicated the highest expression rate on 
CD8+ T cells. It matters to mention that the donors tested have shown high inter-donor variability 
upon stimulation, as well as a high variability in cytokine expression, rendering difficult to take solid 
conclusions about which serum would be the best for further studies. Nevertheless, among the 
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different serums subjected to analysis, serums 2, 3 and 8 increase the overall expression of the 
different cytokines tested on CD8+ T cells. As for the proliferation ability of CD8+ T cells, the results 
were highly variable among the screen donors tested. Their results were once again disparate, since 
each donor, showed different Ki67 proliferation degrees upon stimulation, which is likely associated 
with the inherent inter-donor variability, as previously mentioned. However, CD8+ T cells seemed to 
increase their proliferation performance when in the presence of serums 4, 6 and 8. As a concluding 
remark, after analysing all the data from the different assays performed, serum 8 was chosen since 
provided the finest and more optimal results. Also, this serum would be used afterwards in different 
immune assays within the research group.  
Conclusions 
Although the work developed throughout this thesis provided an initial characterization of 
MAIT cells in the context of chronic HBV, further investigation is essential to better understand the 
role and functionality of these cells within a chronic infection environment, as well as their potential 
as a new immunotherapeutic approach.  
For instance, a similar preliminary characterization as the one described in this thesis should 
be done using liver samples from both control and chronic HBV patients. Such experiment would 
provide an important comparative analysis between peripheral blood MAIT cells data and those 
present in the liver, since it is known that MAIT cells comprise approximately 40% of the total 
number of T cells in this organ. Additionally, this would be crucial to confirm the hypothesis that 
MAIT cells can overcome T cell exhaustion and remain functional in chronic HBV patients.  
After establishing the dynamics and function of MAIT cells during a chronic infection, there 
is also a need to confirm whether these cells can be used as immunotherapy against chronic HBV. 
Since MAIT cells are naturally unable to recognize and kill HBV infected hepatocytes due to the lack 
of an HBV specific TCR, initial experiments might focus on the coupling of an HBV specific TCR to 
functional MAIT cells and delivery of these constructs into the affected organs/ cells.  
Although some studies with patient and in vitro experiments have shown that MAIT cells 
might sense a viral infection through a cytokine-driven network, there is still a lot of basic research 
needed to validate these cells as a therapeutic approach for chronic HBV and other viral diseases. For 
instance, it is not clear yet whether MAIT cell activation driven by a viral infection is protective or 
deleterious for the host, and thus new models are needed to better modulate the activity of these cells 
and its consequences. It is also important to confirm such data in in vivo models. Furthermore, it is 
essential to prove the specificity of MAIT cells responses. Since these cells can be activated merely 
by cytokines, in the absence of an APC, it is theoretically possible that these cells respond to stimuli 
without any local infection. Thus, experiments showing that activation of these cells in a TCR-
independent manner could lead to the death of virally infected cells would be very interesting. Finally, 
we still need to understand how the activation of MAIT cells might lead to antiviral effects and define 
how much MAIT cells participate in early events of adaptive and other innate immune responses. 
Again, in vivo models would be better suited to address this issue.  
In conclusion, we show that MAIT cells in chronically infected HBV patients are activated by 
IL-12 and IL-18 stimulation as healthy controls, they produce cytokines necessary for cytotoxic 
activity at comparable levels as healthy controls despite having upregulated exhaustion markers PD-1, 
TIM-3 and LAG3. The canonical description of exhausted T cells involves the loss of IFNγ and TNFα 
production with upregulated exhaustion markers. This study shows that MAIT cells do not follow this 
classical exhaustion pathway and retain functionality in tolerizing environments, meaning MAIT cells 
are a promising target for immune-cell based therapies in chronic infections or tumour treatment 
where the active site of disease is a tolerizing environment. Also, since we used 3 separate flow 
panels, to test MAIT cells regarding their activation, exhaustion and cytokine expression is important 
75 
 
to state that even though these panels were used individually, all of them evaluated stimulated MAIT 
cells.  Moreover, the final goal of this project was to assess if MAIT cells from chronically infected 
HBV patients were as functional as MAIT cells from healthy patients, not better or in high 
percentage. 
It is clear that a lot of questions are still unanswered regarding the role of MAIT cells, but 
since these cells represent a substantial fraction of circulating and tissue specific T cells in the human 
body, further investigation is needed to settle what their contribution is in the immune response 
against HBV and other viral infections.  
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